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Chapter 1
Outline of this Thesis
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The studies in this thesis began with the observation that the nucleoporin
NUP98 was at the breakpoint of t(7;11)(p15;p15) chromosomal translocations
found in patients with acute myeloid leukemia. We set out to determine the
molecular mechanism by which the translocation-generated fusion protein
NUP98-HOXA9 might contribute to the generation of leukemia. To this end, we
developed an in vitro cell transformation assay and determined which domains
of the fusion protein provide critical oncogenic properties. We found that NUP98-
HOXA9 had transformation potential that was dependent on the presence of the
(phenylalanine-glycine) FG repeat-containing domain of NUP98 and that this
potential correlated with the ability of the NUP98 portion to bind the
transcriptional coactivators, CBP (CREB-binding protein) and p300. In addition,
inhibition of CBP caused repression of transactivation activity associated with
the NUP98 portion of the fusion.  Thus, NUP98-HOXA9 appears to behave as a
transcription factor and this aberrant function may be critical for its ability to
contribute to leukemogenesis (Chapter 3).
To obtain additional insight into the mechanisms by which the NUP98 proto-
oncogene contributes to the development of various leukemias, we then
performed two distinct studies. First, we identified proteins that normally interact
with the amino-terminal portion of NUP98 that is present in all fusion proteins,
arguing that such proteins could contribute critical oncogenic properties, just like
CBP and p300. We found that Rae1, a protein of previously unknown function,
binds to the GLEBS (Gle2p binding sequence)-like motif of NUP98. We
performed a detailed functional analysis of the Rae1 protein, which revealed that
Rae1 is a nuclear export factor for mRNA (Chapter 5).  Second, we analyzed the
physiological role of NUP98 by using a gene knockout approach in the mouse.
Because NUP98 is essential for mouse embryogenesis, we studied cells derived
from homozygous mutant embryos to determine how the nuclear pore complex
(NPC) and transport through it was affected by the loss of NUP98 (Chapter 4).
We were further intrigued by three observations: first, the potential interaction
between the FG repeats of NUP98 and CBP in the leukemic process, second,
that CBP and p300 have been found to bind multiple transcription factors
involved in hematopoiesis (reviewed in Blobel, 2000) and third, that CBP and
p300 themselves can occur as fusion proteins found in leukemias (Borrow et al.,
1996; Ida et al., 1997; Kitabayashi et al., 2001; Panagopoulos et al., 2001; Taki
et al., 1997). These observations prompted us to investigate the normal roles of
CBP and p300 in blood cell development and function. To this end we made
mice bearing specific mutations in a transcription factor-binding domain of p300
and CBP, termed KIX, which were predicted to interfere with their ability to bind
to CREB and c-Myb, two transcription factors whose knockouts in mice produce
hematopoietic defects, but not with the overall structure and function of the
proteins (Mucenski et al., 1991; Rudolph et al., 1998; Sumner et al., 2000)
(Chapter 6).  This approach allowed us to dissect out the function of a specific
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domain of p300 and CBP by studying the effect of disrupting its interaction with
two factors involved in hematopoiesis.
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2.1 Hematopoiesis
The constant renewal of cells required in hematopoiesis makes it particularly
susceptible to acquired genomic mutations that can cause dysregulation that
leads to diseases such as leukemia.  Studies of myeloid leukemia-associated
chromosomal translocations have shown that many of the genes involved have
functions in the regulation of transcription, frequently as transcription factors, but
also as coactivators and tyrosine kinases that can modulate transcription factor
function. Fusion proteins coded by these translocations often retain
transcriptional activity, and in some cases may gain new functions not normally
possessed by either of the fusion partners (Scandura et al., 2002).  Thus, the
fusion proteins can lead to dysregulated transcription and subsequent
leukemogenesis.
Regulation and dysregulation in hematopoiesis
The maintenance and regulation of the hematopoietic process is critical for the
health of an organism.  In this section, I will first summarize three aspects of
hematopoiesis where regulation is most critical: cell proliferation, survival, and
differentiation.  I will then outline the various hematopoietic lineages that are
derived from pluripotent hematopoietic stem cells.  Finally, I will briefly describe
the kinds of diseases that can result from dysregulation of hematopoiesis.
Hematopoiesis requires appropriate cell proliferation, survival and
differentiation.
Normal hematopoiesis is regulated by complex signal transduction pathways
that transmit extracellular signals from the cell surface to the nucleus.  These
extracellular signals, such as hormones, cytokines, and growth factors, bind to
specific receptors on the cell surface and thereby initiate intracellular signaling
pathways.  In response to the binding of their ligands, most receptors undergo a
conformational change that either allows them to interact with or activate a
kinase or causes the receptor itself to gain a kinase activity.  This associated or
intrinsic kinase activity begins a phosphorylation cascade, ending in the
activation of one or more transcription factors. These transcription factors in turn
induce the transcription of their target genes.  Indeed, cell fate is largely
determined by the type of transcription factors expressed in response to
extracellular signals.  In this manner, the key aspects of hematopoiesis,
proliferation, survival and differentiation are regulated.
Cell proliferation is controlled through regulation of the cell cycle.
The appropriate proliferation of hematopoietic cells is necessary for an organism
to maintain normal hematopoiesis throughout its lifespan.  Hematopoietic stem
cells must be able to replicate themselves effectively without losing their
pluripotent status.  Additionally, an organism must be able to produce sufficient
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numbers of mature blood cells to meet its ongoing needs, as well as more
immediate needs brought about by illness or injury.  Experimental evidence
suggests that the ability to proliferate is greatest in the most pluripotent stem
cells and is gradually lost as a cell becomes more differentiated (Zhu and
Emerson, 2002).  Thus, hematopoiesis involves a constant balancing act
between the requirements of proliferation and differentiation in the blood cell
population.
Cell proliferation is controlled through regulation of the cell cycle. The cell cycle
consists of four phases, S phase during which DNA is replicated, M phase
during which the cell undergoes mitosis, and G1 and G2, phases in which the cell
prepares to enter S and M phases respectively.  In addition, non-dividing cells
are said to be in phase G0.   Non-proliferating progenitor cells remain arrested in
G0 until an extracellular signal sends them into active cell cycling.  Checkpoints
during G1 and G2 phases are present to ensure that cells with DNA damage are
not replicated unless the damage is repaired.  This helps to prevent mutations
from accumulating in the genome.  Once a cell has entered S phase it is
committed to a round of cell division and the presence or absence of the
cytokine or growth factor signal is no longer relevant. However, when the cell
again reaches G1, if it is to undergo another round of division, the appropriate
signals must be present or the cell will again move into G0 (Sherr, 1996).  In
living organisms, the amount of time it takes to progress through one round of
the cell cycle does not appear to be regulated by external signals (although it
can be in vitro), thus the ability to shift cells from G0 to G1 and vice versa
provides the primary means by which the rate of cell proliferation is controlled
(Pardee, 1989)
A stem cell that has committed to proliferation can produce daughter cells, which
have the same pluripotent potential as itself (self-renewal) or which have lost the
ability to contribute to some lineages (differentiation). Cells respond to both
proliferation and differentiation signals during the G1 phase of the cell cycle.
Changes in the dynamics of the cell cycle caused by transcription factors could
influence the decision of a stem cell to self-renew or to differentiate.  For
instance, the transcription factor, Notch-1, when expressed constitutively in
human hematopoietic progenitor cells cultured in vitro, produces a shortening of
the G1 phase of the cell cycle and also inhibition of cell differentiation, which
could be explained by the reduced time frame during which cells can respond to
pro-differentiation signals (Carlesso et al., 1999). Moreover, transcription factors,
such as c-Myb, that are upregulated in early hematopoietic cells, favor cell
proliferation by increasing progression into the cell cycle, while other
transcription factors which are expressed in more mature hematopoietic cells
have the opposite effect (Friedman, 2002).
17
Cell survival is mediated by extracellular signals.
Also critical to the maintenance of appropriate numbers of differentiated and
progenitor hematopoietic cells is the regulation of cell survival.  Appropriate
cytokine and growth factor expression is necessary for cells to survive, although
expression of certain genes can increase (e.g. the pro-apoptotic protein, Bax) or
decrease (e.g. the anti-apoptotic factor, bcl-2) the requirement for these signals.
Although it is crucial to the organism that healthy, viable hematopoietic cells
survive, it is also necessary that old, damaged or superfluous cells be
destroyed.  Cells that die accidentally, through necrosis, can cause harm to
surrounding cells by releasing their intracellular contents and causing an
inflammatory response.  Programmed cell death or apoptosis provides a means
of destroying unnecessary or unwanted cells without causing harm to
neighboring cells, by inducing the cell to shrink, the nucleus to fragment, and a
signal to be produced that is recognized by macrophages which then consume
the cellular remnants (Wickremasinghe and Hoffbrand, 1999).  It is clearly
advantageous to an organism to be able to rid itself of unwanted cells in a
planned manner that does not cause collateral damage to adjacent cells.
Extracellular signals and the transcription factors they induce are
responsible for determining cell differentiation fates.
In addition to being able to control the overall number of hematopoietic cells,
organisms must be able to regulate the differentiation and renewal of
hematopoietic stem cells.  Hematopoietic stem cells are capable of both
renewing themselves and differentiating into all of the mature hematopoietic cell
lineages.  The differentiation process is believed to involve multiple decision
points at which a cell will undertake a certain differentiation pathway and
consequently lose its ability to progress down other differentiation paths.  Once
a cell has begun to differentiate, it cannot go back; differentiation is a one-way
street.  There is, however, evidence that some signs of lineage-specificity, such
as expression of lineage-specific genes, precede actual lineage commitment
(Rothenberg, 2000).  As cells become more differentiated, they lose their ability
to self-renew and to proliferate and begin a maturation process that is specific
for a particular lineage.  The processes by which hematopoietic stem cells
become specific lymphoid, myeloid or erythroid lineage cells are only partially
understood.
It has been observed that a specific set of cytokines, cell surface receptors, and
transcription factors is associated with the differentiation of each of the mature
hematopoietic lineages; however, the understanding of the exact role of each of
these factors in the commitment and differentiation processes is still being
debated. Cytokines and growth factors have been proposed to have either an
instructive or a selective role in lineage commitment (Morrison et al., 1997).   In
the instructive model, cytokines and growth factors directly influence the cell to
become specific for a certain lineage by inducing the expression of lineage-
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associated transcription factors. In the selective model, cells specify for a certain
lineage by a cell autonomous and possibly stochastic process, and the presence
of cytokines and growth factors determines only which lineages can survive
without contributing to the decision to commit (Cross and Enver, 1997; Morrison
et al., 1997).
The prevailing view of the role of transcription factors in lineage commitment has
changed somewhat in recent years.  Although many transcription factors have
been considered to be lineage-specific, studies have indicated that the earliest
progenitor cells express RNA transcripts of multiple lineage-associated
transcription factors, albeit at low levels (Hu et al., 1997; Krause, 2002). It has
been speculated that this low-level transcription of genes coding for transcription
factors associated with many different lineages represents a primed state from
which the cell can choose any of several different fates.  Differentiation to a
specific cell lineage would then require the up-regulation of the relevant lineage-
specific transcription factors and the repression of others (Hu et al., 1997).  The
means by which this specification would take place is unknown; however, most
theories fall into either a stochastic or deterministic view of differentiation.  One
stochastic model predicts that the expression of one set of transcription factors
may exceed a threshold level by chance and that the increased expression of
these transcription factors would have an inhibitory effect on the expression of
other transcription factors (Enver and Greaves, 1998).  Alternatively,
extracellular signals could cause the upregulation of certain transcription factors
over others and thus determine cell fate.
All hematopoietic lineages have a common stem cell precursor.
The earliest progenitor in the hematopoietic lineage is the hematopoietic stem
cell, which is capable of infinite self-renewal and of differentiating into all of the
hematopoietic lineages.  One of the earliest differentiation choices made by a
hematopoietic stem cell is thought to be the decision to commit to either the
lymphoid lineages or the myeloid/erythroid lineages.  This is supported by the
discovery of two types of progenitor cells, the common lymphoid precursor
(CLP) and the common myeloid precursor (CMP).  In bone marrow
transplantation assays in mice, the CLP was found to give rise to only lymphoid
lineage cells, while the CMP was found to repopulate only the myeloid and
erythroid lineages (Akashi et al., 2000a; Akashi et al., 2000b; Kondo et al.,
1997).  CLPs and CMPs can be distinguished from each other by the
transcription factors and cytokine receptors they express.  CLPs have the
interleukin-7 (IL-7) receptor on their surface and express the transcription factors
PU.1 and c-Myb strongly, while CMPs express the erythropoietin (EPO), and c-
mpl or thrombopoietin (TPO), receptors and show upregulation of the
transcription factors, SCL, GATA-2, NF-E2, and c-Myb (Akashi et al., 2000a;
Akashi et al., 2000b).  Other research on hematopoietic stem cells implies that
lymphoid T- and B-cells come from separate myeloid/T-cell and myeloid/B-cell
progenitors (Katsura, 2002). This model may be supported by findings that
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suggest that under certain conditions B-cells can be induced to become
macrophages and by the existence of mixed myeloid/B-cell and myeloid/T-cell
leukemias (Katsura, 2002).  A third model explains these potentially conflicting
results by hypothesizing two pathways for macrophage commitment, one
through myeloid precursors and an alternate pathway from a B-cell precursor
(Rothenberg, 2000).  It remains to be seen whether any of these models truly
represent the commitment steps taken by hematopoietic stem cells.
Figure 1.  Schematic of hematopoietic lineage differentiation from a common
hematopoietic stem cell.  Abbreviations used: CLP, common lymphoid precursor; CMP,
common myeloid precursor; GMP, granulocyte/monocyte precursor; MEP,
megakaryocyte/ erythroid precursor; NK cell, natural killer cell.  Adapted from Akashi et
al., Nature (2000).
Lymphoid Lineage
Whether or not they come from the same immediate precursor cell, B- and T-
lymphocytes resemble each other in both function and certain structural
characteristics.  B- and T-cells are both central players in the immune response,
although they act in different ways. B-cells contribute to the immune response
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by producing antibodies to foreign antigens, while T-cell act as either CD4+
helper cells, which assist other cells in making their response to a foreign
antigen, or CD8+ cytotoxic cells, which recognize and kill infected cells. The
antigen receptors on B- and T-cells bear striking similarities.  In order for the
mature receptor to be expressed, both the B-cell receptor, immunoglobulin, and
the T-cell receptor (TCR) genes must undergo V(D)J recombination, which
requires the rearrangement of the V (variable), D (diversity), and J (joining) gene
segments (Schatz, 1999).   This rearrangement allows an amazing degree of
receptor diversity to be encoded in a compact manner in the genome; however,
it may provide an increased opportunity for chromosomal translocations to
occur, which could lead to leukemia (Scandura et al., 2002).  In addition, both B-
and T-cells undergo an extensive selection process during maturation to ensure
that the cells that are released into the periphery do not react against the
organism itself.  Cells that do not pass this selection process die by apoptosis
and as a result, the number of lymphoid lineage cells produced by an organism
is very large compared to the number of cells that actually become mature
lymphocytes.
T-cells are derived from progenitors that have relocated from the bone marrow
to the thymus and undergo their commitment and maturation there. T-cells go
through a CD4 CD8 double-negative stage, followed by a double-positive stage
prior to the selection of mature single-positive T lymphocytes.  The TCR on a
single positive T lymphocyte recognizes either major histocompatibility complex
(MHC) I or II. MHC I molecules are expressed on virtually all cells with nuclei,
while MHC II molecules are expressed primarily on cells such as macrophages
and B-cells that recognize foreign antigens. Both MHC I and II present peptides
(derived from proteins that have been degraded inside the cell) on the cell
surface, which alerts other cells that recognize MHC I or II to the presence of
foreign peptides in these cells.  CD4 and CD8 act as co-receptors, which help T-
cells to bind specific MHC molecules; CD8 is specific for MHC I, and CD4 is
specific for MHC II.  Interestingly, while the processes of MHC specification and
single-positive T-cell selection occur in parallel, they do not appear to be linked
mechanistically (Keefe et al., 1999). The combination of specificities provided by
these receptors enables the helper and cytotoxic T lymphocytes to accomplish
their different tasks. Specificity for MHC I allows cytotoxic T-cells to recognize
virus infected cells and assist directly in their destruction, while MHC II specificity
enables helper T-cells to recognize and activate macrophages or B-cells that
have been sensitized by the same antigen as the T-cell.  The strength of a
developing T-cell’s reaction to the MHC determines its fate.  Either too strong or
too weak of a reaction leads to negative selection via apoptosis.  Only T-cells
that have an appropriate response to the MHC are selected to continue in the
differentiation process (Wolfer et al., 2001).  Most maturing T-cells fail to meet
the rigorous standards necessary to continue to the mature single-positive stage
and die by apoptosis as double-positive cells.
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In mammals, B-cells differentiate and mature in the bone marrow of adults and
in the livers of embryos. B-cells go through several stages before they are fully
mature.  These stages are marked by the expression of specific antigen
receptors and other cell surface proteins.  Only about 10% of the B-cells
produced in the bone marrow survive to become mature peripheral B-
lymphocytes (Cariappa and Pillai, 2002).  The remaining cells are either
negatively selected and destroyed in the bone marrow for a defect such as self-
recognition or else they fail to attain a place in a splenic follicle and apoptose
because of survival signal deprivation.  B-cells that do survive can become
either memory cells or plasma cells upon activation by antigen with the
assistance of helper T-cells.  Memory cells retain specificity to a specific antigen
and can activate other B-cells or differentiate into plasma cells in case of
reexposure to the same antigen.  Plasma cells are terminally differentiated
antibody-secreting B-cells.
Natural killer (NK) cells also belong to the lymphoid lineage, and probably share
a common precursor with T-cells.  Unlike T-cells they do not have rearranged
TCR genes and they do not undergo MHC class specification.  NK cells are
important in defending against foreign and cancerous cells with reduced
expression of MHC I that might not be detected by cytotoxic T-cells.
Myeloid Lineages
The myeloid lineage is comprised of monocytes and granulocytes.  Monocytes,
or macrophages as they are known once they leave the bloodstream and enter
the tissue, are responsible for destroying old, damaged or apoptotic cells as well
as foreign organisms via phagocytosis.  Granulocytes include neutrophils,
whose primary role is the phagocytosis of small organisms such as bacteria;
eosinophils, which are involved in tempering allergic responses and destroying
some parasites; and basophils, which secrete histamine to control inflammatory
reactions.  The granulocyte subcategory is actually based on the appearance of
these cells under a microscope and may not reflect the degree to which these
cells are related.  Eosinophils may develop from the CMP along a separate
pathway from that taken by neutrophils and monocytes, which are believed to
share a common intermediate precursor (Ward et al., 2000; Zhu and Emerson,
2002). There is also some evidence that basophils may actually derive from the
megakaryocytic rather than the myeloid lineage (Arock et al., 2002).  Further
study will be necessary to clarify the origins of these cells.
Erythroid/Megakaryocytic Lineage
Erythrocytes, the most numerous hematopoietic cells, develop in the bone
marrow, where during the normal maturation process they lose their nuclei,
ribosomes and mitochondria before moving into the blood.  The function of red
blood cells is to transport oxygen, which binds to the hemoglobin contained in
erythrocytes.  Erythrocyte production is stimulated by EPO, which is produced
by the kidneys. EPO production is increased in response to hypoxia or blood
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loss, causing more erythrocytes to be made.  The number of erythrocytes
produced is a tightly regulated process in normal individuals, which may indicate
that a high level of redundancy exists in the regulatory elements responsible for
erythropoiesis.
Megakaryocytes, the largest of the hematopoietic cells, are found in the bone
marrow, and in the mouse, also in the spleen.  During the maturation process,
megakaryocytes undergo endomitosis, rounds of chromosomal replication
without cell division.  This results in a highly polyploid nucleus with a large
cytoplasm.  The DNA content of megakaryocytes varies between 8N and 128N
with the modal ploidy in both humans and most mice being 16N (Jackson et al.,
1990; Long, 1998).  When megakaryocytes are sufficiently mature, they shed
platelets, which are actually fragments of the cytoplasm of the megakaryocyte.
Platelets act at sites of blood vessel damage to help seal the break and cause
the blood to clot.  Platelet production is stimulated by TPO, which is produced in
the kidneys, liver, smooth muscle and bone marrow (Kaushansky, 1998).
Serum TPO levels are found to vary inversely with platelet count, because
platelets bind TPO and remove it from the serum, providing a feedback loop for
regulation of platelet production (Kaushansky, 1998).
Loss of regulation in hematopoiesis can lead to a variety of diseases.
Dysregulation of hematopoiesis at any stage may have serious consequences
for an organism.  While some defects can be compensated for, others may lead
to disease or even death.  Improper regulation can lead to underproduction or
overproliferation of one or more blood cell types, a loss of the ability to destroy
defective cells, or an inability of cells to mature beyond a certain stage, causing
a deficit of one or more mature hematopoietic lineages.  An example of a
disease marked by underproduction of a specific lineage is anemia.  Anemia is
characterized by a decrease in the number of red blood cells, or a reduction or
defect in the hemoglobin they contain.  Anemia has many causes including
blood loss, iron deficiency and genetic defects.  Anemia is also a common
symptom of leukemia.  Depending on the source of the anemia, the disease can
be either short term or chronic.  In response to anemia, red blood cells are
frequently rushed into the blood before they are fully mature and in severe
cases, erythropoiesis may begin to occur in organs outside the bone marrow,
such as the spleen or liver (termed extramedullary hematopoiesis), in an attempt
to meet the demand.
On the opposite end of the spectrum are chronic myeloproliferative disorders, in
which too many cells of one or more non-lymphoid lineages are produced. In
these diseases the maturation process of the affected lineage may or may not
be intact.  In some cases, one lineage is produced at the expense of another
lineage and in many cases the cells being produced possess some defect of
physiology or function.  Myeloproliferative disorders are frequently clonal in
nature, that is, a mutation or mutations acquired in a single stem cell gives its
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progeny a growth advantage over normal cells and allows them to
overproliferate (Solberg, 2001).  Polycythemia vera, in which the erythrocyte
count and often the leukocyte count is increased, and essential
thrombocythemia, in which the platelet count is elevated, are examples of
myeloproliferative disorders.  Interestingly, all chronic myeloproliferative
disorders display an increase in megakaryocyte numbers, size and ploidy
(Jacobsson et al., 1999).  Sometimes these disorders can progress into a
myelodysplastic syndrome, typified by an overproliferation of abnormal cells or
even leukemic disease (Solberg, 2001).
Leukemia combines the overproliferation of one or more hematopoietic cell
lineages with blocks in the differentiation and apoptotic pathways.  This leads to
the uncontrolled expansion of a cell population without the brakes that
programmed cell death or the loss of proliferative ability associated with terminal
differentiation would provide.  Like chronic myeloproliferative disorders,
leukemia is usually clonal.  Leukemias are generally classified as either acute or
chronic and most often affect either the lymphoid or myeloid lineages, although
erythroid and megakaryocytic leukemias exist as well.  Chromosomal
translocations are frequently found in leukemia and the aberrant gene products
encoded have been the focus of much study.  Two types of leukemia, chronic
myeloid leukemia (CML) and acute myeloid leukemia (AML) are of particular
interest in this thesis.
CML is most often associated with the chromosomal rearrangement known as
the Philadelphia (Ph) chromosome.  This translocation results in a fusion
between the BCR and ABL genes.  The fusion protein encoded by this
translocation, p210BCR/ABL is a tyrosine kinase that is constitutively active and has
been shown to cause cancer in transgenic animals and transformation in cell
culture assays (Cross and Reiter, 2002; Shet et al., 2002). Other fusion proteins
that function as tyrosine kinases have been found in the small subset of CML
that does not involve the Ph chromosome, indicating that the deregulation of
tyrosine kinase function is a critical factor in the genesis of CML (Bain, 2002).
CML has two phases, a long chronic phase during which immature and mature
myeloid cells are overproduced and found in the periphery, followed by a blast
crisis characterized by a block in maturation of one or more lineages (Shet et al.,
2002).  Which lineage is blocked during blast crisis may be determined by
additional mutations that have been acquired; loss of p53 in CML patients has
been associated with myeloid blast crisis, while loss of p16INK4a has been found
in patients with lymphoid blast crisis (Shet et al., 2002).  One interesting
difference between CML and non-malignant chronic myeloproliferative disorders
has been found regarding megakaryocyte ploidy.  While in chronic
myeloproliferative disorders the megakaryocytes are found on average to have a
greater modal ploidy than in normal individuals, in CML, patients have been
found to have megakaryocytes with a modal ploidy of 8N rather than the 16N
found normally, indicating a shift towards immaturity (Jacobsson et al., 1999).
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The significance of this finding has not been determined, but it is of interest that
we have found that disrupting the ability of c-myb to bind p300 also leads to a
decreased modal ploidy in megakaryocytes (Chapter 6).
AML is the most common form of acute leukemia in adults.  It encompasses
eight subgroups, which differ according to the myeloid lineages involved and the
degree of maturation those cells attain.  AML is also the most frequent type of
leukemia to arise from mutations caused by prior cancer therapy (Scandura et
al., 2002).  AML differs from CML in that it presents with an overproliferation of
immature myeloid cells and consequently progresses much faster than CML.
Many of the translocations associated with AML involve transcription factor
genes, implying that transcriptional dysregulation may be a primary factor in the
generation of AML (Alcalay et al., 2001; Scandura et al., 2002).  The partner
genes found in these translocations have a diversity of functions, but some are
thought to have roles in apoptosis and cell survival regulation (Alcalay et al.,
2001).
Domains that may contribute to transcriptional activity are often present in fusion
proteins associated with AML including transactivation domains, DNA binding
domains, domains with protein acetyltransferase activity, and domains that allow
interaction with other factors that possess chromatin-remodeling activity
(Scandura et al., 2002).  In the context of the fusion protein, the aberrant nuclear
localization of certain domains may alter their transcriptional regulatory
properties or reveal novel transcriptional properties. This potential for gain or
alteration of transcriptional function could help to explain the role of proteins
involved in leukemia-associated translocations, such as NUP98, that may seem
otherwise to have little or no function in hematopoiesis.
2.2 Nucleoporins
All transport of proteins and RNA between the cytoplasm and the nucleus
occurs via pores in the nuclear envelope. These pores allow both active
transport and passive diffusion of molecules into and out of the nucleus.
Passage through these pores is regulated by structures within the pores called
nuclear pore complexes (NPC), which are made up of proteins called
nucleoporins.  In this section I will discuss some features of nucleoporins and
their roles in the NPC and then describe the involvement of two specific
nucleoporins, NUP98 and NUP214, in chromosomal translocations associated
with leukemia.
Structure of the NPC
The NPC has an octagonal symmetry around a central pore. Within this pore is
a transporter structure which allows the passive diffusion of small molecules and
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the active transport of larger molecules through the central channel (Rout and
Aitchison, 2001).  Parallel with the nuclear envelope around the transporter is a
ring structure from which eight filaments extend into the cytoplasm and eight
filaments extend in to the nucleus joined by a ring at their distal ends to form a
basket.  The NPC is anchored to the nuclear lamina, a filamentous meshwork,
which acts as a support structure for the nuclear envelope.  Localization of
specific nucleoporins within the NPC varies, with some being located throughout
the NPC, while others are located either primarily or entirely at the nuclear or
cytoplasmic side of the NPC.  Structures called annulate lamellae, which also
contain nucleoporins and have structural similarity to the NPC are found in the
cytoplasm (Lyman and Gerace, 2001).  The function of annulate lamellae is not
clear, but they may represent stores of nucleoporins not currently required for
NPCs, or alternatively, they may consist of accumulations of nucleoporins, which
are awaiting breakdown (Daigle et al., 2001; Lyman and Gerace, 2001).
Figure 2.  Structure of the Nuclear Pore Complex showing major components and
relative locations of the nucleoporins NUP98 and NUP214.  (Adapted from Ryan et al.
2000).
The number of distinct nucleoporins that make up the NPC has been a topic of
speculation.  A proteomics study of the yeast NPC has defined 29 proteins in the
NPC, although the definition of nucleoporin used in this study may exclude some
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proteins with important NPC functions (Rout et al., 2000; Vasu and Forbes,
2001).  Because the mammalian NPC is known to be larger and more complex
than the yeast NPC, it has widely been assumed that there are more
nucleoporins in mammalian NPCs and estimates have been in the range of 50
to 100 proteins (Stoffler et al., 1999; Wente, 2000).  A recent study; however,
has used a proteomics approach to define the proteins in the mammalian NPC
and has also identified 29 nucleoporins (Cronshaw et al., 2002).  Whether this is
the exact number of nucleoporins in the yeast and mammalian NPCs remains to
be verified by other approaches, but it seems likely that the number for yeast or
mammals will not turn out to be vastly larger.
In both yeast and mammals, roughly one third of nucleoporins in the NPC have
domains containing multiple repeats of phenylalanine (F) and glycine (G), known
as FG repeats (Cronshaw et al., 2002; Wente, 2000).  Besides repeats of the
FG dipeptide alone, the family of FG repeat-containing nucleoporins also can
have the variant FG repeats GLFG (where L is leucine) or FXFG (where X is any
amino acid).  FG repeat-containing nucleoporins interact with transport factors,
called karyopherins, and some of these karyopherins have been shown to bind
directly to FG repeats (Bayliss et al., 2000; Bayliss et al., 2002; Fribourg et al.,
2001; Strasser et al., 2000). The localization of these FG repeat-containing
nucleoporins throughout the NPC provides evidence for a model in which
transport factors move proteins or RNA through the NPC by means of docking
interactions with FG repeat-containing domains.
Transport through the NPC
Import and export of molecules through the NPC occur in similar but distinct
manners.  In both protein import and export, a karyopherin recognizes a
targeting signal on the protein, for import a nuclear localization signal (NLS) and
for export a nuclear export signal (NES).  In some cases this karyopherin may
both recognize the targeting signal and interact with nucleoporins; in other
instances a pair of karyopherins work together, with one recognizing the
targeting signal and one binding to nucleoporins.  This interaction of
karyopherins with nucleoporins is thought to direct the import or export complex
through the NPC; however the specifics of this process are not known.  It may
involve the binding of the transport complex to nucleoporins with progressively
higher affinity until the other side of the NPC is reached, or it may be an
essentially stochastic process in which the passage of some molecules through
the NPC is restricted more than that of others (Ben-Efraim and Gerace, 2001;
Ribbeck and Gorlich, 2001).  The manner in which the transport complex is
disassembled upon reaching its destination differs between import and export,
but involves Ran, a small GTP-binding protein in both cases.  When an import
complex reaches the nuclear side of the NPC, Ran-GTP binds to the
karyopherin causing the complex to disassociate.  In the case of an export
complex, Ran-GTP travels from the nucleus as part of the export complex and
upon reaching the cytoplasm is converted to Ran-GDP by Ran GTPase
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activating protein causing Ran to be inactivated and the complex to destabilize
and disassemble.  Export of RNA from the nucleus occurs in much the same
way as export of protein; however, before the RNA can be exported from the
nucleus, it must form a complex with RNA-binding proteins.  These proteins
provide the NES and interact with RNA transport factors, such as Rae1, which
facilitate the export process (Pemberton et al., 1998).
NUP98 and NUP214 are involved in multiple leukemia-associated fusion
proteins.
Two nucleoporins, NUP98 and NUP214 have been found to be involved in
multiple chromosomal translocations associated with leukemia (Table1).  Both
NUP98 and NUP214 are FG repeat-containing nucleoporins that have been
directly implicated in NPC transport (Radu et al., 1995a; Radu et al., 1995b; van
Deursen et al., 1996).  In all of the reported leukemias associated with
translocations involving NUP98 or NUP214, RNA fusion transcripts are found
which include the FG repeat domain, although the reciprocal fusion transcripts
are also found in some cases (Lam and Aplan, 2001). The ubiquitous presence
of the FG repeat-containing fusion transcripts argues for the importance of these
repeats in leukemogenesis.  A common theme for the fusion partners of NUP98
and NUP214 is less evident.  NUP98 is involved in chromosomal translocations
with numerous homeobox genes, but little similarity has been found between its
many other fusion partners and those of NUP214.  A recent study; however,
indicates that the non-homeobox fusion partners of NUP98 and NUP214 all
have motifs that are predicted to form coiled-coil domains (Hussey and
Dobrovic, 2002).  It is speculated that these coiled-coil regions might act as
oligomerization domains, which could allow interaction with transcription factors
or cofactors.  In addition, there is some evidence that several of these fusion
partners may have roles in transcription themselves.  This would argue that
alterations in normal transcriptional regulation might be the critical factor in the
leukemogenic potential of these fusion proteins.  A closer inspection of these
nucleoporins and their fusion partners provides some clues to their roles in
leukemogenesis.
NUP98 localizes in the NPC to the midpoint of the nuclear basket and is also
found in the nucleoplasm and in distinct structures within the nucleus, termed
GLFG bodies (the GLFG domain has been shown to be required for this specific
nuclear localization (Griffis et al., 2002)).  NUP98 contains a total of 37 FG,
FXFG and GLFG repeats and is the only known vertebrate GLFG repeat-
containing nucleoporin (Griffis et al., 2002; Lam and Aplan, 2001; Radu et al.,
1995b).  In addition to the FG repeat domain, NUP98 also contains a Gle2p-
binding sequence (GLEBS)-like domain, which is a binding site for the RNA
export factor, Rae1 (Bharathi et al., 1997; Brown et al., 1995; Murphy et al.,
1996; Whalen et al., 1997).  The gene encoding NUP98 also codes for another
protein, NUP96, which is not a member of the FG repeat-containing family of
nucleoporins.  The two proteins can be produced as a single transcript or
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NUP98 can be synthesized alone from an alternatively spliced RNA; in both
cases the protein produced is cleaved by autoproteolysis (Fontoura et al., 1999;
Rosenblum and Blobel, 1999). Studies indicate that NUP98 is primarily involved
in RNA export from the nucleus, although a function in the import and export of
proteins has not been ruled out (Powers et al., 1997).   Some recent studies
have helped to elucidate the role of NUP98 in RNA export.  NUP98 has been
shown to be the target through which vesicular stomatitis virus matrix protein
inhibits the expression of host genes by blocking mRNA export (Enninga et al.,
2002).  Treatment with interferon γ has been shown to increase NUP98
expression through a STAT1-dependent pathway and this increased NUP98
expression relieves the block in mRNA export from the nucleus.  Another study
has shown that the various localizations of NUP98 in the nucleus (NPC,
nucleoplasm, and GLFG bodies) exchange in a transcription-dependent manner
and that blocking transcription arrests this mobility (Griffis et al., 2002). This
could be evidence that NUP98 may physically escort RNA to the NPC for export.
Translocation Malignancy Fusion partner HD
t(7;11)(p15;p15) AML, t-AML, MDS, t-MDS, CML HOXA9 Yes
t(7;11)(p15;p15) CML HOXA11 Yes
t(7;11)(p15;p15) AML HOXA13 Yes
t(11;12)(p15;q13) AML HOXC11 Yes
t(11;12)(p15;q13) AML HOXC13 Yes
t(2;11)(q31;p15) AML HOXD11 Yes
t(2;11)(q31;p15) AML, t-AML, t-MDS HOXD13 Yes
t(1;11)(q23;p15) t-AML, t-MDS PMX1 Yes
inv(11)(p15;q22) AML, t-AML, t-MDS DDX10 No
t(11;20)(p15;q11) AML, t-AML, t-MDS TOP-1 No
t(9;11)(p22;p15) AML LEDGF No
t(5;11)(q35;p15) AML NSD1 No
t(8;11)(p11.2;p15) AML NSD3 No
t(4;11)(q21;p15) T-ALL RAP1GDS1 No
Table 1.  Summary of chromosomal translocations involving NUP98.  Shown are the
malignancies the translocation is associated with, the fusion partner of NUP98 and
whether a homeodomain is contributed by the partner gene.  Abbreviations used: HD,
homeodomain; AML, acute myeloid leukemia; t-AML, therapy-related acute myeloid
leukemia; MDS, myelodysplastic syndrome; t-MDS, therapy-related myelodysplastic
syndrome; CML, chronic myeloid leukemia; T-ALL, T-cell acute lymphoid leukemia.
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Chromosomal translocations involving NUP98 have been found in de novo and
therapy-related AML, CML and myelodysplastic syndrome (MDS).  To date,
fourteen genes have been identified in leukemia-associated chromosomal
translocations with NUP98.  In all cases, the N-terminus of NUP98 is found by
reverse transcription polymerase chain reaction (RT-PCR) to be fused to the C-
terminus of the partner gene; in some cases the reciprocal transcript is also
detected.  The N-terminal portion of NUP98 contained in these fusions includes
the GLEBS-like domain and the majority of the FG repeats, and all of the
translocations result in in-frame fusions of NUP98 and its partner gene.
Homeobox-domain containing proteins are the most common fusion
partners of NUP98.
Eight of the fourteen genes fused to NUP98 in leukemia-associated
chromosomal translocations are members of the homeobox gene family.
Homeobox genes are transcription factors, which contain a 61 amino acid helix-
turn-helix DNA-binding homeodomain, and function primarily in embryonic
patterning, but have also been found in some adult tissues, including blood cells
(Lawrence et al., 1997; Magli et al., 1997).  Homeobox genes are divided into
two types; Class I homeobox (HOX) genes, which have a highly conserved
homeodomain sequence and Class II homeobox genes, which contain
degenerate homeodomain sequences.  Class I HOX genes in both mice and
humans are arranged in four clusters (A, B, C and D) of 9 to 11 genes with each
cluster on a different chromosome (Cillo et al., 2001).  The ordering of HOX
genes within each cluster corresponds to their temporal and spatial expression
in the embryo, with the most 3’ HOX genes being expressed earliest and in the
most anterior positions in the developing embryo (Cillo et al., 2001; van
Oostveen et al., 1999).  HOX genes of the A, B and C clusters have been found
to be expressed in normal hematopoietic cells, with the A cluster predominantly
expressed in myeloid cells and the B and C clusters expressed mostly in
erythroid cells, but little evidence of expression of HOX genes of the D cluster in
hematopoietic cells has been found (Lam and Aplan, 2001).  Class II homeobox
genes are found scattered throughout the genome and some of them have also
been found to be expressed in hematopoietic cells (Lam and Aplan, 2001;
Shivdasani and Orkin, 1996; van Oostveen et al., 1999).
In all of the translocations between NUP98 and homeobox family members, the
N-terminus of NUP98 is fused to the homeodomain-containing C-terminus of the
homeobox gene, which may indicate that this domain has a role in the
leukemogenic function of the fusion proteins.  Class I HOX genes belonging to
the A, C and D, but not the B clusters have been found in translocations with
NUP98.   HOXA9 was the first identified fusion partner of NUP98 and the
NUP98-HOXA9 fusion is the most common fusion involving NUP98, accounting
for approximately 1% of AML cases, as well as having been reported in some
CML cases (Ahuja et al., 2001; Look, 1997).  Mice nullizygous for HOXA9 have
hematopoietic defects including reduced numbers of lymphocytes and
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granulocytes and smaller than normal spleens and thymuses (Lawrence et al.,
1997).  In addition they were found to have fewer myeloid, B-cell and erythroid
progenitors, although no attendant anemia was reported (Lawrence et al., 1997).
The NUP98-HOXA9 translocation, as well as the other translocations involving
NUP98, is often found in therapy-related secondary leukemias.
Other homeobox genes that have been found as fusion partners of NUP98 in
leukemia are HOXA11, HOXA13, HOXC11, HOXC13, HOXD11, HOXD13 and
PMX1 (Fujino et al., 2002; Nakamura et al., 1999; Panagopoulos et al., 2003;
Raza-Egilmez et al., 1998; Suzuki et al., 2002; Taketani et al., 2002a; Taketani
et al., 2002b; Taketani et al., 2002c).  Knockouts and transgenic overexpression
of these genes in mice caused skeletal abnormalities; however, no
hematopoietic defects were reported (Davis and Capecchi, 1994; Davis et al.,
1995; Fromental-Ramain et al., 1996; Godwin and Capecchi, 1999; Hostikka
and Capecchi, 1998; Martin et al., 1995; Papenbrock et al., 2000; Patterson et
al., 2001; Small and Potter, 1993; Sur and Toftgard, 2000).  Interestingly, PMX1
has been shown to interact with Maf proteins, some of which are known to
regulate the expression of certain hematopoietic-specific genes (Kataoka et al.,
2001).  This could point to an indirect dysregulation of hematopoiesis caused by
expression of the NUP98-PMX1 fusion protein.  Alternatively, and perhaps more
likely, the similarities between this group of NUP98-containing fusion proteins
may indicate that the primary contribution of the homeobox-containing fusion
partners is their DNA-binding capabilities, while the original function of the
homeobox protein may be lost entirely rather than being misregulated.
The other proteins that have been found in fusions with NUP98; DDX10,
LEDGF, NSD1, NSD3, RAP1GDS1 and TOP1 have few similarities although
several have been suggested as possible transcription cofactors.  DDX10 is a
ubiquitously expressed member of the DEAD box family of putative RNA
helicases.  Two variants of the NUP98-DDX10 fusion protein have been found in
AML, with slightly different breakpoints in NUP98 and also differing in whether
the C terminus of DDX10 fused to NUP98 contains the DEAD box domain or
not; however both variants retain the RNA helicase domain and a charged
amino acid region (Arai et al., 1997).  There is some evidence based on the
amino acid sequence of DDX10 that it may have activity as a transcriptional
activator, but there is currently no in vivo or in vitro data to back this up (Arai et
al., 1997).  LEDGF, lens epithelium-derived growth factor, and p52, which is
coded by an alternatively spliced RNA from the same gene, are both found in
translocations with NUP98 in AML as well.  The C termini of p52 and LEDGF
both contain highly charged regions of amino acids, which are included in the
fusion product (Ahuja et al., 2000b).  Both p52 and LEDGF are reported to be
transcriptional coactivators and in addition LEDGF functions as a survival factor
(Ahuja et al., 2000b; Shinohara et al., 2002).  NSD1 and NSD3 are members of
a family of proteins whose function has not been determined, but which contain
domains that are found in development- and chromatin reorganization-
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associated proteins (Arai et al., 1997).  In addition, studies have shown NSD1 to
possess both activation and repression domains (Huang et al., 1998).
Haploinsufficiency for NSD1 in humans has been linked to Sotos syndrome, a
disease that is typified by large body size early in life and mental retardation
(Kurotaki et al., 2002).  NSD3 has been found to be overexpressed in breast
cancer cell lines and the third member of the family, NSD2, which has not been
found in a translocation with NUP98, is associated with multiple myeloma
(Angrand et al., 2001).  RAP1GDS1, which has been found in an acute
lymphoblastic leukemia-associated translocation with NUP98, codes for
SmgGDS, a guanine nucleotide exchange factor, which regulates the interaction
of GDP and GTP with GTPases (Cimino et al., 2001; Hussey et al., 1999; Vikis
et al., 2002).   Whether SmgGDS might interact with Ran in nuclear transport
has not been shown (Hussey et al., 1999).  The entire coding region of
RAP1GDS1, except for the initial methionine is included in the fusion with
NUP98, including a large region of armadillo repeats that may mediate protein-
protein interactions (Hussey et al., 1999). The NUP98-TOP1 fusion transcript
has been found in a number of therapy-related AML and MDS cases.
Topoisomerases act to separate the two strands of DNA and all of the domains
needed for this function appear to be retained in the NUP98 fusion (Ahuja et al.,
1999; Panagopoulos et al., 2002; Pommier, 1998).  Analysis of the breakpoints
of some of the NUP98-TOP1 fusions, combined with the therapy-related nature
of the disease, has led to the view that treatment with topoisomerase inhibitors
plays an important role in the generation of this chromosomal translocation
(Ahuja et al., 2000a).
Besides NUP98, one other nucleoporin, NUP214 (CAN), has been found to be
involved in leukemia-associated chromosomal translocations.  NUP214 is
located at the cytoplasmic face of the NPC, and has been implicated in protein
import and RNA export (Kraemer et al., 1994; van Deursen et al., 1996).
NUP214 is also a member of the family of FG repeat-containing nucleoporins
and both FG and FXFG repeats are found in its C terminus (Kraemer et al.,
1994). Chromosomal translocations have been found that fuse NUP214 to DEK
in AML and to SET in acute undifferentiated leukemia (von Lindern et al., 1992a;
von Lindern et al., 1992b).  In both cases, the FG-repeat containing C terminus
of NUP214 is fused to the N-terminus of DEK or SET and the resulting fusion
proteins localize to the nucleus (Fornerod et al., 1995; von Lindern et al., 1992a;
von Lindern et al., 1992b).  DEK is a chromatin-associated protein that induces
positive supercoiling in DNA and has also been found to bind RNA (Fornerod et
al., 1995; Kappes et al., 2001; McGarvey et al., 2000; Waldmann et al., 2002).
SET has been reported to have functions in chromatin remodeling, as well as
cell cycle regulation and has recently been shown to act as a transcription factor
(Compagnone et al., 2000; Zhang et al., 2001).
The involvement of FG repeat-containing nucleoporins in so many different
leukemia-associated fusion proteins is very suggestive.  The importance of the
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FG repeats in the binding of transport factors could indicate that the contribution
of these nucleoporins to the leukemogenic process primarily involves a
dysregulation of transport.  Our work, however; indicates that the contribution of
NUP98 to these leukemia-associated fusion proteins represents a gain of
function caused by aberrant localization within the nucleus that allows the
interaction of the FG repeats with the transcriptional co-activators, CBP and
p300.  This interaction, which we show to confer increased transactivation
potential, may be critical in causing dysregulation of transcription that could lead
to leukemogenesis.
2.3 CBP and p300
CBP and p300 are transcriptional coactivators with a high degree of similarity
that have been shown to interact with numerous transcription factors, including
many that have been implicated in hematopoiesis. In this section I will discuss
the normal functions of p300 and CBP, the effect of the loss of one or both
alleles of CBP or p300 in mice and humans and briefly describe some of the
transcription factors that are known to interact with p300 and CBP.  I will also
review the evidence for the participation of CBP and p300 in leukemic fusion
proteins.
p300 and CBP function as transcriptional coactivators.
CBP and p300 carry out their functions as transcriptional coactivators in at least
two distinct ways.  First, CBP and p300 are believed to act as adaptor molecules
that facilitate the interaction between transcription factors and the basal
transcription machinery.  CBP and p300 have been shown to interact or
colocalize with several components of the basal transcription machinery
including RNA Polymerase II (Pol II), Transcription Factor II B (TFIIB) and TATA
Binding Protein (TBP) (Blobel, 2002).  In addition, E1A, a viral protein that acts
as an inhibitor of p300 and CBP coactivator functions, has been suggested to
produce this inhibitory effect by competing with Pol II and TFIIB for binding to
CBP and p300 (Goodman and Smolik, 2000).
A second way in which p300 and CBP are thought to function as coactivators is
through their protein acetyltransferase activity.  Acetylation of histones opens up
the chromatin structure and is usually linked to transcriptional activation.  CBP
and p300 have been shown to acetylate all four core histones in vitro (Blobel,
2002; Chan and La Thangue, 2001).  In addition, transcription factors and other
nuclear proteins have also been shown to be acetylated by CBP and p300.
Acetylation of some transcription factors has been shown to increase their ability
to bind DNA or stabilize their interaction with p300 and CBP (Blobel, 2002; Chan
and La Thangue, 2001).
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There is also increasing evidence that p300 and CBP may act as scaffolds for
the assembly of transcriptional complexes (Chan and La Thangue, 2001; Giles
et al., 1998).  By recruiting multiple transcription factors and other transcriptional
activators such as acetyltransferases to the basal transcription machinery, p300
and CBP not only facilitate transcription, but also may influence which genes are
expressed.  This influence could be exerted through competition between
transcription factors for binding to CBP and p300 or through the cooperative
interaction of transcription factors that are bound to p300 and CBP.
p300 and CBP are required for normal embryo development.
Homozygous null mutations in either p300 or CBP result in similar embryonic
lethal phenotypes.  Mice lacking p300 die between embryonic days 9 and 11.5
and analysis of the embryos showed that they were smaller than their wild type
littermates and had defects in neural tube closure and heart development (Yao
et al., 1998).  Mice nullizygous for CBP or homozygous for a truncated CBP
protein both died at a similar embryonic stage to the p300 knockouts and also
displayed neurulation defects. In addition, some traits in common with human
Rubinstein-Taybi syndrome (RTS), such as skeletal abnormalities were found,
and defective blood vessel formation and hematopoiesis were also noted (Oike
et al., 1999a; Oike et al., 1999b; Tanaka et al., 2000).  The CBP nullizygous
embryos appeared pale, and colony-forming assays using cells from yolk sacs
or embryos produced reduced numbers of colonies compared to wild-type
controls (Tanaka et al., 2000).  It is unknown whether the p300 knockout
embryos possess a similar hematopoietic defect.  Mice compound heterozygous
for both p300 and CBP null mutations died during embryogenesis and analysis
of the embryos showed that they were smaller than their wild type littermates
and exhibited neural tube closure defects similar to the homozygous mutants
(Yao et al., 1998).
Heterozygous mutations in p300 or CBP lead to distinct phenotypes.
The comparability of the phenotypes of the homozygous knockouts of p300 and
CBP, as well as the compound heterozygous knockout, indicate that p300 and
CBP must have many redundant functions as would be predicted by the
similarity of the proteins.  However, studies of animals heterozygous for CBP or
p300 have revealed some phenotypic differences.  Although both p300 and CBP
heterozygous mice are born at below the expected Mendelian frequencies,
implying that they both possess abnormalities, long term study of mice
heterozygous for CBP has revealed an increase in hematologic diseases
including leukemia, plasmacytoma, and histiocytic sarcoma in CBP, which are
not observed in aged p300 heterozygotes (Kung et al., 2000; Tanaka et al.,
2000; Yao et al., 1998).  In some cases these diseases were accompanied by a
loss of heterozygosity.  Further studies of CBP and p300 heterozygotes utilizing
serial transplantation of bone marrow indicate that cells from CBP heterozygotes
have a reduced ability to contribute to hematopoiesis compared to p300
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heterozygous or wild-type cells (Rebel et al., 2002).  Studies of chimeric mice
derived from ES cells null for either p300 or CBP confirmed this result and gave
additional evidence for different roles of p300 and CBP in hematopoiesis (Rebel
et al., 2002).  Analysis of these chimeric mice showed that neither the p300-/- nor
the CBP-/- cells made major contributions to the peripheral blood in the chimeric
animals, although transplantation assays showed that p300-/- cells, but not CBP-/-
cells could reconstitute the bone marrow in recipient mice.  In vitro experiments
using null ES cells showed that CBP, but not p300 null ES cells could
differentiate into hematopoietic cells.  Taken together, these results seem to
indicate that CBP has a more critical role than p300 in hematopoietic stem cell
renewal, while in the differentiation of hematopoietic cells, the reverse seems to
be true (Rebel et al., 2002).
In humans, loss of one allele of p300 or CBP also results in distinct phenotypes.
Loss of a single allele of CBP results in RTS, a disease characterized by mental
retardation and skeletal abnormalities (Petrij et al., 1995). RTS patients have
also been found to have a high incidence of certain types of tumors (Miller and
Rubinstein, 1995).  No hereditary human disease has been found that is linked
to loss of a single p300 allele; however, inactivating mutations of p300, often
accompanied by loss of heterozygosity, have been reported in human breast,
colorectal, gastric and pancreatic tumors and cancer cell lines (Gayther et al.,
2000; Muraoka et al., 1996).  Inactivating mutations in CBP have been reported
in human cancers cell lines, but not in primary tumors (Ozdag et al., 2002).
Transcription factors bind to CBP and p300 via at least five main protein
interaction domains.
CBP and p300 each have at least five distinct protein-interaction domains, which
are highly conserved between the two proteins and through evolution. The most
N-terminal of these domains is the RID (receptor interaction domain) domain,
which has been found to bind a variety of nuclear receptors.  p300 and CBP also
possess three cysteine-histidine rich domains; two of which, CH1 and CH3,
contain zinc fingers and have been found to bind numerous transcription factors.
The KIX domain interacts with cyclic AMP response element (CRE) binding
protein (CREB) and c-Myb, among other transcription factors, and its structure
has been solved in complex with the phosphorylated kinase inducible domain
(KID) of CREB and shown to contain three helices, which provide critical
contacts with CREB (Parker et al., 1998; Parker et al., 1999; Radhakrishnan et
al., 1997).  The most C-terminal protein-binding domain is the Interferon
regulatory factor-3 binding domain (IbiD) that is in a glutamine rich region of
p300 and CBP (Lin et al., 2001). It is likely that at least some aspects of the
phenotypes associated with the loss of p300 or CBP may be attributed to
transcription factors that normally bind to p300 and CBP through these domains.
Loss of p300 or CBP may affect the ability of these transcription factors to
induce expression of their target genes; therefore, the phenotypes associated
with knockouts of CBP- and p300-binding transcription factors may have some
35
similarities to the phenotypes of CBP and p300 mutants. Of special interest in
our study were the phenotypes of mice with mutations in transcription factors
that have been shown to bind to the KIX domain of CBP and p300, in particular
CREB and c-Myb.
Figure 3.  Domains of p300 and CBP.  Abbreviations used: RID, receptor interaction
domain; CH1,2 and 3, cysteine/histidine-rich domains; Br, Bromo domain; IbiD, IRF3-
binding domain; HAT, histone acetyltransferase.
 p300 and CBP bind to transcription factors implicated in hematopoiesis.
CREB is a transcription factor that activates its target genes by binding to a CRE
near the promoter in response to an increase in intracellular cyclic AMP.  CREB
binds to p300 and CBP in a phosphorylation-dependent manner, and has been
shown to be involved in glucose regulation, cell survival and memory (Mayr and
Montminy, 2001). In addition, CREs have been found in several T-cell genes
and CREB knockout mice have been shown to have T-cell defects (Barton et al.,
1996; Rudolph et al., 1998).  CREB nullizygous mice are smaller than their wild-
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type littermates and die immediately after birth from respiratory problems, but
analysis of embryos revealed that in addition to brain defects, they possess
reduced numbers of fetal thymocytes and a severely diminished αβ T-cell
lineage, although the γδ T-cell lineage is unaffected (Rudolph et al., 1998).  It is
possible that the severity of the CREB phenotype may be attenuated by the
upregulation of other CREB gene family members, such as CREM and ATF-1
(Mayr and Montminy, 2001).
c-Myb is a transcription factor that is expressed in hematopoietic precursors
including the HSC, CLP and CMP (Akashi et al., 2000b).  Mice lacking c-Myb die
from anemia at approximately embryonic day 15 and further evaluation of the
fetal livers of c-Myb nullizygous embryos has shown that they are severely
deficient in all hematopoietic lineages except megakaryocytes, which are less
severely affected (Mucenski et al., 1991; Sumner et al., 2000).  Studies of
chimeric mice derived from c-Myb-/- ES cells showed that c-Myb-/- ES cells do not
contribute to any mature definitive (hematopoiesis occurring in the fetal liver or
adult bone marrow) hematopoietic lineages and that while cells derived from the
c-Myb-/- ES cells populate the fetal liver they do not proliferate (Sumner et al.,
2000).  The authors of this study theorize that the megakaryocytes seen in the
fetal liver are just the remaining cells derived from primitive (occurring in the yolk
sac) hematopoiesis, not derived from definitive hematopoietic precursors, which
might also explain the mature phenotype of the megakaryocytes.
Evidence exists that the interaction of certain transcription factors with other
transcription factors may be influenced by the presence of CBP or p300 as a
binding partner.  CBP has been shown to increase the cooperative interaction
between Myb and C/EBPβ in vitro  (Mink et al., 1997).  In this case, an inability
of Myb to interact with p300 or CBP might cause a decrease in activity of
C/EBPβ.  By contrast, c-Myb and GATA-1 have been shown to compete for CBP
binding, even though they bind to different CBP domains, and this competition
has been shown to contribute to their mutual inhibition of transcriptional activity
(Takahashi et al., 2000).  In this situation, loss of interaction between CBP or
p300 and c-Myb could result in more CBP or p300 being available to interact
with GATA-1, which could result in an increase in transcription of GATA-1 target
genes.  The possibility of other such p300/CBP-mediated transcription factor
interactions makes a brief summary of the phenotypes associated with other
hematopoietic transcription factors that interact with CBP and p300 relevant to
this thesis (Table 2).
p300 and CBP are partners in several leukemic fusion proteins.
p300 and CBP have been found to be involved in several rare AML-associated
chromosomal translocations.  These translocations are frequently found in
leukemias that develop after treatment of prior disease, although de novo cases
have also been reported.
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Both p300 and CBP are found in fusions with MLL, a gene that is involved in a
number of chromosomal translocations.  MLL is a homolog of the Drosophila
gene, trithorax, which regulates the expression of HOX genes and thus plays a
role in embryonic patterning (Yu et al., 1998). In addition to a multi-lineage
defect in primitive hematopoiesis, embryos nullizygous for MLL display loss of
HOX gene expression, while mice heterozygous for MLL display disrupted HOX
gene expression in addition to growth abnormalities (Hess et al., 1997; Yu et al.,
1995).  Translocations between MLL and CBP or p300 are found in therapy
related cases of AML, and in all of them the N-terminus of MLL, including a DNA
binding domain, a methylation domain and a transcriptional repression domain is
joined to the C-terminus of p300 or CBP.  In the MLL-p300 fusion, the p300
portion of the fusion includes a region just N-terminal of the HAT domain through
the C-terminus (Ida et al., 1997).  In the case of the MLL-CBP fusion, two
different fusions have been detected, the most common of which fuses MLL to
almost the entirety of CBP, and a rare fusion which includes a similar portion of
CBP as that seen in the p300-MLL fusion (Lavau et al., 2000; Sugita et al.,
2000).  In at least some cases, the RNA transcripts of the reciprocal fusions are
also detected, making it unclear which is responsible for the leukemogenic
phenotype; however, transplant experiments in mice using bone marrow
transduced with an MLL-CBP fusion caused a long myeloproliferative phase,
followed by AML in all of the recipient mice (Lavau et al., 2000).  This result
indicates that at least the MLL-CBP and MLL-p300 fusion proteins probably
possess leukemogenic properties.
CBP and p300 are also found in translocations with MOZ, and CBP has been
found in a translocation with a related gene, MORF.  MOZ and MORF are
putative histone acetyltransferases and are homologous to SAS2, which is
involved in transcriptional silencing in yeast  (Borrow et al., 1996; Panagopoulos
et al., 2001; Roth, 1996).  The fusions that join the putative acetyltransferase
domain containing N-terminus of MOZ or MORF to CBP or p300 have been
found to include almost the entire coding sequence of CBP or p300 (Borrow et
al., 1996; Kitabayashi et al., 2001; Panagopoulos et al., 2001).  The reciprocal
fusions, which are sometimes detected as RNA transcripts, would possibly place
the C-terminus of MOZ or MORF under the control of the p300 or CBP
promoter, but would contain very little coding sequence from p300 or CBP.
The contributions of p300 and CBP to the leukemogenic properties of these
fusion proteins have not been fully determined.  Colony assays performed using
myeloid precursors transduced with MLL-CBP fusions containing different
domains of CBP showed that the bromo and HAT domains of CBP fused to the
N terminus of MLL are sufficient for transformation, suggesting that chromatin
remodeling properties contributed by CBP are important for the leukemogenic
potential of the MLL-CBP fusion protein (Lavau et al., 2000). In addition to the
HAT domain, the CH3 domain of CBP or p300 is present in all of the leukemia-
associated fusion proteins found to date. It is possible that in some of the fusion
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proteins, the CH3 domain could be important for allowing interaction with the
basal transcription machinery.  Further study will be necessary to determine the
actual causes of the leukemogenesis associated with these fusion proteins.
Conclusions
Transcriptional control of gene expression is one of the primary means by which
hematopoiesis is regulated and loss or gain of transcriptional activity can
severely disrupt this process.  This is seen in the case of gene knockout
experiments in mice, in which loss of expression of hematopoietic transcription
factors can cause a disruption in hematopoietic cell numbers, the loss of a
specific hematopoietic cell lineage, or even a complete ablation of
hematopoiesis.  In addition, loss or reduction of factors which assist in
transcription, such as the transcriptional coactivators p300 and CBP, can lead to
hematopoietic specific defects in spite of the wide expression of these proteins.
Finally, mutations such as chromosomal translocations, can lead to a gain of
transcriptional activity.  This may be caused by the loss of a repressive domain
or the gain of a domain that leads to an increase in activity for an already
transcriptionally active fusion partner such as a transcription factor, as is
probably the case for the p300-MLL and CBP-MLL fusions, or it may involve a
gain of a completely novel transcriptional function for an existing domain, as
seems to be the case for the FG-repeat containing domains of nucleoporins
NUP98 and NUP214.  This inappropriate increase in transcription is likely to be
a major cause of some leukemias.
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Genes encoding the Phe-Gly (FG) repeat-containing nucleoporins NUP98 and CAN/NUP214 are at the break-
points of several chromosomal translocations associated with human acute myeloid leukemia (AML), but their
role in oncogenesis is unclear. Here we demonstrate that the NUP98-HOXA9 fusion gene encodes two nuclear
oncoproteins with either 19 or 37 NUP98 FG repeats fused to the DNA binding and PBX heterodimerization
domains of the transcription factor HOXA9. Both NUP98-HOXA9 chimeras transformed NIH 3T3 ﬁbroblasts,
and this transformation required the HOXA9 domains for DNA binding and PBX interaction. Surprisingly, the
FG repeats acted as very potent transactivators of gene transcription. This NUP98-derived activity is essential
for transformation and can be replaced by the bona ﬁde transactivation domain of VP16. Interestingly, FG
repeat-containing segments derived from the nucleoporins NUP153 and CAN/NUP214 functioned similarly to
those from NUP98. We further demonstrate that transactivation by FG repeat-rich segments of NUP98
correlates with their ability to interact functionally and physically with the transcriptional coactivators CREB
binding protein (CBP) and p300. This ﬁnding shows, for the ﬁrst time, that a translocation-generated fusion
protein appears to recruit CBP/p300 as an important step of its oncogenic mechanism. Together, our results
suggest that NUP98-HOXA9 chimeras are aberrant transcription factors that deregulate HOX-responsive
genes through the transcriptional activation properties of nucleoporin-speciﬁc FG repeats that recruit CBP/
p300. Indeed, FG repeat-mediated transactivation may be a shared pathogenic function of nucleoporins im-
plicated human AML.
An expanding subgroup of chromosomal translocation-gen-
erated oncoproteins in human acute myeloid leukemias (AML)
involve the FG repeat-containing nuclear pore complex (NPC)
proteins NUP98 (39) and CAN/NUP214 (13, 22). The NUP98
gene is found at the breakpoints of two distinct chromosomal
rearrangements: t(7;11)(p15;p15) (7, 18, 33), and inv(11)(p15;
q22) (2), which link NUP98 to the class I homeotic transcrip-
tion factor HOXA9 and the putative RNA helicase DDX10,
respectively. In each rearrangement, the chromosomal break-
points are located within two ﬂanking introns of the NUP98
gene that separate the FG repeat-rich N terminus of NUP98
from its C terminus, which contains a ribonucleoprotein
(RNP)-binding motif (39). Although each translocation gener-
ates two reciprocal chimeric products, only those driven by the
NUP98 promoter and containing the FG repeat region are
predicted to mediate leukemogenesis (2, 7, 33). Another
nucleoporin gene, CAN/NUP214, is found at the breakpoint
of two independent chromosomal rearrangements: t(6;
9)(p23;q34), which fuses CAN/NUP214 to DEK (49), and
inv(9;9)(q34;q34), which links it to SET (50). The leukemia-
speciﬁc transcripts, DEK-CAN/NUP214 and SET-CAN/
NUP214, both encode nuclear fusion proteins. The proteins
contain identical C-terminal portions of CAN/NUP214, in-
cluding its FG repeat-rich region, and a coiled-coil domain
(13, 22). DEK and SET are both nuclear proteins that have no
sequence similarity other than the presence of acidic motifs
that may participate in DNA binding (13, 14, 31).
The involvement of two FG repeat-containing nucleoporins
in multiple translocations associated with human leukemia
raises intriguing questions about their role in leukemogenesis.
In particular, the consistent presence of FG repeat regions
suggests that such domains could serve a common function in
the transformation of hematopoietic cells. Many of the known
components of the NPC have regions rich in FXFG, GLFG
and/or FG repeats (amino acids are given in single-letter code,
with X indicating any amino acid). Such repeats (called FG for
simplicity) are presumed contact sites for soluble nucleocyto-
plasmic transport factors carrying different kinds of cargo;
however, their precise functions in vivo remain to be deter-
mined (35, 36).
HOXA9, expressed in both the primitive pluripotent precur-
sors and the myeloid progenitors of human bone marrow
(42), is the only nucleoporin fusion partner with an estab-
lished physiological role in hematopoietic development. HOXA9
knockout mice have multiple hematopoietic defects, including
reduced numbers of peripheral blood granulocytes and lym-
phocytes, as well as myeloid and pre-B-cell progenitors, and
their spleens and thymuses are smaller than normal (25). Be-
sides its involvement in t(7;11)-mediated myeloid leukemogen-
esis, HOXA9 has been implicated in the formation of myeloid
leukemias in the BXH-2 strain of mice (29). BXH-2 mice carry
an endogenous murine leukemia virus that acts as a viral mu-
tagen predisposing the animals to myeloid malignancies (4, 5).
In this experimental tumor model, about 3% of all leukemias
in BXH-2 mice display proviral activation of HOXA9 (34).
Constitutive expression of HOXA9 alone is not sufﬁcient for
efﬁcient transformation of murine hematopoietic cells; it re-
quires coexpression of MEIS1 (23, 34), a PBX1-related diver-
* Corresponding author. Present address: Mayo Clinic, 200 First St.
SW, Rochester, MN 55905. Phone: (507) 266-4598. Fax: (507) 266-
5201.
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gent homeodomain-containing protein that cooperatively binds
DNA with HOXA9 in vitro (44).
In this study, we show that the t(7;11)-derived fusion gene
generates two chimeric proteins via alternative splicing within
NUP98. Investigation of the structural and functional regions
of the chimeric NUP98-HOXA9 proteins demonstrated that
HOXA9-mediated DNA binding and interaction with PBX are
essential for transformation of NIH 3T3 ﬁbroblasts. In both
chimeras, the NUP98 portions contained very potent transcrip-
tion activation domains, which replace a strong transcriptional
repressor domain within the amino-terminal half HOXA9. In-
terestingly, the transcriptional coactivators CREB binding pro-
tein (CBP) and potentially p300 interacted and functionally
cooperated with the NUP98 FG-repeat-rich portions. Abbro-
gation of NUP98-HOXA9-mediated transformation cor-
responded to the loss of NUP98-mediated transcriptional
activity and CBP binding. Thus, NUP98-HOXA9 seems to
recruit CBP/p300 as part of its oncogenic mechanism. Because
CBP and p300 are coactivators for a number of gene-speciﬁc
transcription factors, they could also be critical accessory fac-
tors for other fusion proteins that deregulate transcription.
MATERIALS AND METHODS
RT-PCR. First-strand cDNA was synthesized from 1 g of total RNA with
avian myeloblastosis virus reverse transcriptase (Promega) and primer p1 or p4
in a total volume of 20 l. The mixtures were incubated 1.5 h at 42°C. Reverse
transcription RT mixture was used at 2 l per PCR (total volume, 50 l). The
PCR primer combinations were as indicated in Fig. 1A (p1, 5-GGCTGTCGT
AGTATTAAATCCAGGGG-3; p2, 5-GATTATCAGGCTAACAGGAAGG
GC-3; p3, 5-CCACAACTGGCTTGTTTGGGTC-3; p4, 5-CGTGAAGCCA
GTTGGCTG-3). The PCRs were performed with AmpliTaq Gold (Perkin-
Elmer Cetus) in buffer supplied by the manufacturer and supplemented with 2.5
mMMgCl2. The PCR cycles were 30 s at 94°C, 1 min at 50°C, and 3 min at 72°C.
Expression constructs and mutagenesis. All cDNA fragments were initially
cloned in pTZ19 containing the synthetic sequence GAATTCGCCGCCACCA
TGTATGACGTCCCAGATTACGCAAGTTTGCCCGGGTATGATTTCCTGA
TTATGCTAGC derived from pHA1triple-tag#10 (13). This sequence contained
a 5 Kozak consensus motif, sequences encoding two consecutive inﬂuenza virus
HA1 epitopes (51) (indicated in italics), and a 3 NheI site. NUP98b cDNA was
isolated from a gt10 human bone marrow (BM) cDNA library (no. HL1168a;
Clontech, Palo Alto, Calif.). Full-length NUP98a cDNA was reconstructed from
NUP98b cDNA and sequences encoding amino acids 254 to 444 obtained from
a partial NUP98a cDNA clone that was isolated from a human placental library
(Hu2002B#29203). A cDNA encoding the HOXA9 portion of the t(7;11)-gen-
erated fusion protein was produced by PCR ampliﬁcation of DNA extracted
from our gt10 human BM cDNA library. cDNA clones encoding NUP98a-
HOXA9 and NUP98b-HOXA9 were created from HOXA9, NUP98a, and
NUP98b cDNA constructs by overlap extension PCR. A cDNA encoding the
NUP98b portion of NUP98b-HOXA9 was generated by insertion of an oligo-
nucleotide in the NUP98b cDNA so that codon 469 is followed by a stop codon.
NUP98b-HOXA9(FIKI) cDNA was generated from NUP98b-HOXA9 by insert-
ing the oligonucleotide TTTATAAAGATC between codons 47 and 48 of the
homeodomain. NUP98a-HOXA9(W6A) cDNA was obtained by standard PCR-
based site-directed mutagenesis. NUP98a(51–223)-HOXA9 and NUP98b(51–
223)-HOXA9 mutants were constructed by deleting a 819-bp StuI-KpnI fragment
from NUP98a-HOXA9 and NUP98b-NUP98b cDNA, respectively. To generate
FIG. 1. NUP98 and NUP98-HOXA9 genes generate an alternatively spliced transcript in human BM cells. (A) Overview of the RT-PCR procedure with
representations of relevant NUP98-HOXA9 cDNA portions and the expected PCR products. The positions of the primers used in the various RT reactions and PCRs
are indicated by horizontal bars. To detect NUP98a and NUP98b transcripts in normal BM cells, we used primer 1 (p1) to generate cDNA and primer set p1 and p2
for PCR ampliﬁcation (40 cycles). Seminested PCR was used to detect NUP98-HOXA9-speciﬁc transcripts in BM cells from a patient with t(7;11)-positive leukemia;
p4 was used for the RT step, p2 and p4 were used in the ﬁrst round of ampliﬁcation (40 cycles), and p1 and p2 were used in the seminested round of PCR (30 additional
cycles). The oligonucleotide probe for detection of NUP98a- and NUP98b-derived PCR fragments is depicted as p3. (B) Autoradiogram of RT-PCR products detected
by probe p3. Lanes: 1, 754- and 181-bp fragments from NUP98a and NUP98b transcripts in normal human BM; 2, negative control for lane 1 (same sample as in lane
1 but without reverse transcriptase); 3, 754- and 181-bp fragments from NUP98a-HOXA9 and NUP98b-HOXA9 transcripts in BM from a patient with t(7;11)-positive
leukemia; 4, negative control for lane 3. Since our RT-PCR technique was not quantitative, the intensities of the 181- and 754-bp PCR bands may not be correlated
with the actual transcript levels. Moreover, Northern blot analysis revealed that the BM RNA from the t(7;11) patient was partially degraded.
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NUP98b(51–469)-HOXA9, NUP98b(1–223)-HOXA9, CAN/NUP214(1864–
2090)-HOXA9, NUP153(1121–1479)-HOXA9, and VP16(413–490)-HOXA9
cDNAs, we cloned PCR-ampliﬁed NheI fragments containing the desired nu-
cleoporin and VP16 portions into the NheI site of our clone encoding the
HOXA9 portion of NUP98-HOXA9. For NUP98b(51–469)-HOXA9, we gen-
erated a 156-bp NheI fragment encoding the ﬁrst 50 amino acids of NUP98b,
which was PCR ampliﬁed from NUP98b cDNA. For NUP98b(1–223)-HOXA9,
we PCR ampliﬁed a 171-bp NheI fragment from NUP98b cDNA encoding amino
acids 224 to 253 and 445 to 469. For CAN/NUP214(1864–2090)-HOXA9, a 684-
bp NheI fragment encoding the last 226 amino acids of human CAN/NUP214
was generated by RT-PCR from BM RNA. For NUP153(1121–1479)-HOXA9, a
1,695-bp NheI fragment encoding the last 563 amino acids of human NUP153
was obtained by PCR ampliﬁcation from vector pHA1-NUP153 (3). For VP16
(413–490)-HOXA9 a 220-bp NheI fragment encoding amino acids 413 to 490 of
the herpes simplex virus type 1 VP16 protein was ampliﬁed from plasmid pCMX-
VP16 (12). All DNA fragments generated by PCR ampliﬁcation were sequenced.
pTZ19 cDNA fragments were cloned into pSRMSVtkCD8 (for transformation
studies), pSP64 or pSP73 (for in vitro transcription-translation purposes), and the
pUH10-3 derivative (16) termed pUHD10S (13) (for overexpression in HtTA
cells).
Retroviral stocks and transformation analysis. cDNA inserts were cloned into
the ClaI site of the ecotropic retroviral expression vector pSRMSVtkCD8 (17).
293T cells were cotransfected with various pSRMSVtkCD8 constructs and the
ecotropic packaging pSV-	E-MLV (30). Culture supernatants containing viral
particles were harvested at 6- to 10-h intervals from days 2 to 4 posttransfection,
ﬁltered (Acrodisc 13 syringe ﬁlter [pore size, 0.45 m]; Gelman Sciences, Ann
Arbor, Mich.), and supplemented with 6 g of Polybrene per ml. Low-passage-
number NIH 3T3 cells were seeded at low cell density and infected the next day
with virus at 8- to 12-h intervals for 48 h. Infected NIH 3T3 cells were harvested
24 to 72 h later and immunostained with anti-CD8 antibodies. CD8-positive cells
were then isolated by ﬂuorescence-activated cell sorting (17). To test for anchor-
age-independent growth, we suspended 2 
 104 CD8 NIH 3T3 cells in Iscove’s
medium supplemented with 15% fetal bovine serum and 0.3% soft agar and
plated this mixture in a 3-cm-diameter dish. The cells were then cultured at 37°C
under 8% CO2, and colonies were counted after 3 weeks. The cells were plated
in triplicate for each experiment, with total number of colonies reported as the
average of the counts from the three dishes. BM transformation assays were
performed as described previously (24).
Indirect immunoﬂuorescence. NIH 3T3 or HtTA cells were seeded on 12-well
microscope slides for at least 12 h, ﬁxed in 3% paraformaldehyde for 15 min on
ice, washed three times with phosphate-buffered saline (PBS), permeabilized in
PBS–0.2% Triton X-100 for 10 min, washed ﬁve times in PBS–2% nonfat milk
(Kroger Co., Cincinnati, Ohio), and incubated overnight with the ﬁrst antibodies.
Monoclonal antibody 12CA5 (Boehringer Mannheim) was incubated at 4 g per
ml in PBS–2% nonfat milk. Afﬁnity-puriﬁed anti-hNUP98 polyclonal antibodies
(raised in rabbits against NUP98 amino acids 51 to 223) were diluted 1:20, and
anti-hCRM1 antiserum (raised in rabbits against the peptide sequence EREI
ALRQADEEK) was diluted 1:1000. Primary antibodies were visualized with
ﬂuorescein isothiocyanate (Sigma)- or Texas red-conjugated goat anti-mouse or
goat anti-rabbit antibodies at 4 g per ml in PBS–2% nonfat milk. The cells were
examined by confocal laser-scanning microscopy.
Coimmunoprecipitations. Retrovirally transduced NIH 3T3 cells (7 
 106 to
8 
 106) expressing HA1-NUP98a-HOXA9, HA1-NUP98b-HOXA9, or the
HOXA9 portion of these fusion proteins (designated HA1-HOXA9[portion])
were washed three times with PBS and then incubated for 20 min in 10 ml of
short-term labeling medium (methionine-free Dulbecco’s modiﬁed Eagle’s me-
dium, 5% dialyzed fetal bovine serum) at 37°C to deplete the intracellular pools
of methionine. The cells were then incubated in 6.5 ml of short-term labeling
medium containing 0.18 mCi of [35S]methionine per ml and harvested 4 h later.
Four to ﬁve million HtTA cells (16) were transfected with 40 g of pUHD10S
vectors encoding HA1-NUP98a-HOXA9 or HA1-HOXA9[portion] (by using
Superfect transfection reagent [Qiagen]). At 40 h posttransfection, the cells were
metabolically labeled with [35S]methionine for 4 h as described above. Labeled
NIH 3T3 or HtTA cells were washed three times with ice-cold PBS and scraped
from the dishes and total-cell lysates were prepared in 1 ml of NP-40 lysis buffer
(1% Nonidet P-40 [NP-40], 50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 5 mM
EGTA, 5 mM EDTA, 15 mM MgCl2, 60 mM -glycerolphosphate, 1 mM
dithiothreitol, 0.1 mM Na3VO4, 0.1 mM NaF, 15 mM p-nitrophenylphosphate,
1.8 g of aprotinin per ml, 1 g of leupeptin per ml, 1 g of pepstatin per ml, 10
g of soybean trypsin inhibitor per ml, 0.1 mM benzamidine, and 1 mM phe-
nylmethylsulfonyl ﬂuoride). Lysates were kept on ice for 10 min, vortexed gently
at 2-min intervals, and centrifuged for 5 min at 14,000 
 g. The supernatants
wereﬁlteredthrougha0.45-m-pore-sizelow-protein-bindingsyringeﬁlter(Super-
Acrodisc; Gelman Sciences), and precleared in 100 l of protein A-sepharose
(50% slurry in NP-40 lysis buffer) for 1.5 h at 4°C. Primary immunoprecipitations
were performed by adding 50 l of Sepharose-coupled 12CA5 antibody (50%
slurry) or 50 l of protein A-Sepharose (50% slurry) preincubated with either 40
l of afﬁnity-puriﬁed NUP98 antiserum or 50 l of a CBP/p300 cocktail consist-
ing of equal parts of CBP (A-22), CBP (C-20), CBP (415), p300 (N-15), and p300
(C-20) antisera (purchased from Santa Cruz Biotechnology). Following a 3-h
rotation at 4°C, the pellets were washed ﬁve times in NP40 lysis buffer and
antigens were released by boiling for 2 min in 100 l of boiling buffer (20 mM
Tris-HCl [pH 8.0], 0.5% SDS, 1 mM dithiothreitol). After centrifugation, the
supernatants were collected and split into 20- and 80-l aliquots. The 20-l
aliquots were separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and electroblotted to a polyvinylidene diﬂuoride mem-
brane (MSI, Westboro, Mass.), and the amount of HA1-tagged protein was
assessed by Western blot analysis. The blots were blocked for 1 h in PBS–5%
nonfat milk and subsequently incubated with 1 g of 12CA5 antibody per ml in
PBS for 1 h. Bound antibodies were visualized with an ECL chemiluminescence
kit (Amersham Life Science Inc., Cleveland, Ohio). Washings between antibody
incubations were performed in PBS–0.05% Tween 20 (ﬁve washings for 10 min
each). The 80-l aliquots were diluted with 4 volumes of RIPA buffer (52) and
incubated overnight at 4°C with 50 l of protein A-Sepharose (50% slurry)
preincubated with 50 l of our CBP/p300 antiserum cocktail (see above). After
ﬁve washes with RIPA buffer, the beads were boiled in SDS-PAGE sample buffer
and the precipitated proteins were analyzed by SDS-PAGE and ﬂuorography.
Transactivation assays. GAL4 fusion proteins were tested for transcriptional
activation properties on the GAL4-responsive reporter construct G5B/pGL2.
This reporter was constructed by inserting a XhoI-SmaI fragment from G5BCAT
(27), containing ﬁve GAL4 DNA binding sites and the adenovirus E1b TATA
box, into pGL-2 (Promega Corp., Madison, Wis.) cut with HindIII (repaired with
Klenow polymerase) and XhoI. For transcriptional repression studies, we used a
GAL4-responsive reporter construct that contained ﬁve tandem copies of the
GAL4 DNA binding site upstream of the simian virus 40 (SV40) early promoter
(a kind gift from C. Abate-Shen). Blunt-ended cDNA fragments encoding rele-
vant portions of FG repeat-rich nucleoporins or HOXA9 were cloned into the
SmaI sites of either pM1 or pM2, such that in-frame fusions were created
between sequences encoding the GAL4 DNA binding domain and the FG
repeat-rich nucleoporin motifs or HOXA9 sequences. NIH 3T3 cells (2 
 104)
were seeded in 24-well dishes. The next day, cells in each 24-well dish were
cotransfected (with Superfect) with 0.66 g of GAL4 fusion protein expression
plasmid, 0.33 g of G5B/pGL2 reporter plasmid, 25 or 2.5 ng of CMV-E1A
vectors (where applicable), and 10 ng of pRL-CMV internal control plasmid
(Promega Corp.). The cells were harvested after about 16 h, and enzyme assays
were performed to assess reporter gene expression. Reporter gene-derived lu-
ciferase activity was normalized to Renilla luciferase derived from pRL-CMV.
Transfections and analyses with the GAL4-NUP and GAL4-HOXA9 fusion
constructs were performed in triplicate. To test for a potential effect of E1A on
GAL4-NUP98 protein levels, 0.5 
 106 NIH 3T3 cells were seeded in 10-cm
dishes. A day later, the cells were cotransfected with 15.8 g of GAL4 fusion
protein expression plasmid and 60 ng of CMV-E1A vectors [these DNA con-
centrations correspond to the 0.66 g of GAL4-NUP98(1–469) plasmid and 2.5
ng of CMV-E1A vector per 2 
 104 NIH 3T3 cells as used in our transactivation
assay]. At 24 h posttransfection, the cells were harvested and immunoprecipita-
tions and Western blot analysis with 12CA5 antibodies were performed as de-
scribed above.
For CBP potentiation experiments NIH 3T3 cells were cotransfected with 0.1
g of GAL4-NUP98b(1–469) or 0.5 g of GAL4-CREB(160–284), 0.25 g of
G5B/pGL2 reporter plasmid, 0, 0.2, or 0.6 g of RSV-CBP (or equimolar
amounts of empty Rous sarcoma virus [RSV] vector as a negative control), and
10 ng of pRL-TK internal control plasmid (Promega Corp.). Transactivation
assays in Ba/F3 cells were performed as previously described in detail (28). All
transfection experiments were done either in duplicate or in triplicate and re-
peated several times.
In vitro DNA binding assays. Proteins for electrophoretic mobility shift assays
(EMSAs) were produced in vitro from SP6 expression plasmids with a coupled
reticulocyte lysate system as previously described (11). To ensure that approxi-
mately equal amounts of each lysate were added to the DNA binding reaction
mixtures, proteins were synthesized in parallel in the presence of [35S]methi-
onine, subjected to SDS-PAGE, quantitated on a PhosphorImager (Molecular
Dynamics), and normalized for the number of methionine residues. DNA bind-
ing reactions were performed as previously described (11). Single-stranded oli-
gonucleotides were labeled with [-32P]ATP, annealed, puriﬁed, and used with
core sequences matching the consensus TGATTTAT.
RESULTS
The NUP98-HOXA9 fusion gene encodes two proteins. To
construct a NUP98-HOXA9 fusion cDNA encoding the pre-
dicted chimeric oncoprotein (7, 33), we ﬁrst isolated NUP98
cDNA clones from a human BM library. We identiﬁed two
independent cDNA clones containing the 5 and 3 ends of the
human NUP98 coding sequence (7); however, both cDNAs
lacked a segment that encodes amino acids 254 to 444 of the
NUP98 protein, including 18 FG repeats. We named this al-
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ternatively spliced product NUP98b. The full-length NUP98
cDNA, referred to as NUP98a, was reconstructed from partial
BM and placental cDNAs (see Fig. 2A). To conﬁrm expression
of both mRNA transcripts from the NUP98 locus, we analyzed
human BM RNA by RT-PCR (Fig. 1A). In this assay, NUP98a
and NUP98b RNAs should generate diagnostic PCR frag-
ments of 754 and 181 bp, respectively. Both ampliﬁcation
products were obtained (Fig. 1B, lane 1). Sequencing of the
fragments indicated that they indeed differed in the 573-bp
segment encoding amino acids 254 to 444 of the full-length
NUP98 protein (not shown).
We then adapted the above RT-PCR strategy to screen for
alternative NUP98-HOXA9 fusion transcripts. A nested RT-
PCR assay based on RNA from a patient with t(7;11)(p15;
p15)-positive acute myeloid leukemia (AML) yielded the ex-
pected ampliﬁcation products of 754 and 181 bp (Fig. 1B, lane
3). Subcloning and DNA sequence analysis of the fragments
revealed that they had originated from NUP98a-HOXA9 and
NUP98b-HOXA9 fusion transcripts (data not shown), indi-
cating that the leukemic cells express both chimeric iso-
forms.
FIG. 2. Structural and functional properties of NUP98-HOXA9 isoforms
and mutants. (A) Schematic representations of the NUP98 and NUP98-HOXA9
isoforms and mutants used in this study. Indicated NUP98 motifs include the
nucleoporin-speciﬁc FG repeats (each repeat is denoted by a vertical bar), the
NUP98 RNP-binding motif (solid box), and NUP153 and CAN/NUP214 se-
quences (indicated in grey). Numbers correspond to the amino acids of the
full-length NUP98 (7). Indicated in the HOXA9 portion of the fusion protein is
the homeodomain (HD). Numbers in italics correspond to the amino acids of the
full-length HOXA9 (44). (HA1) represents two consecutive HA1 epitopes rec-
ognized by monoclonal antibody 12CA5. (B) Summary of the subcellular local-
ization studies (N, nuclear localization; NE, nuclear envelope localization) of the
NUP98 and NUP98-HOXA9 isoforms and mutants. (C) Anchorage-indepen-
dent growth of NIH 3T3 cells expressing NUP98-HOXA9 isoforms and mutants.
The number of colonies (per 2 
 104 CD8 cells with a diameter of at least 90
to 100 m) was determined after 3 weeks of growth in soft agar. The values are
the means and standard deviations of 4 to 13 experiments (if more than 4
experiments were performed, the actual number of experiments is indicated in
the ﬁgure). (D) Soft agar dishes demonstrating efﬁcient colony formation by NIH
3T3 cells infected with NUP98b-HOXA9. In contrast, NIH 3T3 cells infected
with pSRMSVtkCD8 (empty vector) displayed only minimal anchorage-inde-
pendent growth.
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NUP98-HOXA9 chimeras are nuclear proteins that trans-
form NIH 3T3 ﬁbroblasts. Hemagglutinin (HA1) epitope-tagged
versions of cDNAs containing NUP98a, NUP98b, NUP98a-
HOXA9, NUP98b-HOXA9, and the separate NUP98b and
HOXA9 portions of NUP98b-HOXA9 (Fig. 2A) were cloned
into the pSRMSVtkCD8 retroviral vector (17) and expressed
in NIH 3T3 cells by retroviral gene transfer. To determine the
subcellular localization of the HA1-tagged proteins, NIH 3T3
ﬁbroblasts were immunostained with 12CA5 monoclonal an-
tibody against the HA1 epitope. HA1-NUP98a and HA1-
NUP98b both showed punctate staining of the nuclear rim
(Fig. 3A and B), typical of NPC-associated proteins (39). By
contrast, the HA1-NUP98a-HOXA9 and HA1-NUP98b-
HOXA9 chimeras were found located in the nuclei of NIH 3T3
cells (Fig. 3C and D). Typically, such nuclei displayed a very
ﬁne granular staining pattern whereas the nucleoli did not
stain at all. To determine whether the HA1-NUP98-HOXA9
chimeras also associate with NPCs, cells were double stained
for HA1 and CRM1, a transport factor localized mainly at the
nuclear envelope (NE). Our HA1-speciﬁc signals did not co-
localize with CRM1 signals at the NE, indicating that there is
no detectable localization of chimeric protein at the NE (data
not shown). Like the fusion proteins, the HOXA9 portion
without NUP98 showed nuclear localization but the staining
pattern was less granular (Fig. 3F). The NUP98b fragment
derived from the chimera was concentrated at the NE, al-
FIG. 3. NUP98-HOXA9 isoforms and engineered mutants are localized in the nucleus. NIH 3T3 cells were transduced with retroviral expression vectors and
immunostained with 12CA5 monoclonal antibodies that recognize the HA1 epitope encoded by the 5 end of the various cDNA constructs. (A) NUP98a; (B) NUP98b;
(C) NUP98a-HOXA9; (D) NUP98b-HOXA9; (E) NUP98b portion; (F) HOXA9 portion; (G) NUP98b-HOXA9(FIKI); (H) NUP98b-HOXA9(W6A); (I)
NUP98a(51–223)-HOXA9; (J) NUP98b(51–223)-HOXA9; (K) NUP98b(51–4693)-HOXA9; (L) NUP98a(1–223)-HOXA9; (M) CAN/NUP214(1864–2090)-
HOXA9; (N) NUP153(1121–1479)-HOXA9; (O) VP16(413–490)-HOXA9; (P) empty pSRMSVtkCD8 vector (negative control).
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though a substantial proportion of this truncated protein was
found in the nucleus, even at low to moderate levels of expres-
sion (Fig. 3E). In all cases, protein expression was conﬁrmed by
performing immunoprecipitations with anti-HA1 monoclonal
antibodies on lysates of metabolically labeled cells (data not
shown).
To determine the oncogenic potential of the NUP98-
HOXA9 proteins, we used an NIH 3T3 ﬁbroblast transfor-
mation assay. This assay is commonly used in the ﬁeld for
structure-function studies on leukemia oncoproteins, and the
results with ﬁbroblasts are generally in agreement with those
of other transformation assays. NIH 3T3 ﬁbroblasts express-
ing NUP98a-HOXA9 or NUP98b-HOXA9 formed colonies
efﬁciently in soft agar (Fig. 2C and D), indicative of cellu-
lar transformation. By contrast, NIH 3T3 ﬁbroblasts over-
expressing NUP98a, NUP98b, or the NUP98b or HOXA9
portions of the chimeric constructs, did not form colonies
above background levels observed with NIH 3T3 cells in-
fected with retroviral stocks prepared from the empty vector
pSRMSVtkCD8 (Fig. 2C and D). These results indicate that
the in vitro cellular oncogenicity of the NUP98-HOXA9 pro-
teins requires both the C-terminal HOXA9 sequences and the
N-terminal region of NUP98 containing the nucleoporin-spe-
ciﬁc FG repeats.
NUP98-HOXA9-mediated transformation depends on its
ability to bind DNA and heterodimerize with PBX. The nuclear
localization of NUP98-HOXA9 proteins suggested that DNA
binding activity might be important for their oncogenic po-
tential. The HOXA9 portion contained within the NUP98-
HOXA9 oncoprotein has two distinct regions implicated in
DNA binding: (i) the homeodomain and (ii) a short trypto-
phan-containing motif required for binding to the PBX tran-
scriptional cofactors. This motif is located immediately N-ter-
minal of the homeodomain. HOX-PBX heterodimers have
increased DNA binding afﬁnity and speciﬁcity, allowing selec-
tive recognition and activation of genes containing HOX re-
sponse elements (9–11, 26, 37, 38, 40, 47, 48). We determined
the in vitro DNA binding activity of the NUP98-HOXA9 on-
coproteins by EMSAs. Because the consensus DNA binding
site for HOXA9 is unknown, we selected the PBX1-HOXA10
consensus DNA binding sequence as a target for interaction
with the HOXA9 homeodomain. This consensus sequence has
a TTAT core motif, preferentially recognized by homeobox
proteins of the Abd-B-like gene family, including HOXA9 (6,
45). DNA binding of in vitro-synthesized HOXA9, NUP98-
HOXA9 isoforms, or their truncated derivatives to the PBX1-
HOXA10 bipartite probe was determined in the presence or
absence of in vitro-translated PBX1a protein. Both full-length
HOXA9 and the HOXA9 portion of NUP98-HOXA9 bound
the DNA target alone, while addition of PBX1a to the binding-
reaction mixtures increased their activities (Fig. 4A, com-
pare lane 2 with lane 3 and lane 8 with lane 9). Both NUP98-
HOXA9 chimeras displayed cooperative DNA binding with
PBX1a; however, the DNA binding of PBX1a/NUP98b-
HOXA9 heterodimers to the consensus site was considerably
greater than that of PBX1a/NUP98a-HOXA9 dimeric com-
plexes (compare lanes 4 and 5 with lanes 6 and 7). As expected,
the NUP98b portion failed to demonstrate any activity by itself
(lanes 10 and 11). To show formation of PBX/NUP98-HOXA9
heterodimers in vivo, we prepared lysates from NIH 3T3 cells
expressing HA1-NUP98b-HOXA9 and performed EMSAs
with HOXA10 and PBX1-HOXA10 probes. Typically, a slow-
er-migrating complex was formed with the PBX1-HOXA10
probe than with the HOXA10 consensus probe (Fig. 4D, com-
pare lanes 1 and 5), indicative for the formation of PBX/
NUP98b-HOXA9 heterodimers in vivo (Fig. 4D).
To conﬁrm that NUP98-HOXA9 requires an intact homeo-
domain as well as a functional N-terminal PBX-interaction
motif for binding to the bipartite DNA probe, we constructed
two NUP98b-HOXA9 mutants. In one [NUP98b-HOXA9
(FIKI) (Fig. 2A)], the oligopeptide FIKI was inserted in the
third helix of the HOXA9 homeodomain, while in the other
[NUP98b-HOXA9(W6A) (Fig. 2A)], the conserved trypto-
phan in the PBX-interaction motif was replaced with an ala-
nine. The NUP98b-HOXA9(FIKI) mutant completely failed
to interact with the DNA probe (Fig. 4A, lanes 12 and 13). The
DNA-binding capacity of the NUP98b-HOXA9(W6A) mu-
tant was unaffected in the absence of PBX, but its cooperative
binding to the probe was severely impaired (compare lane 6
with lane 14 and lane 7 with lane 15).
We then asked whether NUP98-HOXA9 proteins mediate
their oncogenic effects by a speciﬁc DNA-binding mechanism.
When the NUP98b-HOXA9(FIKI) and NUP98b-HOXA9
(W6A) mutants were assayed for their ability to induce
NIH 3T3 colonies in soft agar, both mutants showed a com-
plete loss of transforming potential (Fig. 2C), despite their
effective expression (data not shown) and localization in the
nucleus (Fig. 3G and H). Like NUP98b-HOXA9, both mutants
displayed the ﬁne granular nuclear staining pattern. Thus,
HOXA9-mediated DNA binding and interaction with PBX are
essential for transformation, suggesting that NUP98-HOXA9
chimeras are altered transcription factors rather than altered
transport factors.
NUP98 FG repeats are critical for transactivation and trans-
formation. To evaluate the role of the NUP98 portions in
NUP98-HOXA9-mediated transformation, we prepared a se-
ries of N-terminal deletion constructs and tested their ability to
transform NIH 3T3 cells. Mutant NUP98a(51–223)-HOXA9,
which lacks 8 of 37 FG repeats in the NUP98a segment (Fig.
2A), retained its ability to transform NIH 3T3 ﬁbroblasts (Fig.
2C). Moreover, mutant NUP98b(51–223)-HOXA9, which
lacked the same 8 FG repeats and had only 11 repeats left,
remained transforming, although the number of colonies
formed was only half of that induced by NUP98b-HOXA9
(Fig. 2A and C). However, when the seven N-terminal and four
C-terminal FG repeats of mutant NUP98b(51–223)-HOXA9
were separately fused to HOXA9 [designated NUP98b(51–
469)-HOXA9 and NUP98b(1–223)-HOXA9, respectively],
all transforming ability was abolished (Fig. 2C), despite their
proper expression in NIH 3T3 cells (data not shown). Each of
the above mutants was localized in the nucleus (Fig. 3I to L)
and bound with PBX1a to the PBX1-HOXA10 bipartite DNA
probe (Fig. 4B, lanes 2 to 11). Hence, the lack of oncogenicity
of NUP98b(51–469)-HOXA9 and NUP98b(1–223)-HOXA9
did not arise from aberrant localization within cells or an in-
ability to bind speciﬁc cellular DNA targets.
We reasoned that if NUP98-HOXA9 proteins operate as
deregulated transcription factors in t(7;11)-associated leuke-
mia, the NUP98 portion may provide a transcription-regula-
tory domain. To overcome interference from endogenous ho-
meodomain proteins, we created fusion proteins containing
the GAL4 DNA binding domain and various FG repeat-con-
taining NUP98 segments to test for potential transcriptional
activity. Each GAL4 fusion construct was cotransfected into
NIH 3T3 cells with a reporter plasmid containing ﬁve GAL4
DNA binding sites (Fig. 5A). The HOXA9 portion of the
chimeras fused to the GAL4 DNA binding domain displayed
very little ability to activate transcription of this reporter. By
contrast, both the NUP98a and the NUP98b portions, when
fused to GAL4, were very strong activators of gene transcrip-
tion. GAL4-NUP98a(51–223) and GAL4-NUP98b(51–223),
which both transformed NIH 3T3 cells when linked to the
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HOXA9 C terminus, were also efﬁcient transcriptional activa-
tors (Fig. 5A). However, NUP98b(51–469) and NUP98b(1–
223), the two short segments derived from NUP98b that failed
to transform ﬁbroblasts as fusion partners of HOXA9, lacked
transcriptional activation potential as GAL4 fusions (Fig. 2C).
Furthermore, a selection of the above GAL4 fusion con-
structs stimulated the GAL4 reporter in Ba/F3 cells (myeloid
progenitors that are dependent on interleukin-3 for growth
[Fig. 5B]), demonstrating that FG repeats of NUP98 can act as
transactivators in myeloid cells, where NUP98-HOXA9 chime-
ras are implicated in myeloid leukemia. Taken together, these
studies suggest that the FG repeat-rich portions of NUP98a
and NUP98b function as novel transactivation domains critical
for NUP98-HOXA9-mediated transformation.
FG repeats of CAN/NUP214 and NUP98 are functionally
exchangeable. FG repeats from the other nucleoporin impli-
cated in AML, CAN/NUP214 (49, 50), might function similarly
to those from NUP98 in our transformation and transactiva-
tion assays. To investigate this possibility, we prepared two
CAN/NUP214 cDNA fragments, one encoding the last 227
amino acids of CAN/NUP214 [CAN/NUP214(1864–2090)]
and including 19 FG repeats (2 FXFG and 17 FG) and another
encoding the last 469 amino acids [CAN/NUP214(1605–2090)]
and including all 34 FG repeats from DEK-CAN/NUP214 and
SET-CAN/NUP214 (3 FXFG and 32 FG). In addition, to test
the generality of FG repeats in these assays, we generated a
cDNA fragment encoding the last 359 amino acids of NUP153
[NUP153(1121–1479)], which contains 16 FG repeats (8 FXFG
and 8 FG). The NUP153 and NUP214 segments prepared
showed no signiﬁcant sequence similarity to NUP98 other than
FG repeats and a prevalence for Asn, Gln, Ser, and Thr resi-
dues in the spacer sequences between the FG repeats (the nu-
cleoporin portion of NUP98a-HOXA9 consists of 17 GLFG, 2
FXFG, and 18 FG repeats; that of NUP98b-HOXA9 has 10
GLFG, 1 FXFG, and 8 FG repeats). CAN/NUP214(1605–2090)-
HOXA9, CAN/NUP214(1864–2090)-HOXA9, and NUP153
(1121–1479)-HOXA9 were all nuclear proteins (Fig. 3M and
N), displayed the predicted molecular weight (data not shown),
and efﬁciently bound DNA (Fig. 4C, lanes 2 to 5). When they
FIG. 4. NUP98-HOXA9 fusion proteins bind cooperatively with PBX1a to a
PBX1-HOXA10 bipartite DNA sequence. (A to C) EMSAs of in vitro-translated
proteins whose identities are indicated above the gel lanes. EMSAs were per-
formed with a radiolabeled probe containing a PBX1-HOXA10 bipartite binding
site in the absence () or presence () of in vitro-translated PBX1a. Cooper-
ative DNA binding was observed for fusion proteins with an intact HOXA9
homeodomain. Typically, the binding afﬁnity for the bipartite probe increased
when the NUP98 portion fused to HOXA9 became smaller. The differences in
intensities of the protein-DNA complexes within each panel (A or B) represent
true variations in DNA binding activity. FP, free probe. (D) NUP98b-HOXA9
and PBX form heterodimers in NIH 3T3 cells. Radiolabeled probe containing
the PBX1-HOXA10 or HOXA10 binding site was added to lysates of cells
expressing the HA1-tagged NUP98-HOXA9 fusion proteins, and the formation
of protein-DNA complexes in the absence () or presence () of 12CA5 mono-
clonal antibody was studied. For each lysate, the shifted complexes formed with
the PBX1-HOXA10 probe (arrow to the left of lane 5) are larger than those
formed with the HOXA10 probe (arrow to the left of lane 1), indicating that
NUP98-HOXA9 and PBX form heterodimers in vivo. The shifted complex
ablates when incubated with 12CA5 antibody, conﬁrming the presence of HA1-
NUP98b-HOXA9 in such complexes.
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were assayed for their colony-forming properties, CAN/NUP214
(1605–2090)-HOXA9 and NUP153(1121–1479)-HOXA9, but
not CAN/NUP214(1864–2090)-HOXA9, induced colony for-
mation in soft agar [Fig. 2C; the average number of colonies
generated by CAN/NUP214(1605–2090)- and NUP153(1121–
1479)-HOXA9 expression was 78 and 35%, respectively, of
that seen with NUP98b-HOXA9]. We then generated fusion
proteins of GAL4 and the CAN/NUP214 and NUP153 por-
tions to determine their transactivation potential. GAL4-CAN/
NUP214(1605–2090) strongly activated reporter gene tran-
scription (Fig. 5A), whereas GAL4-CAN/NUP214(1864–2090)
had very little transactivation potential (comparable to the
HOXA9 portion of the NUP98-HOXA9 fusion). GAL4-NUP153
(1121–1479) displayed moderate transactivation of the report-
er. We noticed that the levels of GAL4-NUP153(1121–1479)
protein were about 5- to 10-fold lower than those of the other
FIG. 5. Transcriptional regulatory properties of HOXA9 and FG repeat-containing segments of nucleoporins. (A) Schematic representation of the fusion proteins
containing the GAL4 DNA binding domain and HOXA9, NUP98, NUP153, CAN/NUP214, and VP16 protein regions corresponding to the amino acids indicated (the
various protein domains are indicated as described in the legend to Fig. 2). Transfection assays were performed in NIH 3T3 cells with reporter plasmid p5GB/GL2.
Synthesis of the GAL4 fusion proteins was veriﬁed by Western blot analysis (data not shown). The asterisk indicates that there were no major differences in the levels
of the various effector proteins, with the exception of NUP153(1121–1479), which was consistently expressed at approximately 10-fold-lower levels (data not shown).
(B) Schematic representation of GAL4 fusion proteins tested for transcriptional properties in Ba/F3 cells (IL-3-dependent myeloid progenitor cells). The reporter used
was p5GB/GL2. (C) HOXA9 is a strong repressor of gene transcription in NIH 3T3 cells. The reporter was the pGL2-promoter vector with ﬁve GAL4 DNA-binding
sites ligated upstream of the SV40 promoter (43). Data in all panels are expressed as the fold difference in luciferase activity obtained with the GAL4 fusion proteins
compared to that obtained with the GAL4 DNA binding domain alone. Values are the means and standard deviations of three independent experiments.
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GAL4-NUP fusion proteins (data not shown), possibly ac-
counting for its lower effect. Thus, our observations suggest
that FG repeat-rich regions from heterologous nucleoporins
can replace NUP98 in the NUP98-HOXA9 chimeras if they
contain appreciable transcriptional activation potential.
We also swapped the NUP98 portion of NUP98b-HOXA9
for the transactivation domain of VP16 (amino acids 413 to 490
[Fig. 2A]) (12). The resulting VP16(413–490)-HOXA9 protein
showed nuclear localization (Fig. 3O), bound to the PBX1-
HOXA10 DNA probe with PBX1a (Fig. 4C, lanes 6 and 7),
and transformed NIH 3T3 cells (about 40% of the efﬁciency of
NUP98b-HOXA9 [Fig. 2C]). Thus, a heterologous transacti-
vation domain fused to HOXA9 DNA binding and PBX het-
erodimerization domains is sufﬁcient for transformation of the
NIH 3T3 ﬁbroblasts. This result supports the idea that NUP98-
HOXA9 proteins are oncogenic transcription factors rather
than oncogenic transport factors.
The aberrant function of NUP98-HOXA9 could also be due
to loss of a transcriptional repression function present in full-
length HOXA9. Indeed, the similar HOXA7 is a repressor of
gene transcription (43). To test for HOXA9-dependent tran-
scriptional repression activity, we cotransfected into NIH 3T3
cells GAL4-HOXA9 and a reporter plasmid containing ﬁve
GAL4 DNA binding sites upstream of a luciferase gene driven
by an SV40 promoter. As shown in Fig. 5C, GAL4-HOXA9
functioned as a very strong transcriptional repressor. For com-
parison, the HOXA9 portion from NUP98-HOXA9 fused to
GAL4 did not display appreciable transcriptional repression
whereas GAL4-NUP98b activated the SV40 promoter sever-
alfold. These data suggest that the N terminus of HOXA9
contains a motif that functions as an inhibitor of transcription
and is replaced by a nucleoporin-mediated transactivation
function in t(7;11) leukemic cells.
CBP/p300 is necessary for NUP98-mediated transactiva-
tion. To further elucidate the mechanism whereby NUP98 FG
repeats act as transactivators, we ﬁrst examined the role of the
CBP and p300 in this process. CBP and p300 are direct targets
of chromosomal rearrangements in human leukemias, and
both function as coactivators of a variety of gene-speciﬁc acti-
vators (20). To this end, we tested if the adenovirus 12S E1A
protein inhibits GAL4-NUP98 function (12S E1A binds to the
CH3 domain of CBP/p300 and inhibits associated transactiva-
tor function). Surprisingly, expression of 12S E1A protein dra-
matically repressed NUP98-dependent transcription activity in
a dose-dependent manner (Fig. 6A). As shown in Fig. 6B,
expression of E1A did not reduce the overall level of GAL4-
NUP98(1–469) protein in NIH 3T3 cells. When we expressed
a 12S E1A(2–36) mutant that cannot bind to CBP/p300, we
observed no inhibition of FG repeat-mediated transcriptional
activation. As expected, 12S E1A expression had no effect on
the activity of CBP/p300-independent transactivation mediat-
ed by CREB residues 160 to 284 [GAL4-CREB(160–284)]
(Fig. 6A) (52), conﬁrming that E1A speciﬁcally targeted CBP/
p300-dependent transactivation in our assay.
These results suggested that CBP would potentiate GAL4-
NUP activity. We determined this by cotransfecting GAL4-
NUP98b(1–469) expression vector with increasing amounts
of RSV-CBP plasmid. CBP was found to stimulate GAL4-
NUP98b(1–469)-induced reporter activity in a dose-dependent
fashion (Fig. 6C). By contrast, the CBP/p300-independent
transactivator GAL4-CREB(160–284) was not potentiated by
RSV-CBP. Together, the above data implicate CBP/p300 in
NUP98-dependent transcriptional activity.
FG repeat-rich portions of NUP98 bind CBP/p300 in vitro
and in vivo. GAL4-NUP98 activity was inhibited by E1A and
synergized with CBP, suggesting that FG repeat-rich portions
of NUP98 may bind to CBP/p300. To test this possibility, we
performed pull-down assays with glutathione S-transferase
(GST)–CBP fusion proteins puriﬁed from Escherichia coli and
in vitro-translated NUP98 fragments. Both NUP98 portions of
the NUP98-HOXA9 chimeras bound effectively to GST-CBP
(1–1892), a CBP portion that contains three major CBP do-
mains for transcription factor binding (Fig. 7A, lanes 4). By
contrast, no substantial binding was detected with GST-CBP
(1892–2441), a CBP portion containing a glutamine-rich do-
main that binds p53 and SRC-1 (lane 3). Given that the NUP98
portions of both NUP98-HOXA9 chimeras bound to CBP(1–
1892), we investigated whether NUP98-dependent transactiva-
tion correlates with physical binding to CBP. In vitro-translat-
ed NUP98 fragments corresponding to GAL4-NUP98 mutants
with known transactivation activities (Fig. 5A) were tested for
binding to GST-CBP(1–1892) and GST-CBP(1892–2441). As
shown in Fig. 7A, NUP98 mutants that displayed transcription-
al activity as GAL4 fusion proteins bound GST-CBP(1–1892)
whereas those that lacked transactivation potential as GAL4
fusions failed to interact signiﬁcantly with GST-CBP(1–1892).
None of the NUP98 mutants showed signiﬁcant interaction
with GST-CBP(1892–2441). The HOXA9 portion of the fu-
sion, which is not transcriptionally active when fused to GAL4,
also failed to demonstrate noticeable association with either
GST-CBP(1–1892) or GST-CBP(1892–2441). Thus, it appears
that efﬁcient binding of NUP98 fragments to CBP in vitro
correlates with their ability to activate transcription.
To conﬁrm that the NUP98-HOXA9 proteins do interact
with CBP/p300 in vivo, we prepared lysates of [35S]methio-
nine-labeled NIH 3T3 cells expressing either HA1-NUP98a-
HOXA9, HA1-NUP98b-HOXA9, or the HA1-tagged HOXA9
portion and performed two sequential immunoprecipitations,
ﬁrst with 12CA5 monoclonal antibody then with an CBP/p300-
speciﬁc antibodies (52). An in vivo interaction between each of
the NUP98-HOXA9 chimeras and CBP/p300 (seen as a broad
band) was detected (Fig. 7B; the results shown are repre-
sentative of three independent experiments). CBP/p300 was
not detectable in an immunocomplex with the HOXA9 por-
tion of the fusion protein alone, demonstrating that the FG
repeat-rich portions of NUP98 mediate binding of CBP/p300
toNUP98a-HOXA9andNUP98b-HOXA9.Conﬁrming our ﬁnd-
ings in NIH 3T3 cells, a speciﬁc interaction between NUP98 se-
quences and CBP/p300 was also detected in lysates of [35S]
methionine-labeled HtTA cells transiently transfected with an
HA1-NUP98a-HOXA9 expression vector (Fig. 7B; the results
are representative of two experiments). Western blot analysis
with 12CA5 antibody revealed that the various HA1-tagged
proteins studied for coimmunoprecipitation of CBP/p300 were
expressed at comparable levels. This excludes the possibility
that gross variations in HA1-tagged protein levels underlie the
observed differences in binding to CBP/p300.
DISCUSSION
Although several distinct chromosomal translocations in hu-
man leukemias disrupt FG repeat-containing nucleoporins, a
role for these components in the transformation of blood cells
has not been established. Remarkably, we demonstrate that
FG repeat-rich segments, which normally function in transport
of macromolecules across the NE, perform a critical role in
NUP98-HOXA9-mediated transformation, where they func-
tion as potent activators of transcription that physically and
functionally interact with the transcriptional coactivators
CBP and p300. Additional evidence to support a model in
which NUP98-HOXA9 proteins act as oncogenic transcription
factors includes (i) their nuclear localization, (ii) the speciﬁc
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DNA binding activity of the chimeras, and (iii) the require-
ment for intact HOXA9 DNA binding and PBX cofactor
interaction. Interestingly, FG repeats from NUP98-HOXA9
could be replaced by CAN/NUP214 FG repeats, indicating
that FG repeat-mediated transactivation may be a shared
pathogenic function of nucleoporins in AML.
Deregulation of HOX activity by NUP98-HOXA9. Verte-
brate HOX genes are developmental regulators that also me-
diate key steps in the proliferation and differentiation of fetal
and adult hematopoiesis in a lineage- and stage-speciﬁc man-
ner (25). Although the repertoire ofHOX gene expression dur-
ing hematopoiesis is beginning to emerge, the genetic targets
regulated by HOX proteins remain elusive, as is the case for
the PBX and MEIS family members, which may cooperate
with the implicated HOX proteins. NUP98-HOXA9-mediated
transformation depends on its ability to bind DNA with mem-
bers of the PBX family of HOX cofactors, implying that
NUP98-HOXA9 affects the control of PBX/HOXA9-regulated
target genes.
Like HOXA7, HOXA9 can function as a very efﬁcient
inhibitor of gene transcription. The HOXA9 portion of the
NUP98-HOXA9 chimeras displayed no such repressor func-
tion, indicating that residues in the N terminus of full-length
HOXA9 mediate gene repression. It is unlikely that the mere
loss of HOXA9 repressor status is sufﬁcient for the develop-
ment of AML, because overexpression of a carboxy-terminal
HOXA9 fragment does not transform NIH 3T3 cells. However,
to gain oncogenic properties, the carboxy-terminal HOXA9
portion requires a transcriptional activator, which favors a
model of leukemogenesis in which the FG repeats of NUP98-
HOXA9 strongly activate HOXA9-responsive target genes
whose deregulated expression interferes with proper execution
of myelopoiesis. Transformation driven by cooverexpression of
HOXA9 and MEIS1 does not seem to require a gain of trans-
activation function of HOXA9, suggesting that the mechanism
of target gene deregulation involved may be different from that
of NUP98-HOXA9-induced leukemias.
FG repeat-rich nucleoporins as potent oncogenic transacti-
vators. Most striking is the ﬁnding that FG repeat-containing
portions from the N terminus of NUP98a and NUP98b can
FIG. 6. NUP98 transactivation function requires CBP/p300. (A) GAL4-NUP98b(1–469) transcriptional activity is repressed by E1A, an inhibitor of CBP/p300. NIH
3T3 cells were transfected with p5GB/GL2 ﬁreﬂy luciferase reporter plasmid, and expression vectors for GAL4(1–147), GAL4-NUP98b(1–469), or GAL4-CREB(160–
284) (a CBP/p300-independent-glutamine-rich activator from CREB; amino acids 160 to 284), and wild-type or mutant E1A [mutant E1A(2–36)]. Luciferase activity
derived from the p5GB/GL2 luciferase reporter was normalized to Renilla luciferase derived from the internal control reporter pRL-CMV. The mean activity and
standard deviation is presented relative to the activity of GAL4-NUP98b(1–469) in the absence of E1A. (B) GAL4-NUP98 levels do not change in the presence of E1A.
Western blot analysis of proteins precipitated with 12CA5 antibody from lysates of UCLA cells transiently transfected with GAL4-NUP98(1–469) (predicted molecular
mass, 50 kDa), GAL4, or NUP98(1–469) plus E1A. Precipitated proteins were visualized with 12CA5. The asterisk indicates a protein precipitated nonspeciﬁcally
with 12CA5. (C) Full-length CBP potentiates GAL4-NUP98b(1–469) transcriptional activity in NIH 3T3 cells. The p5GB/GL2 luciferase reporter was cotransfected
with expression vectors for GAL4-NUP98b(1–469) or GAL4-CREB(160–284), and equimolar amounts of CBP (RSV-CBP) or empty vector (RSV). Luciferase activity
derived from the p5GB/GL2 luciferase reporter was normalized to Renilla luciferase derived from the internal control reporter pRL-TK. Mean activation and standard
deviation is expressed as the ratio of luciferase activity in the presence of RSV-CBP plasmid DNA divided by the level of luciferase activity in its absence. The results
represent at least two independent experiments.
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function as transactivation domains. Indeed, the oncogenic
potential of NUP98-HOXA9 correlates with NUP98-mediated
transcriptional competence. A certain threshold level of trans-
activation function is apparently required for oncogenicity,
after which the correlation between transactivation and trans-
formation is qualitative. However, we cannot exclude the
possibility that NUP98 contributes another function to the
NUP98-HOXA9 chimeras beside transcriptional activation.
Nevertheless, our ﬁnding that the completely unrelated VP16
transactivation domain can functionally replace NUP98 sug-
gests that other potential NUP98 functions are not necessary
for oncogenesis in NIH 3T3 cells. Moreover, speciﬁc FG re-
peat-rich domains of two heterologous nucleoporins, CAN/
NUP214 and NUP153, were oncogenic and contained tran-
scriptional activation properties, further strengthening the
correlation between transformation and transactivation for
these domains. The transactivating FG repeat-rich segment of
CAN/NUP214 is retained in the DEK-CAN/NUP214 and
SET-CAN/NUP214 leukemic fusion proteins (49, 50). This
suggests that the shared pathogenic mechanism of FG repeat-
containing nucleoporins is to activate gene transcription. Al-
though the precise function of DEK remains to be established,
there is evidence to suggest that DEK is a sequence-speciﬁc
DNA binding protein (15). Interestingly, the nuclear protein
SET interacts directly with MLL (also called HRX) (1), which
binds to DNA and positively regulates HOX gene expres-
sion (53). The MLL region that binds SET is consistently
retained in all MLL leukemic fusion proteins (1). Thus,
SET-CAN/NUP214 may contribute to leukemogenesis by
interfering with the proper expression of MLL-controlled
HOX proteins.
CBP/p300: the link between NUP98 FG repeats and the
transcription machinery. How does a protein that mediates
macromolecule transport through the nuclear pores act as a
regulator of transcription? Thus far, no evidence supporting a
direct connection between NPC proteins and the basal tran-
scription machinery has been reported, suggesting that the FG
repeat segments of NUP98 may be fortuitous rather than gen-
uine activators of gene transcription. Our results show that
transactivation of FG repeat-rich segments of NUP98 corre-
lates with their ability to interact and functionally collaborate
with the transcriptional coactivators CBP/p300. Thus far,
NUP98-HOXA9 is the ﬁrst translocation-generated fusion
protein known to recruit CBP/p300 as part of its oncogenic
mechanism. However, there is additional evidence to suggest a
more central role for CBP/p300 in both hematopoiesis and
leukemia. First, CBP and p300 are direct targets of at least
three independent chromosomal rearrangements in human
leukemias. Both CBP and p300 are fused to MLL through,
respectively, the t(11;16) (41, 46) and t(11;22) (19) transloca-
tions. In addition, CBP is linked to MOZ through the t(8;16)
translocation associated with AML (8). Second, CBP/p300 in-
FIG. 7. Transcriptionally active FG repeat-rich portions of NUP98 bind CBP/p300. (A) GAL4-NUP98 transcriptional activity correlates with binding to CBP in
vitro. GST pull-down assays were performed with the indicated [35S]methionine-labeled NUP98 or HOXA9 portions produced in vitro and GST-CBP fusion proteins
puriﬁed from E. coli. The 25% input (lane) shows 25% of the NUP98 or HOXA9 segments used in each pull-down assay. Typically, in vitro-translated NUP98 portions
appear as doublets, representing fragments with and without a HA1 tag (the NUP98 portions were cloned in pSP73 as HA1 fusion genes that retained the endogenous
NUP98 translation initiation codon). GST acts as a negative control for binding. Comparable amounts of GST and GST-CBP fusion proteins were used in each
pull-down assay. The experiment shown is representative of three independent experiments. (B) In vivo interaction between NUP98-HOXA9 oncoproteins and
CBP/p300. Total-cell lysates were prepared from [35S]methionine-labeled HtTA or NIH 3T3 cells expressing the indicated HA1-tagged proteins. Two sequential
immunoprecipitations were performed as detailed in Materials and Methods. The ﬁrst and second immunoprecipitations (IP) were performed with the indicated
antisera. A CBP/p300 antiserum cocktail was used for most efﬁcient detection of these transcriptional coactivators. The positions of CBP/p300 and a molecular mass
marker are indicated.
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teracts and functionally cooperates with the AML1/CBF
transcription factor complex in myeloid cell differentiation
(21), underscoring a role for CBP/p300 as a hematopoietic
transcriptional coactivator. Moreover, the AML1/CBF tran-
scription factor complex is the most frequent target of chro-
mosomal translocations in human leukemias. Thus, aberrant
formation of this complex by AML1 or CBF fusion proteins
may affect the role of CBP/p300 in myeloid cells.
Interaction of CBP with RNA polymerase II in vitro requires
RNA helicase A, a nuclear 3-5 double-stranded DNA-RNA
helicase containing a consensus DEAH box motif (32). The
NUP98-DDX10 fusion protein in AML patients with the inv
(11)(p15q22) chromosomal rearrangement contains the NUP98
portion that binds CBP and the DEAH box of the putative RNA
helicase DDX10, which may have afﬁnity for CBP as well (2).
Thus, it will be of interest to determine whether NUP98-DDX10
promotes leukemogenesis by deregulation of CBP/p300 func-
tion. It is also tempting to speculate that NUP98 and CBP/p300
may interact at the NE, perhaps to promote transcription near
the nuclear pores. However, in preliminary studies, we could
not detect colocalization of NUP98 and CBP/p300 at nuclear
pores or coimmunoprecipitate CBP/p300 with endogenous
NUP98 by using NUP98-speciﬁc antibodies (8a). This suggests
that nuclear relocation of the FG repeats and/or their fusion
with a speciﬁc DNA binding domain may be essential for their
interaction with CBP/p300.
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The NUP98 gene encodes precursor proteins that generate two
nucleoplasmically oriented nucleoporins, NUP98 and NUP96. By
using gene targeting, we have selectively disrupted the murine
NUP98 protein, leaving intact the expression and localization of
NUP96. We show that NUP98 is essential for mouse gastrulation, a
developmental stage that is associated with rapid cell prolifera-
tion, but dispensable for basal cell growth. NUP98 cells had an
intact nuclear envelope with a normal number of embedded
nuclear pore complexes. Typically, NUP98-deﬁcient cells contained
on average approximately 5-fold more cytoplasmic annulate la-
mellae than control cells. We found that a set of cytoplasmically
oriented nucleoporins, including NUP358, NUP214, NUP88, and
p62, assembled inefﬁciently into nuclear pores of NUP98 cells.
Instead, these nucleoporins were prominently associated with the
annulate lamellae. By contrast, a group of nucleoplasmically ori-
ented nucleoporins, including NUP153, NUP50, NUP96, and NUP93,
had no afﬁnity for annulate lamellae and assembled normally into
nuclear pores. Mutant pores were signiﬁcantly impaired in trans-
port receptor-mediated docking of proteins with a nuclear local-
ization signal orM9 import signal and showedweak nuclear import
of such substrates. In contrast, the ability ofmutant pores to import
ribosomal protein L23a and spliceosome protein U1A appeared
intact. These observations show that NUP98 disruption selectively
impairs discrete protein import pathways and support the idea that
transport of distinct import complexes through the nuclear pore
complex is mediated by speciﬁc subsets of nucleoporins.
Transport between the nucleus and the cytoplasm occursthrough nuclear pore complexes (NPCs) embedded in the
nuclear envelope (NE). NPCs have an 8-fold rotational symme-
try in the plane parallel to the NE (reviewed in ref. 1). Each NPC
contains a membrane-embedded central framework that em-
braces a central pore. The central framework consists of a
ring-like spoke complex that is sandwiched between a cytoplas-
mic and a nuclear ring. Each cytoplasmic ring supports eight
fibrils that extend into the cytoplasm, whereas each nuclear ring
carries eight filaments that join distally to form a basket-like
assembly (1, 2). The vertebrate NPC has an estimated molecular
mass of 125 MDa and is composed of 80–100 different
proteins called nucleoporins, of which 16–20 have been cloned
(3). In contrast, the Saccharomyces cerevisiae NPC is only 66
MDa (4) and is composed of 35–50 nucleoporins, of which
more than 30 have now been identified (5).
Nucleocytoplasmic transport is mediated by soluble transport
factors that belong to the karyopherin family of transport
receptors, whose members can be subdivided into importins and
exportins. Typically, a given transport receptor binds to an
import or export signal-containing cargo in one compartment,
guides it to and accompanies it through an NPC, releases it in the
opposite compartment, and then shuttles back to the first
compartment to repeat the cycle (see refs. 3, 6, and 7). The small
GTPase Ran and its regulatory factors play a central role in this
process (6, 8). Ran is presumably maintained as RanGTP in the
nucleus by the nucleotide exchange factor RCC1, and as
RanGDP in the cytoplasm by the GTPase-activating protein
RanGAP. RanGTP is bound to cargo-containing export factors
as they dock to and translocate through the NPC. At the
cytoplasmic face of the NPC, RanGTP becomes exposed to
RanGAP activity and converts to RanGDP, which triggers
disassembly of the trimeric export complex. In contrast, cargo-
containing import factors dock and translocate through the NPC
without Ran. At the nuclear face, import factors associate with
RanGTP and release their cargo.
Several interactions between individual FG (Phe-Gly) repeat-
containing nucleoporins and transport factors have been re-
ported, leading to the idea that such interactions could play a
pivotal role in the docking, translocation, andor termination
steps of the transport process (6, 7, 9). In yeast, most FG
nucleoporins are symmetrically located on both the nuclear and
the cytoplasmic sides of the NPC, but the position of some
nucleoporins is asymmetric (1, 5). In mammalian cells, both
NUP358 and NUP214 are positioned at the tips of cytoplasmic
fibrils, whereas NUP98 and NUP153 are located near the
midsection of the nuclear basket. A so-called p62 subcomplex,
which consists of four FG nucleoporins (p62, p58, p54, and p45),
is found at both the cytoplasmic and nuclear periphery of the
central gated channel. Additionally, p62 binds to the distal and
nuclear basket.
To obtain insight into the in vivo role of the murine FG-repeat
nucleoporin NUP98, we disrupted it by a genetic approach. Our
analyses show that NUP98 is required for proper NPC assembly
and function.
Materials and Methods
Generation of NUP98 Knockout Mice and Genotyping. The NUP98
targeting vector contained an 8.0-kb NUP98 129SvJ genomic
DNA fragment in which an 500-bp SpeIStuI fragment [con-
taining 3 sequences of NUP98 exon 3 (encoding amino acids
33–118) and 5 sequences of NUP98 intron 3] had been replaced
by a PGK-neo cassette. We electroporated this targeting vector
into embryonic stem (ES) cells and performed drug selections as
previously described (10). We identified correctly targeted ES
cell clones by Southern blot analysis using a 5 external probe on
PstI-cut genomic DNA. Mutant mice were derived from these
targeted ES clones as described in detail (11).
Abbreviations:NPC, nuclearpore complex;AL, annulate lamellae;NE, nuclear envelope; ES,
embryonic stem; En, embryonic day n; RT-PCR, reverse transcription–PCR; NLS, nuclear
localization signal; TEM, transmission electron microscopy; rp, ribosomal protein.
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Generation of Embryo-Derived Cell Lines. Embryos [embryonic day
8.5 (E8.5)] from NUP98 intercrosses were grown on a
monolayer of mitotically inactivated mouse embryonic fibro-
blasts (MEFs) in ES cell medium (11). Cell lines derived from
these embryos were grown without MEFs and genotyped by
Southern blot analysis. To reestablish NUP98 expression, we
cloned human HA1-tagged NUP98(1–920) cDNA (for details,
see ref. 12) into the ecotropic retroviral expression vector
pSRMSCV. Retroviral stocks were prepared and used for
retroviral gene transfer as described (12).
Western Blot Analyses and Reverse Transcription–PCR (RT-PCR).West-
ern blot analyses were performed as described (12, 13). RT-
PCRs were performed with a ThermoScript RT-PCR system
(Life Technologies, Grand Island, NY). cDNA was synthesized
from 1 g of total RNA with NUP96 primer 5-GGGGTG-
GAGGGACAGACCAAGAGG-3. PCR and nested-PCR
primer sets were p1p2 and p3p4, respectively: p1, 5-
GTTTAACAAATCATTTGGAACCCCC3-; p2, 5-TTAG-
CAAGGTCATCCATAGATGG-3; p3, 5-AGGGGGCTTTG-
GTACAACGTCAA-3; p4, 5-TACTGGGGCCTGGGG-
GCGCCA-3. The PCRs were performed as recommended by
the manufacturer. Nested-PCR products were cloned into
pGEM-T Easy vector (Promega) and sequenced by standard
methods.
Indirect Immunofluorescence and Electron Microscopy. Immuno-
stainings were carried out essentially as described (13, 14).
Dilutions of primary antibodies were as follows: purified anti-
NUP98(151–221), 1:100; mAb414, 1:250; Kap- (importin ),
Kap- (importin ), importin 7, Kap-3 (importin 5; N. Yaseen),
NUP153 (B. Burke), Kap-2 (transportin; G. Dreyfuss), GLE1
(S. Wente) and 12CA5 (Roche Molecular Biochemicals), all
1:200; p62, 1:25; NUP358 (J. Wu), NUP214, CRM1 (I. Mattaj),
NUP88 (B. Burke), NUP50 (B. Clurman) and NUP96, all
1:1,000. Images were collected on a Carl Zeiss confocal micro-
scope LSM 510 using a 100
 objective. To quantify NPCs,
confocal images of multiple mAb414-labeled cells were collected
(using a 100
 objective and 4
 digital magnification), and the
number of pores within a frame of 138
 144 pixels was counted
and statistically analyzed.
For electron microscopic examinations, cells were trypsinized,
washed three times with PBS, fixed for 4 h with 2.5% (volvol)
glutaraldehyde0.6% formaldehyde (buffered with sodium ca-
codylate, pH 7.2), and then postfixed with 2% (wtwt) buffered
OsO4. Samples were dehydrated in graded ethanol, and then
embedded in Spurr resin. Thin sections were examined by
transmission electron microscopy (TEM) by using a JEOL 1200
EXII. Immunogold labeling of cells with mAb414 antibody was
essentially as described by Cordes et al. (15).
In Vitro Protein Import Studies. Nuclear localization signal (NLS)-
BSA import reactions were performed as described by Palacios
et al. (16). M9-core and ribosomal protein (rp)L23a reactions
were carried out as described by Jakel and Gorlich (17). U1A
reactions were conducted as described by Hetzer and Mat-
taj (18).
Results
NUP98 Is Essential for Mouse Gastrulation but Dispensable for Basal
Cell Growth. The NUP98 gene was disrupted by replacing an exon
3 fragment that encodes for NUP98 amino acids 33–118 and part
of intron 3, with a neo cassette (Fig. 1A). After transfection,
selection of targeted clones, and blastocyst injection, chimeric
mice were obtained that passed the disrupted NUP98 gene
through the germ line (Fig. 1B). F1 heterozygote mice were
intercrossed, but no homozygous NUP98 mutant mice were
found among 198 offspring. Dissections of 8.5-day-old embryos
from heterozygous intercrosses revealed that knockout embryos
(n  5) were grossly retarded in their development (Fig. 1C),
having the size of a normal 6.5- to 7.5-day-old gastrulation-stage
embryo. Histological analysis of these embryos revealed that
they were highly disorganized, with major defects in morpho-
genesis, proliferation, and pattern formation (data not shown).
Fig. 1. Selective disruption of the NUP98 gene. (A) Schematic diagram
showing the NUP98 locus, the targeting vector, and the disrupted NUP98
locus. E3 denotes NUP98 exon 3; the cross-hatched bar indicates the position
of the 5 DNA probe used for Southern blot identiﬁcation of wild-type and
targeted NUP98 alleles. (B) Southern blots containing DNAs extracted from
mouse-tail biopsies or embryonic cell lines. (C) Whole mount preparations of
an E8.5 control (size 3.3 mm) and mutant embryo (2 mm). (D) Schematic
representation of the RT-PCR approach used to analyze NUP98-NUP96 fusion
transcripts generated by wild-type and knockout cells. RT primer marks the
position of the NUP96-speciﬁc reverse transcription primer; primers 1 and 2
were used for PCR ampliﬁcation; primers 3 and 4 were used for nested PCR
ampliﬁcation. (E) Image of UV-visualized RT-PCR products from NUP98
(1.2 kb) and NUP98 (0.9 kb) cells. (F) Sequence alignment of wild-type
andmutant RT-PCR products. Exon 3 sequences are within the boxed area. (G
and H) Quantitative Western blot analyses (7.5% polyacrylamide gel) of
proteins extracted from 2 
 105 NUP98 or NUP98 cells. Blots were
probed with the antibodies indicated.
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When E8.5 NUP98 embryos were cultured in vitro (n  3),
they developed into epithelium-like cell lines over a period of
80–100 days (Fig. 1B). By contrast, E8.5 NUP98 (n 2) and
NUP98 embryos (n 1) developed into epithelium-like cell
lines within 10–20 days after embryo explantation. We conclude
that NUP98 is essential for proper gastrulation, but not for basal
cell growth.
NUP98 Disruption Does Not Abrogate Expression and NPC Targeting of
NUP96. The NUP98 gene encodes a 186-kDa precursor protein
that is proteolytically cleaved into two nucleoporins, NUP98 and
NUP96 (13). Analysis of NUP98 and NUP96 gene transcripts
from NUP98 and NUP98 cells by RT-PCR (Fig. 1D)
revealed that the mutated allele generated transcripts that were
300 bp shorter than those that were derived from the wild-type
allele (Fig. 1E). Cloning and sequencing of the wild-type and
mutant RT-PCR products showed that the mutant product
specifically lacked sequences encoded by exon 3 (encoding for
NUP98 amino acids 26–118, Fig. 1F). This result implied that
mutant transcripts were alternatively spliced, fusing exon 2 and
4 and deleting the disrupted exon 3. Because the alternative
splicing event did not alter the reading frame (Fig. 1F), we
expected that the mutant transcript would generate a truncated
NUP98 protein [designated NUP98(26–118)] of approximately
88 kDa and a wild-type NUP96 protein. Quantitative Western
blot analysis revealed that NUP98 and NUP98 cells
indeed expressed similar amounts of NUP96 protein (Fig. 1G).
When these Western blots were probed with antibody raised
against NUP98(150–221), NUP98 could easily be detected in
NUP98 cells (Fig. 1G). However, both full-length NUP98
and NUP98(26–118) protein were undetectable in
NUP98 cells (Fig. 1G), even when long exposure times were
applied. When embryonic cells were immunostained with anti-
body against NUP96, NEs of both control (Fig. 2C) and
NUP98 cells (Fig. 2D) were labeled in a similar fashion,
demonstrating proper NPC targeting of NUP96 in NUP98-
deficient cells. Taken together, the above studies show that the
NUP98 targeting vector effectively disrupted NUP98 expression
without abrogating the expression and NPC targeting of NUP96.
NUP98 Disruption Causes Annulate Lamellae (AL) Formation. Embry-
onic cells were double-stained with antibody against
NUP98(151–221) and monoclonal antibody mAb414, a com-
monly used NE marker that mainly labels p62 and, to a minor
degree, NUP153, NUP214, and NUP358. Control cells showed
a typical rim-like NUP98 labeling of the NE (Fig. 2A); however,
such staining was not detected in NUP98-disrupted cells (Fig.
2B). Like control cells (Fig. 2A’), NUP98 cells exhibited
uninterrupted rim-like labeling of the NE with mAb414 (Fig.
2B’), indicating that NUP98-deficient nuclear pores were evenly
distributed over the NE. However, mAb414-labeled NUP98-
deficient cells typically displayed two remarkable features: (i) a
considerably reduced label intensity at the NE compared with
control cells, and (ii) numerous dot-like cytoplasmic aggregates
that were very similar in appearance to AL.
To examine the nature of the reduced mAb414 labeling at the
NE in more detail, we analyzed the punctate nuclear-surface
labeling of mAb414-stained control and knockout cells by high-
resolution confocal microscopy. We found that individual
NUP98-deficient nuclear pores (Fig. 2F) showed much lower
intensity staining than did pores of control cells (Fig. 2E). Fig.
2 F and F’ display the same image, with the difference that in F’,
the intensity of the nuclear pore signals is increased by using
computer enhancement to allow for quantitation of NPC density
in control and NUP98 cells. This technique demonstrated
that NPC densities were, indeed, not significantly different in
control and NUP98-deficient cells (Fig. 2G). Ultrastructural
analysis by transmission electron microscopy (TEM) revealed
that neither NPC herniations and invaginations nor other alter-
ations in the morphology of the NE or the NPCs could be
identified in cells that lack NUP98 (compare Fig. 2 H and I).
To determine whether the cytoplasmic mAb414-positive ag-
gregates represented AL, we performed the following analyses.
First, we prepared ultrathin sections of control and NUP98
cells, and used TEM to quantify the number of AL-containing
cells within these sections. We found that 2 of 50 control sections
contained AL. By contrast, 8 of 50 knockout sections were
positive for AL (Fig. 2 J). Second, we immunostained control and
knockout cells with mAb414 and quantitated the number of
aggregates by high-resolution confocal microscopy. We found
that knockout cells contained (on average) 12–13 large aggre-
gates (n  58 cells), whereas control cells had (on average) 2–3
Fig. 2. NUP98 knockout cells have a normal NPC density but increased
numbers of AL. (A–D) Representative confocal images of control (A andC) and
knockout (B andD) cells double stainedwithNUP98(151–221) antibody (A and
B) and monoclonal antibody mAb414 (A’ and B’) or with NUP96 antibody (C
and D) and mAb414 (C’ and D’). (E, F, and F’) Representative high-resolution
confocal images of mAb414-stained nuclear pores (focused on the top of the
nucleus). (E) Control cell. (F) NUP98 cell. (F’) Same image as shown in F
except that the brightness of the image has been enhanced by computer
processing. (G) Quantiﬁcation of nuclear pore densities: bar diagrams show-
ing the average nuclear pore densities of two independent NUP98 lines;
anNUP98 line (n 3 cells) and anNUP98 line (n 12 cells). Error bars
represent standard deviations. (H and I) Analysis of NPC and NE integrity by
TEM. Arrows mark nuclear pores; n, nuclear face; c, cytoplasmic face. (H)
Nuclear pores in a control cell. (I) An NUP98 cell. (J) TEM micrograph
showing AL of a knockout cell. (K) Immunogold electron micrograph with
mAb414. Shown is an AL from an NUP98 cell decorated with 5-nm gold
particles (arrowheads).
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such aggregates (n  27 cells). This approximately 5-fold in-
crease in the number of aggregates correlated well to the 4-fold
increase in AL revealed by TEM analysis. Last, we applied
preembedding immunogold electron microscopy with monoclo-
nal antibody mAb414. This analysis revealed that the only
cytoplasmic structures enriched in gold particles in knockout
cells were AL (Fig. 2K). From these analyses, we conclude that
NUP98 knockout cells form significantly more AL than normal
cells.
NUP98 Disruption Changes the Stoichiometry of Cytoplasmically Ori-
ented Nucleoporins. The decreased mAb414 labeling of the NE in
NUP98 cells prompted us to test whether the stoichiometry of
FG nucleoporins other than NUP98 was affected. To this end, we
immunostained control and NUP98 cells for individual FG
nucleoporins. First we looked at NUP214 and NUP358, two
cytoplasmically oriented nucleoporins. We found that in NUP98-
deficient cells, a substantial amount of each of these proteins had
relocated from the NE to AL (Fig. 3 A and A’, and B and B’, and
Table 1). A large proportion of the NUP214 binding partner
NUP88 had also relocated from the NE to AL (Table 1). p62, an
FG nucleoporin located at both the cytoplasmic and nuclear face of
the central gated channel complex and at the tip of the nuclear
basket, was also redistributed from theNE toAL.NUP98 cells
were permeabilized with digitonin to specifically stain p62 at the
cytoplasmic face of the NPC, revealing a lower intensity of NE
labeling than in control cells (data not shown). These data suggest
that the p62 level at the cytoplasmic face of the NPC is reduced.
Anti-p62 and anti-NUP214 Western blots (Fig. 1H) revealed that
the overall p62 andNUP214 levels were similar in NUP98 and
control cells, confirming that the reduction of nucleoporin levels at
the NE results from a redistribution of protein rather than from a
decline in protein production. In contrast to the above-mentioned
nucleoporins,NUP153 andNUP50, two nucleoplasmically oriented
FG nucleoporins, did not relocate from the NE to AL in
NUP98 cells. Furthermore, NUP93, a nucleoplasmically ori-
ented nucleoporin without FG repeats, was also normally distrib-
uted in NUP98 cells (Table 1). Ectopic expression of HA1-
NUP98 in NUP98 cells restored NE levels of NUP214 (Fig.
3C), NUP358, p62, and NUP88 (data not shown) to normal, and
strongly reduced formation of AL.
Mutant Pores Have Reduced Affinity for a Subset of Transport Re-
ceptors. Several shuttling transport receptors are known to bind to
FG nucleoporins. To test their ability to target to mutant pores, we
immunostained control and knockout cells for a variety of different
transport receptors. We found that NE labeling of Kap- (importin
; Fig. 3 F andG), Kap- (importin ), CRM1, importin 7, Kap-2
(transportin), and GLE1 (Table 1), was much lower in knockout
cells than in control cells. Moreover, these factors were all prom-
inently associated with AL. Efficient NPC docking of these trans-
port factors was restored when we expressed HA1-NUP98 in the
knockout cells (Fig. 3H and data not shown). In contrast to the
above receptors, Kap-3 (importin 5), a transport receptor impli-
Fig. 3. Speciﬁc FG nucleoporins and soluble transport factors relocating from nuclear pores to cytoplasmic AL. Control (A, D, F, and I), NUP98 (B, E, G, and
J ) and HA1-NUP98-expressing NUP98 cells (C andH) were stained for speciﬁc FG nucleoporins or soluble transport factors: (A–C) NUP214. (D and E) NUP153.
(F–H) Kap-. (I and J) Kap-3. Cells were costained with either mAb414 (A’, B’, D’, E’, F’, G’, I’, and J’) or 12CA5 (C’ and H’).
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cated in import of ribosomal proteins (17, 19), did not relocate from
the NE to AL in NUP98 cells (Fig. 3 I and J). Thus, many, but
not all, soluble transport receptors seem to target inefficiently to
nuclear pores of NUP98 knockout cells.
NUP98 Disruption Impairs Distinct Protein Import Pathways. Cells
lacking NUP98 were viable and proliferated in vitro. This fact
implied that none of their major transport pathways was com-
pletely blocked. To determine whether the steady-state local-
ization of nuclear proteins would be altered in NUP98 cells,
we performed immunostainings for CBP, p300, RNA polymer-
ase II, cyclin E, and p21. All these proteins were correctly
localized to the nucleus (data not shown), suggesting that NUP98
disruption does not cause overt changes in the steady-state
distribution of nuclear proteins. To determine whether the rate
of nuclear-protein import through mutant pores was altered, we
carried out several well standardized in vitro protein-import
assays on control and knockout cells. These assays were typically
performed in a transport buffer containing specific soluble
transport receptors, an energy-regenerating system, and a well
characterized fluorescein-labeled protein acting as a substrate
for import into the nuclei of digitonin-permeabilized cells.
Nuclear import of substrates was monitored by fluorescence
microscopy. We found that nuclear import of proteins with an
NLS (Fig. 4 A and B) or M9 (Fig. 4 C and D) import signal
(mediated by Kap- and Kap-2, respectively) was substan-
tially lower in mutant cells than in control cells. By contrast,
Kap-3-mediated nuclear import of the rpL23a (Fig. 4 E and F)
was very similar in knockout and control cells. Nuclear import
of the spliceosome protein U1A, which seems to be independent
of cytosolic-transport factors (18), was also comparable in
control and knockout cells (Fig. 4 G and H).
We also studied how efficiently the above transport complexes
were able to dock to mutant nuclear pores. To this end, we
performed the above import reactions at 4°C, because it is known
that at this temperature import complexes can dock to nuclear
pores, but cannot translocate through them. We found that mutant
pores were impaired in both Kap--mediated docking of NLS-
BSA (Fig. 4 I and J) andKap-2-mediated docking ofM9-core (Fig.
4K andL). Docking of rpL23a and spliceosome proteinU1A to the
cytoplasmic face of normal pores was very weak in comparison to
that of NLS-BSA and M9 core. Nevertheless, there was no dis-
cernable difference in the NPC docking of these two substrates in
control and mutant cells (data not shown).
Discussion
Here we report a selective disruption to the NUP98-NUP96
precursor protein via a genetic approach. Our study shows that
NUP98 is required for mouse gastrulation, yet it is not essential
for cell viability and basal cell growth. We show that the
disruption of the nucleoplasmically oriented NUP98 protein
triggers dramatic changes in nucleoporin stoichiometry at the
Fig. 4. Disruption of NUP98 affects nuclear import of selective transport
substrates. (A and B) Kap--mediated import of ﬂuorescein-labeled NLS-BSA.
(CandD)Kap-2-mediated importofﬂuorescein-labeledM9-coreprotein. (Eand
F) Kap-3-mediated import of ﬂuorescein-labeled rpL23a. (G and H) Import of
ﬂuorescein-labeledU1A. Import reactionswereperformedat roomtemperature
and stopped after 10 min (NLS-BSA, M9-core, and U1A) or 20 min (rpL23a) by
ﬁxation. (I–L)Receptor-mediateddockingofNLS-BSA(Iand J)andM9-core (Kand
L) substrates to nuclear pores of control and NUP98 cells.
Table 1. Effects of NUP98 disruption on NPC binding of
nucleoporins and transport factors
Transport component* NE localization AL binding
FG repeat nucleoporins
NUP153 [NB] Normal No
NUP50 [NB] Normal No
p62 [CCC; NCC; NB] Reduced Yes
NUP358 (RanBP2) [CF] Reduced Yes
NUP214 (CAN) [CF] Reduced Yes
Non-FG repeat nucleoporins
NUP96 [NB] Normal No
NUP93 [NCC; NB] Normal No
NUP88 (NUP84) [CF] Reduced Yes
Soluble transport factors
Kap- (importin ) Reduced Yes
Kap- (importin ) Reduced Yes
Kap-2 (transportin) Reduced Yes
Kap-3 (importin 5) Normal No
Importin 7 Reduced Yes
CRM1 Reduced Yes
GLE1 Reduced Yes
*Components listed in this column showed pronouncedNE staining in control
cells. NB, nuclear basket; CF, cytoplasmic ﬁbrils; CCC, cytoplasmic face of the
central channel; NCC, nuclear face of the central channel.
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cytoplasmic face of the NPC, causing distinct protein import
pathways to operate with reduced efficiency. We show that the
observed defects can be corrected by ectopic expression of
HA1-NUP98 in NUP98 cells, indicating that they are
reversible and caused by the disruption of NUP98.
Nucleoporins Selectively Relocate from Nuclear Pores to AL. The
formation of vast numbers of AL is a striking feature of virtually all
cells that lack NUP98. AL are defined as porous—often stacked—
parallel membranes that contain pore complexes (reviewed in ref.
20). The function of AL is not well understood. Thus far, the only
other genetic alteration that is known to promote AL formation is
the disruption of the Drosophila nuclear lamin Dm0 gene (21).
Characteristically, lamin Dm0-deficient cells form large numbers of
cytoplasmic AL, but do not exhibit major changes in the NPC
density of theirNEs.Consistentwith this observation, we found that
NUP98-deficient cells also form AL while keeping their NPC
density at a level that is similar to that of control cells. Thus, it seems
unlikely that anNPCembedding defectwould triggerAL formation
in NUP98-deficient cells.
In this study, we compared the steady-state distributions of eight
different nucleoporins in knockout and control cells. From our
analysis, two distinct groups of nucleoporins have emerged. One
group, consisting of NUP153, NUP50, NUP93, and NUP96, as-
sembled efficiently intomutant pores and had no detectable affinity
for AL. However, members of the second group, which consisted
of p62, NUP358, NUP214, and NUP88, assembled poorly into
mutant pores and wrongly localized to AL. Intriguingly, all nucleo-
porins in the first group localized to the nuclear basket. Conversely,
all nucleoporins in the second group, with the exception of p62,
were positioned at the cytoplasmic face of the NPC. It seems,
therefore, that loss of NUP98 causes nucleoporins to be selectively
displaced from the NPC and deposited in the cytoplasmic AL.
Whether nucleoporins are displaced seems to depend on their
position within the NPC. Our observations further imply that AL
in NUP98-deficient cells are not membranous cisternae that con-
tain pores identical to those embedded in the NE.
Selective Impairment of Protein Import Pathways. We have genet-
ically removed one of an estimated 80–100 different nucleo-
porins that compose the mammalian NPC, and shown that this
disruption results in pleiotropic changes in NPC stoichiometry.
Therefore, functional changes displayed by mutant nuclear pores
could be a direct consequence of disrupted NUP98 function(s)
or result from impairment of other nucleoporins. Notwithstand-
ing this complexity, which is inherent to the complexity of the
NPC itself, our genetic study provides in vivo evidence for the
concept that transport of distinct import complexes through the
NPC is mediated by specific subsets of nucleoporins.
Several FG nucleoporins are asymmetrically localized at the
cytoplasmic fibrils and the nuclear basket, and bind strongly to
certain transport receptors, leading to the idea that such FG
nucleoporins may be pivotal docking or undocking sites for recep-
tor-cargo complexes (reviewed in refs. 3, 5, 6, and 22). In a recent
report, Rout et al. (5) estimated that most FG nucleoporins are
represented in one copy per filamentous structure emanating from
the NPC. If we assume that the stoichiometry of mammalian pores
is similar, it would imply that someof the cytoplasmic spokes of each
NPC in a NUP98 cell would be devoid of cytoplasmically
oriented FG nucleoporins such as NUP358 and NUP214. Consis-
tent with the idea that FG nucleoporins (asymmetrically localized
at the cytoplasmic fibrils) serve as binding sites for protein-import
complexes, we found that mutant pores mediated inefficient dock-
ing of at least two kinds of cargo-receptor complexes, namely
NLSKap- and M9Kap-2 complexes. The observation that
these two types of receptor-cargo complexes were poorly imported
into mutant nuclei indicates that substrate docking is at least one of
the rate-limiting steps in these particular pathways. We discovered
that Kap-3-mediated import of ribosomal protein L23a and
receptor-independent import of spliceosome protein U1A were
normal, demonstrating that mutant pores are selectively impaired
for discrete protein-import pathways rather than for protein import
in general. These findings provide in vivo evidence for the idea that
transport of distinct import complexes through nuclear pores is
mediated by specific subsets of nucleoporins.
In previous studies, it was found that NLS-protein import was
largely unaffected by immunodepletion of NUP98 from reconsti-
tuted Xenopus nuclei (23) or by microinjection of NUP98 antibody
into Xenopus oocytes (24). Although the effect of these antibody
treatments on the overall NPC stoichiometry is not known, a
plausible explanation for the lack of a clear protein-import defect
would be that cytoplasmically oriented Xenopus nucleoporins such
as the homologues of NUP358, NUP214, and NUP88 remain
properly bound to the NPC. In this light, it will be important to
determine in future experiments whether antibody-based inhibi-
tions of nucleoporins can cause pleiotropic changes in NPC stoi-
chiometry. In future work, it will also be important to discern the
impact of our genetic NUP98 disruption on nuclear export of
mRNA, as several studies have suggested thatNUP98might play an
important role in this particular export pathway (14, 24).
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Abstract
Gle2p is implicated in nuclear export of poly(A)+ RNA and nuclear pore
complex (NPC) structure and distribution in Saccharomyces cerevisiae.
Gle2p is anchored at the nuclear envelope (NE) via a short Gle2p-binding
motif within Nup116p called GLEBS. The molecular mechanism by which
Gle2p and the Gle2p-Nup116p interaction function in mRNA export is
unknown. Here we show that RAE1, the mammalian homologue of Gle2p,
binds to a GLEBS-like NUP98 motif at the NPC through multiple domains
which include WD-repeats and a C-terminal non-WD-repeat extension. This
interaction is direct, as evidenced by in vitro binding studies and chemical
cross-linking. Microinjection experiments performed in Xenopus laevis
oocytes demonstrate that RAE1 shuttles between the nucleus and the
cytoplasm and is exported from the nucleus in a temperature-dependent
and RanGTP-independent manner. Docking of RAE1 to the NE is highly
dependent on new mRNA synthesis. Overexpression of the GLEBS-like
motif also inhibits NE binding of RAE1 and induces nuclear accumulation
of poly(A)+ RNA. Both effects are abrogated either by the introduction of
point mutations in the GLEBS-like motif or by overexpression of RAE1,
indicating a direct role for RAE1 and the NUP98-RAE1 interaction in mRNA
export. Together, our data suggest that RAE1 is a shuttling transport
factor that directly contributes to nuclear export of mRNAs through its
ability to anchor to a specific NUP98 motif at the NPC.
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Introduction
Nucleocytoplasmic transport is a signal-mediated process in which soluble
carriers bind to a specific cargo in one compartment, guide it to and through the
NPC, release it in the other compartment and finally recycle to the original
compartment (Cole and Hammell, 1998; Nigg, 1997; Ohno et al., 1998; Weis,
1998). This model is based primarily on our knowledge of the protein import
machinery (Gorlich, 1997). However, there are several lines of evidence to
suggest that it holds true for protein and RNA export pathways as well. Kinetic
competition studies in Xenopus oocytes have indicated that export of several
classes of RNA, including 5S rRNA, U snRNAs, tRNAs and mRNAs, seems to
be mediated by distinct and class-specific transport factors (Izaurralde and
Mattaj, 1995; Jarmolowski et al., 1994). The first direct mediator of RNA export
identified is the HIV-1 protein REV, which specifically binds to a REV-responsive
element (RRE) in non-spliced viral mRNAs (Fischer et al., 1995). REV contains
a leucine-rich-type nuclear export signal (NES) that is recognized by the nuclear
export receptor CRM1, which mediates export of the viral RNA (Fornerod et al.,
1997a; Fukuda et al., 1997; Stade et al., 1997). CRM1 also mediates export of U
snRNAs, probably via direct binding to the U snRNP-associating protein CBC, or
via an unknown NES-containing bridging factor (Izaurralde et al., 1995a).
Recently, a second export receptor, hLos1p or exportin-t, was shown to bind
tRNA molecules and promote their nuclear export (Arts et al., 1998; Kutay et al.,
1998).
It is generally believed that mRNA molecules are exported from the nucleus as
mRNA-protein (mRNP) particles (Nakielny and Dreyfuss, 1997). The protein
composition of these complex structures is unclear, although a series of
abundant nuclear RNA-binding proteins has been identified (Dreyfuss et al.,
1993; Misteli and Spector, 1998). There is some evidence to suggest that
important signals for export of mRNA are provided by its interacting proteins
(Izaurralde et al., 1997a; Michael et al., 1995; Michael et al., 1997; Nakielny et
al., 1997). However, it is unclear whether multiple proteins provide independent
signals for export of mRNP, whether these signals would be additive,
cooperative or redundant, and whether they occur at different stages of the
export pathway (Nigg, 1997). Several laboratories have screened for mutations
in yeast that result in nuclear accumulation of poly(A)-containing RNAs (outlined
by Doye and Hurt [1997]). Accordingly, a variety of NPC proteins and soluble
factors (often referred to as mRNA transport factors) have been identified with
possible roles in nuclear export of mRNA. The majority of these yeast mutants
display additional defects mostly in NPC structure and distribution but also in
NLS-mediated protein import, RNA processing or nucleolar organization
(summarized in Doye and Hurt, 1997). Therefore, it is very difficult to be sure
whether the observed nuclear accumulation of poly(A)+ RNA is the primary
defect (Ohno et al., 1998; Weis, 1998). Some NPC mutants might be expected
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to induce an mRNA defect, because mRNPs are relatively large and their
passage through the NPC channel may require a nucleoporin-dependent
remodeling process (Mehlin et al., 1995). Mutations in three yeast proteins
induce nuclear accumulation of poly(A)+ RNA in the absence of impaired nuclear
protein import or gross structural NPC defects: Gle1p, an essential RNA export
mediator that interacts with Rip1p (Murphy et al., 1996; Segref et al., 1997);
Mex67p, a poly(A)+ RNA binding protein (Segref et al., 1997); and Dbp5p, a
cytosolic RNA helicase (Snay-Hodge et al., 1998; Tseng et al., 1998). Human
Gle1p (hGlep1) seems to be involved in mRNA export as well, although there is
evidence to suggest that yeast and human Gle1p function differently (Watkins et
al., 1998). The human homologue of Mex67p, TAP, has recently been shown to
function in the nuclear export of retroviral RNAs with a constitutive transport
element (CTE) (Gruter et al., 1998).
Genetic studies in yeast have implicated the Schizosaccaromyces pombe (S .
pombe) Rae1p (Brown et al., 1995; Whalen et al., 1997) and its Saccharomyces
cerevisiae (S. cerevisiae) homologue Gle2p (Murphy et al., 1996) in mRNA
export. Gle2p is known to bind the nuclear envelope (NE) via Nup116p, which
contains a short Gle2p-binding motif called GLEBS, that is conserved in the
mammalian NUP98 protein (Bailer et al., 1998). However, the precise role of
Gle2p and the Gle2p-Nup116p interaction in mRNA export remains a mystery.
Here we report the identification and characterization of the interaction between
human RAE1 and NUP98, and outline a molecular mechanism by which RAE1
and the RAE1-NUP98 interaction can function in nuclear export of mRNA.
Materials and Methods
Expression constructs of NUP98 and mouse RAE1 fragments
Human NUP98 cDNA was obtained as described (Kasper et al., 1999). A full-
length mouse RAE1 cDNA was generated from two partial cDNA clones,
473342 and 465642, obtained from the I.M.A.G.E. consortium. HA1-NUP98,
mouse HA1-RAE1 and mutants thereof were generated by PCR using Pfu DNA
polymerase (Stratagene), and cloned in pUHD10S for expression in HtTA cells
(Kasper et al., 1999). All constructs were verified by DNA sequence analysis.
HA1-RAE1 cDNA was cloned into vector pSP73 (Promega) for in vitro
translation purposes. [35S]-methionine labeled HA1-RAE1 protein was produced
using the Promega TNT-coupled rabbit reticulocyte lysate system as indicated
by the manufacturer. To isolate pure populations of transiently transfected HtTA
and BHKgrß cells HA1-NUP98(150-224) was cloned into the EcoRI-XhoI sites of
vector MSCV-IRES-GFP (Persons et al., 1997).
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Cell culture, transfections and electron microscopy
HtTA-1 and BHKgrß cells (Bastos et al., 1996) were grown in DMEM containing
10% fetal bovine serum (FBS). Cells were transfected with Superfect
transfection reagent (Qiagen) according to the manufacturer’s instructions.
Metabolic labeling of HtTA cells was as described (Kasper et al., 1999). For
indirect immunofluorescence studies HtTA cells were transiently transfected in
24-well dishes, seeded on microscope slides 6-h post-transfection, and stained
16-18 h later. To study the effect of the RNA-polymerase II inhibition on the
RAE1 distribution in HtTA cells, the culture medium was supplemented with 0.04
or 5.0 µg/ml actinomycin D (AMD; Boehringer Mannheim), or 50 µg/ml DRB
(Fluka). To obtain pure populations of transiently transfected HtTA or BHKgrß
cells, GFP-positive cells were isolated by fluorescence-activated cell sorting
(Persons et al., 1997). Electron microscopy was as previously described (van
Deursen et al., 1996).
Antibody production
To generate RAE1-specific antibodies we cloned cDNA sequences encoding
mouse RAE1 amino acids 188 to 347 into pQE30 (Qiagen). HIS-tagged
recombinant mouse RAE1 protein was produced in E. coli DH12S cells, purified
with Ni-NTA agarose beads (Qiagen) according to the manufacturer’s
instructions, and injected into rabbits. NUP98- and CRM1-specific antisera were
generated as described (Kasper et al., 1999). Antibodies were affinity-purified
using recombinant antigen bound to ProBlott (Perkin-Elmer) as previously
reported (van Deursen et al., 1996).
Immunofluorescence, coimmunoprecipitations and Western blotting
Indirect immunofluorescence, coimmunoprecipitations and Western blot
analyses were carried out as previously described in detail (Kasper et al., 1999).
Generation of recombinant proteins
A cDNA fragment encoding NUP98(150-224) was cloned in pQE31 and pGEX-
5X-1, respectively for expression of HIS- and GST-tagged recombinant
NUP98(150-224). Recombinant protein expression in E. coli strain DH12S was
induced by addition of 1 mM IPTG followed by incubation at 25oC for 4 to 5 h.
Harvested bacteria were suspended in 50 mM Tris-HCl, pH 7.5, 1 M NaCl, 2 mM
PMSF, 1 mM leupeptin, 2 mM aprotinin and 1 mM pepstatin. Following 30 min of
lysozyme treatment at 40C, bacteria were lysed by sonication. HIS-NUP98(150-
224) and GST-NUP98(150-224) were then purified from bacterial lysates using
Ni-NTA agarose or glutathione beads (Sepharose 4B), respectively (according
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to standard procedures), and used in pull-down assays. A cDNA fragment
encoding RAE1(1-368) was cloned in pGEX-5X-1 to express GST-RAE1 in E.
coli. Bacterial pellets were suspended in PBS with 2 mM PMSF, 1 mM leupeptin,
and 2 mM aprotinin and 1 mM pepstatin. Lysis was performed by sonification
and GST-RAE1was purified with glutathione beads using standard procedures.
Purified RAE1 was separated from the GST-affinity tag using Factor Xa
protease (Pharmacia).
Pull-down assays and chemical cross-linking
Glutathione beads with 100 ng purified GST-NUP98(150-224) were washed 3
times with binding buffer (20 mM HEPES [pH 7.9], 100 mM KCl, 5 mM MgCl2,
0.1% Tween-20, 20% glycerol, 0.01% bovine serum albumin, 1 mM
dithiothreitol, 1 mM PMSF, 1 mM leupeptin, 2 mM aprotinin and 1 mM
pepstatin), preblocked for 10 min with rabbit serum, washed with binding buffer
and resuspended in 60 µl binding buffer. Then, 10 µl in vitro-transcribed and
–translated [35S]-methionine-labeled HA-RAE1 was added to the beads and the
mixture was incubated at 4oC for 1 h (vortexed every 5 min). Beads were
washed 6 times with binding buffer and boiled in 15 µl SDS sample buffer.
Samples were analyzed by SDS-PAGE (10% polyacrylamide) followed by
autoradiography. Pull-down assays with Ni-NTA agarose aliquots containing 100
ng of HIS-NUP98(150-224) were performed in the same way. For chemical
cross-linking, pellets were resuspended in 10 µl PBS with 1 mM disuccinimidyl
suberate (DSS; Pierce) following the last wash in our pull-down protocol. Cross-
linking was at 4oC for 20 min. Finally, 10 µl SDS sample buffer was added and
boiled samples were analyzed by SDS-PAGE (9% polyacrylamide) followed by
autoradiography.
Tryptic digestion and RNA degradation
Trypsin digestion of in vitro-translated or recombinant RAE1 was as previously
described (Audigier, 1994). The reaction was stopped with 2 µl of 100 mM
benzamidine. For enzymatic RNA degradation, 10 µl in vitro-transcribed and
–translated [35S]-methionine-labeled HA1-RAE1 was incubated with either 0.1
unit Micrococcal nuclease (Sigma) or 10 µg RNase A. Both incubations were at
37oC for 30 min and in the presence of 1 mM PMSF, 1 mM leupeptin, 2 mM
aprotinin and 1 mM pepstatin.
Detection of poly(A)+ RNA
HtTA or BHKgrß cells were stained for specific proteins and poly(A)+ RNA by use
of the following combined immunostaining/in situ hybridization procedure. At 6 h
post-transfection, HtTA cells were seeded on microscope slides and
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approximately 16 h later they were fixed in PBS/3% formaldehyde for 15 min at
4°C. After 5 washes in PBS, cells were permeabilized in PBS/0.5% Triton X-100
for 5 min at 4°C. They were then washed in PBS (5x) and incubated with either
12CA5 antibodies (9 µg/ml) alone or 12CA5 and anti-RAE1 antibodies in
PBS/2% BSA/0.2% Triton X-100/200 units/ml RNasin for 30 min at RT. Cells
were then washed in PBS (5x) and incubated with fluorochrome-coupled
secondary antibodies for 30 min at RT: RAE1 antibodies were detected with
Texas-Red conjugated goat-anti-rabbit antibodies (5 µg/ml) and 12CA5 mouse
monoclonal antibodies were detected with R-phycoerythrin conjugated goat-anti-
mouse antibodies (CalTag Laboratories). Cells were washed in PBS (5x) and
then fixed in PBS/3% formaldehyde for 5 min at RT. After 5 rinses in PBS, the
cells were equilibrated in 2X SSC for the in situ hybridization. Hybridization was
performed by using an FITC-coupled oligo-(dT) 50 mer probe as detailed by
Amberg et al. (Amberg et al., 1992). At the end of the procedure the cells were
mounted on the slides in Vectashield (Vector Laboratories, Inc.) and analyzed
by using laser scanning confocal microscopy. The above procedure is very well
suited for detection of alterations in nuclear poly(A)+ RNA levels. However, due
to the relatively short fixation time of 15 min, a fraction of the cytoplasmic
poly(A)+ RNA pool is lost (Haruhiko Siomi, personal communication). Therefore,
if we wanted to study the cytoplasmic poly(A)+ RNA levels in detail, we extended
the 3% formaldehyde fixation step by 15 min and fixed at RT.
Oocyte injections
[35S]-methionine-labeled protein for microinjection into Xenopus oocytes was
synthesized in a rabbit reticulocyte lysate as indicated by the manufacturer
(Promega). Templates were pT7-CBP80 (Izaurralde et al., 1995a), pSP73-HA1-
RAE1 (mouse) and pT7-GST-NES, encoding a GST fusion with the HIV-1 Rev
nuclear export signal (Fischer et al., 1995). E.coli-expressed Rna1p was
coinjected at a concentration of 80 mM in the injection mixture as described
(Izaurralde et al., 1997b). Microinjections, incubations, and protein extraction
and analysis were performed as described (Jarmolowski et al., 1994). Nuclear
export of RAE1 was quantified by measuring the nuclear and cytoplasmic
fractions of RAE1 with a phosphoimager (we corrected for leakage of RAE1 into
the cytoplasm by quantifying the percentage of cytoplasmic CBP80).
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Results
Human RAE1 interacts with a GLEBS-like NUP98 motif
We overexpressed an HA1-tagged NUP98 cDNA (Fig. 1A) in HtTA cells and
immunoprecipitated the cell lysates with 12CA5 monoclonal antibody against the
tag. A protein of approximately 40 kDa specifically coprecipitated with HA1-
NUP98 (Fig. 1B). We wanted to test whether this interacting protein was the
human homologue of the S. cerevisiae Gle2p because of (1) molecular weight
similarity and (2) the presence a motif within NUP98 that is similar to the Gle2p-
binding sequence of Nup116p (Bailer et al., 1998). We obtained a murine cDNA
clone with similarity to yeast gle2/rae1 cDNA (designated RAE1) and generated
polyclonal antisera in rabbits against the carboxy-terminal half of RAE1. We
overexpressed HA1-NUP98 in HtTA cells, immunoprecipitated the cell lysates
with 12CA5 monoclonal antibody against the HA1 tag, and performed a Western
blot analysis using affinity-purified antibodies raised against mouse RAE1. As
shown in Figure 1C, the RAE1 antibodies recognized the HA1-NUP98
coprecipitating protein, demonstrating that NUP98 indeed interacts with the
human homologue of the yeast Gle2p. To ensure that the interaction of NUP98
with RAE1 was not an overexpression artifact, we precipitated NUP98 from non-
transfected HtTA cells with affinity-purified NUP98 antibodies and determined
whether RAE1 was coisolated by Western blot analysis. RAE1 indeed
coprecipitated with NUP98 from HtTA cells (Fig. 1D, lanes 3 and 4). When
affinity-purified RAE1 antibodies were used in the immunoprecipitation step,
NUP98 was coisolated with RAE1 (Fig. 1D, lanes 1 and 2), thereby confirming
that NUP98 and RAE1 are in a complex in human cells. It should be
emphasized that our data do not rule out the possibility that the NUP98-RAE1
complex is part of a larger protein assembly.
To test the role of the GLEBS-like motif of NUP98 in RAE1 binding, an HA1-
NUP98 mutant lacking amino acids 192 to 221 was generated (Fig. 1E). This
mutant, designated as HA1-NUP98∆(192-221), failed to coimmunoprecipitate
RAE1 (Fig. 1F, lanes 2 and 5), although, like full-length NUP98, it localized at
the NE (data not shown). Hence, the GLEBS-like motif of NUP98 was necessary
for binding RAE1. We then asked whether this region of NUP98 was sufficient
for RAE1 binding. We expressed amino acids 150 to 224 of NUP98 as an HA1-
tagged fusion protein in HtTA cells and performed a co-IP Western analysis. As
shown in Fig. 1G (lane 2), NUP98(150-224) indeed coimmunoprecipitated
RAE1. Additional mutagenesis studies revealed that the actual NUP98
interaction motif is located within residues 181-224 (Fig. 1G, lane 4). Computer
analysis (using the GCG program PEPTIDESTRUCTURE) identified a potential
alpha-helical region from amino acids 187 to 212. Three helix-breaking proline
mutations introduced in this region abrogated the NUP98(181-224) interaction
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Figure 1.   A  GLEBS-like  motif  within
NUP98 is necessary and sufficient for
interaction with human RAE1. (A)
Schematic of the NUP98 structure.
Vertical bars indicate FG repeats;
HA1, hemagglutinin tag; NRM,
nucleoporin RNA-binding motif
(shaded box); gray box, Nup116p
homology region. (B) [35S]-methionine-
labeled proteins immunoprecipitated
with monoclonal antibody 12CA5 from
HtTA cells transiently expressing an
HA1-tagged version of NUP98,
separated by SDS-PAGE (8%
polyacrylamide), and visualized by
autoradiography.   A  molecular weight
standard is indicated to the right. (C) Western blot analysis (8% polyacrylamide) of the 40 kDa
protein coimmunoprecipitated with HA1-NUP98 transiently expressed in HtTA cells (lanes 2 and 4).
Non-transfected cells served as a negative control (lanes 1 and 3). The blots were first incubated
with 12CA5 antibody (lanes 1 and 2) and then with affinity-purified anti-m(ouse)RAE1 antibodies
(lanes 3 and 4). The position of human RAE1 is indicated with an arrow. Molecular weight standards
are indicated to the left. (D) Western blot analysis (8% polyacrylamide) of proteins
coimmunoprecipitated from HtTA lysates with anti-RAE1 (left panel) or anti-NUP98 antibodies (right
panel). The antibodies used to visualize NUP98 or RAE1 proteins are indicated above the lanes.
Molecular weight standards are indicated to the left. (E) Structure of NUP98 mutants used to define
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with RAE1 (Fig. 1G, lane 5), further confirming that the NUP98(181-224)
segment contains the GLEBS-like motif.
The RAE1-NUP98 interaction is direct and mRNA independent
To further characterize the RAE1-NUP98 interaction we produced RAE1 and the
GLEBS-like motif in vitro, and analyzed whether they bind directly, or indirectly
via an adaptor protein or a molecule of mRNA. Presumably, members of the
WD-repeat superfamily all form compact globular propeller structures that are
resistant to proteolysis (Garcia-Higuera et al., 1996a; Garcia-Higuera et al.,
1996b). It has been shown previously that most WD-repeat proteins fold into
their native globular structure when synthesized in vitro in a rabbit reticulocyte
lysate system, but not when synthesized in E. coli (Garcia-Higuera et al., 1996a;
Neer et al., 1994a). We synthesized RAE1 protein both in a rabbit reticulocyte
lysate system (see Fig. 2C, lane 1) and in E. coli (not shown) and performed
pull-down assays with HIS-NUP98(150-224) or GST-NUP98(150-224) purified
from E. coli (see Fig. 2A and B). Both HIS- and GST-NUP98(150-224) bind to
RAE1 (HA-tagged) generated in a rabbit reticulocyte lysate system (Fig. 2C,
lanes 4 and 6), but failed to bind recombinant RAE1 synthesized in E. coli (not
shown). To test the folding of RAE1 purified from E. coli and in a rabbit
reticulocyte lysate, we analyzed their sensitivity to tryptic cleavage (Garcia-
Higuera et al., 1996a; Garcia-Higuera et al., 1998; Neer et al., 1994a). We found
that tryptic cleavage of in vitro-translated [35S]-methionine-labeled HA1-RAE1
removes about 3 kDa and leaves a large stable fragment of 42 kDa, despite the
presence of many potential cleavage sites (data not shown). By contrast, RAE1
from E. coli was extensively degraded because of cleavage at multiple tryptic
sites (data not shown). This result implies that in E. coli RAE1 cannot fold into a
compact, globular structure capable of interacting with NUP98.
To investigate whether RAE1 and NUP98 establish direct contact, we used
chemical cross-linkers (Garcia-Higuera et al., 1996b; Neer et al., 1994a; Yi et
al., 1991). Cross-linking of residues from in vitro-translated [35S]-methionine-
labeled HA1-RAE1 and recombinant HIS-NUP98(150-224) or GST-NUP98(150-
the GLEBS-like motif. The various NUP98 motifs are as indicated in Figure 1A. (F) Western blot
analysis (7% polyacrylamide) of proteins precipitated with 12CA5 antibody from HtTA cells
transiently transfected with HA1-NUP98 or HA1-NUP98∆(192-221). Molecular weight standards are
indicated to the left. (G) Same as (F) for a set of HA1-tagged GLEBS-like motif mutants.
Immunoprecipitated proteins were split in two equal portions, one half was run through a 15%
polyacrylamide gel to verify proper expression of HA1-tagged mutant peptides (upper panel), the
other half on an 8% polyacrylamide gel to determine coimmunoprecipitation of RAE1. Because HA1-
NUP98(150-186) protein (lane 3 upper panel) was expressed at a lower level than the other HA1-
tagged mutants, we also collected longer exposures of the RAE1 immunoblot (the lower panel);
however, we were still unable to detect a RAE1-specific signal in lane 3. With the transfection
protocol applied, levels of HA1-NUP98(150-224) were consistently higher than those of HA1-
NUP98(181-224) which causes the difference in intensity of RAE1 signals in lanes 2 and 4.
Molecular weight standards for each gel are indicated to the left.
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Figure 2. Chemical cross-linking of in vitro-translated HA1-RAE1 to E. coli purified GLEBS-like
motifs. (A) Purified recombinant HIS-NUP98(150-224) (approximately 11 kDa) protein separated by
SDS-PAGE (15% polyacrylamide gel) and detected by CBB staining. (B) Purified recombinant GST
(29 kDa) and GST-NUP98(150-224) (approximately 38 kDa) protein run on a 10% polyacrylamide
gel and stained with CBB. (C) Pull-down assays performed with [35S]-methionine-labeled HA1-RAE1
synthesized in vitro (45 kDa), and GST- or HIS-NUP98(150-224) fusion proteins purified from E. coli.
5% input shows 5% of the labeled HA1-RAE1 protein used in each pull-down assay. Typically, the in
vitro-translated RAE1 appears as a doublet, representing fragments with and without a HA1 tag (the
RAE1 cDNA was cloned in pSP73 as a HA1 fusion gene that retained the endogenous RAE1
translation initiation codon). GST beads and Ni-NTA agarose acted as negative control for binding in
GST-NUP98(150-224) and HIS-NUP98(150-224) pull-down assays, respectively. Comparable
amounts of GST, GST-NUP98(150-224) and HIS-NUP98(150-224) proteins were used in each pull-
down assay. The experiment shown is representative for two independent experiments. A cross-
linked GST-NUP98(150-224)/RAE1 product of approximately 84 kDa and a cross-linked HIS-
NUP98(150-224)/RAE1 product of approximately 56 kDa were obtained specifically in DSS-treated
samples. Note that cross-linking of RAE1 to HIS-NUP98(150-224) was more efficient than to GST-
NUP98(150-224). Molecular weight standards are indicated to the right.
224) should yield specific cross-linked products of ~56 kDa and ~83 kDa,
respectively. The predicted cross-linked products were indeed obtained with
DSS (Fig. 2C, lanes 3 and 5), a reagent that cross-links mainly lysine residues,
but not with BMH, a sulfhydryl-reactive cross-linker (data not shown). DSS-
mediated coupling of RAE1 to the GLEBS-like motif of NUP98 revealed that the
interaction is direct and not mediated though another protein.
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Figure 3. Poly(A)+ RNA is not a cofactor in the binding reaction between RAE1 and the GLEBS-like
motif of NUP98 in vitro. (A) Pull-down assay performed with GST-NUP98(150-224) fusion protein
purified from E. coli and [35S]-methionine-labeled in vitro-translated HA1-RAE1 pre-treated with or
without Micrococcal nuclease. GST alone did not pull-down HA1-RAE1 (not shown). (B) As (A) but
pre-treated with or without RNase A. GST alone did not pull-down HA1-RAE1 (not shown). (C) Pull-
down assay with GST-NUP98(150-224) and in vitro-translated HA1-RAE1 in the presence of various
concentrations of poly(A)+ RNA isolated from HtTA cells. GST alone does not pull-down HA1-RAE1
as indicated in lane 6.
It has been reported that RAE1 can be UV cross-linked to poly(A)+ RNA
(Kraemer and Blobel, 1997), and theoretically, binding between RAE1 and
GLEBS-like motif may be established via mRNA. To investigate this possibility,
we synthesized [35S]-methionine-labeled HA1-RAE1 protein, removed the mRNA
from the reticulocyte lysate with either Micrococcal nuclease or RNase A, and
performed pull-down assays with GST-NUP98(150-224) beads. Neither the
nuclease (Fig. 3A) nor the RNase A treatment (Fig. 3B) had any effects on the
binding ability of RAE1 to NUP98 in vitro. Pull-down assays were also performed
after addition of various amounts of poly(A)+ mRNA isolated from HtTA cells.
However, the binding efficiency of HA1-RAE1 to the GLEBS-like motif was
similar irrespective of the mRNA amount present during the binding reaction
(Fig. 3C). In summary, our in vitro-binding studies indicate that the interaction
between RAE1 and the GLEBS-like motif of NUP98 is direct and mRNA-
independent.
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Figure 4. Multiple domains of
RAE1 are necessary but not
sufficient for interaction with
NUP98.  (A) .  Schemat ic
representation of HA1-RAE1
deletion mutants. The four WD-
repeat motifs are indicated as
gray boxes. All mutants
expressed an N-terminal HA1
tag. (B) Western blot analysis of
proteins precipitated with 12CA5
antibody from lysates of HtTA
cells transiently transfected with
HA1-RAE1 or various deletion
mutants. Precipitated proteins
were visualized with 12CA5
(upper panel) and anti-NUP98
antibodies (lower panel). The
HA1-RAE1 mutants used are
indicated above the lanes.
Molecular weight standards are
indicated to the left. Results
shown are representative for
three independent experiments.
(C-G) Confocal images detailing
the subcellular distribution HA1-
RAE1 delet ion mutants
moderately expressed in HtTA
cells and stained with 12CA5
antibody. Note that the ability to
coprecipitate NUP98 correlates
with prominent NE staining.
The COOH-terminal non-WD-repeat extension of RAE1 is essential for NUP98
binding
To start investigating how RAE1 binds to the GLEBS-like motif of NUP98 at the
NPC, we generated a series of mutants with deletions in the N- or C-terminal
non-WD-repeat extensions and tested them for their ability to interact with
NUP98 by using a coimmunoprecipitation approach (see Fig. 4A). Mutant HA1-
RAE1(33-368), which lacks the entire non-WD-repeat N-terminal extension, was
able to coprecipitate NUP98, although with reduced efficiency compared to
wildtype RAE1 (Fig. 4B, lanes 1 and 3; n = 3 independent experiments).
Extension of this deletion into the first WD repeat [HA1-RAE1(66-368)],
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abolished interaction with NUP98 (Fig. 4B, lane 6). HA1-RAE1(1-329), which
lacks the C-terminal 39 amino acids, again failed to coprecipitate NUP98 (Fig.
4B, lane 5). By contrast, mutant HA1-RAE1(1-359), which lacks the C-terminal 9
residues containing a highly conserved basic motif that has been shown to be
essential for Rae1p function in S. pombe (Whalen et al., 1997), could
coprecipitate NUP98 (Fig. 4B, lane 4). Hence, the basic motif of RAE1 may
attribute a critical cellular function of RAE1 other than binding to NUP98.
In non-transfected HtTA cells, RAE1 was localized prominently at the NE, but
substantial amounts of RAE1 were also found in the nucleus and the cytoplasm
(see Fig. 6B). A very similar distribution pattern was observed in HtTA cells that
moderately overexpress HA1-RAE1 (see Fig. 4C), however, more robust
overexpression resulted in a disproportionate increase of RAE1 levels in the
nucleus (not shown). As expected, all deletion mutants but the ones that failed
to coprecipitate NUP98, displayed overt NE localization when transiently
expressed in HtTA cells (see Fig. 4D-F). The above experiments suggest that
both the WD repeat propeller and the C-terminal non-WD-repeat extension of
RAE1 contribute to NUP98 binding.
 Point mutation’s individual WD-repeats differentially affect NUP98 binding
The HA1-RAE1(66-368) mutant suggested that the WD repeat propeller of
RAE1 is implicated in NUP98 binding. To further define the role of the WD
repeats in the RAE1-NUP98 interaction, we mutated single WD-repeats at their
highly conserved aspartic acid residue positioned in the turn connecting the ß
strands b and c of a propeller blade (Fig. 5A and B). We targeted these
particular residues because their conservation in 85% of all known WD-repeats
indicates that they perform an important role within the propeller structure
(Garcia-Higuera et al., 1998; Neer et al., 1994b; Neer and Smith, 1996).
Moreover, it has been reported that point mutations at the conserved aspartic
acid residues of the WD-repeat proteins Gß and sec13 can cause local
distortions in the structure of individual propeller blades without affecting the
overall structure of the propeller (Garcia-Higuera et al., 1998). We expressed the
point mutants in HtTA cells and determined their ability to interact with NUP98.
We found that the point mutation in propeller blade 4 (Fig. 5C, lane 3), but not
the point mutation in blade 2 or 3 (Fig. 5C, lanes 1 and 2, respectively),
abolished RAE1’s ability to bind to NUP98. Accordingly, HA1-RAE1-D2 and -D3
(Fig. 5E and F, respectively) displayed a prominent NE localization when
transiently expressed in HtTA cells. However, HA1-RAE1-D4 (Fig. 5G) was
undetectable at the NE. Together, the above studies underscore that the WD-
repeat propeller is implicated in the binding of RAE1 to NUP98. Moreover, they
suggest that individual WD repeats differentially support the RAE1-NUP98
interaction.
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Figure 5. A  single point
mutation in a highly
conserved WD-repeat
residue abrogates RAE1-
NUP98 interaction at the
NPC. (A) A scale drawing of
HA1-RAE1 depicting the
positions of the highly
conserved D residues within
the last three WD repeats
that we individually mutated
to A. (B) Schematic
representation of a blade
from a WD repeat propeller
structure (Garcia-Higuera et
al., 1998). The four ß
strands within the blade are
indicated with a to d. Note
that the position of the
conserved D residue in the
hairpin turn between strand
b and c is highlighted (star).
(C) Western blot analysis of
proteins precipitated with
12CA5 antibody from
lysates of HtTA cells
transiently transfected with
HA1-RAE1 or the point
mutants .  Prec ip i ta ted
proteins were visualized
with 12CA5 (upper panel)
and anti-NUP98 antibodies
(lower panel). The HA1-
RAE1 mutants used are
indicated above the lanes.
Molecular weight standards
are indicated to the left.
Resu l t s  shown a re
representative for three
independent experiments.
(D-G)  Representa t ive
confocal images detailing
the subcellular distribution of
HA1-RAE1mutants in HtTA
cells (12CA5 antibody
staining).
RAE1 shuttles between the nucleus and the cytoplasm
RAE1 could be permanently or transiently bound to NUP98 at the NPC, or both.
As a first step to investigate whether RAE1 has dynamic properties, we
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Figure 6. RAE1 shuttles between the nucleus and the cytoplasm and its association with the NE
requires RNA polymerase II activity. (A) A mixture of in vitro-translated [35S]-methionine labeled
CBP80, HA1-RAE1 (seen as a doublet that represents HA1-RAE1 and RAE1), and GTS-NES was
injected into Xenopus laevis oocytes nuclei, either in the absence (lanes 1-6) or presence (lanes 7-
12) of 80 mM Rna1p. Following injection, oocytes were incubated at 20oC and protein samples from
nuclear (N) and cytoplasmic fractions (C) were collected at 10, 30 or 90 minutes. Proteins were
separated by SDS-PAGE and detected by fluorography. (B) Kinetics of RAE1 distribution after
nuclear injection. Values were obtained from 3 experiments; error bars represent standard
deviations. (C) Comparison of nuclear export of RAE1 at 20 °C (lanes 1-2) and 0° (lanes 3-4).  (D)
Nuclear uptake of RAE1 after cytoplasmic injection after 0.2 (lanes 1-2), 6 (lanes 3-4) or 9 hours
(lanes 5-6).
microinjected in vitro-translated [3 5S]-methionine-labeled mouse RAE1 into
Xenopus oocytes and analyzed its ability to shuttle between the nucleus and the
cytoplasm. The NLS-containing protein CBP80 was coinjected with RAE1 to
serve as a control for nuclear protein import, and proper injection and dissection
of the oocytes (Izaurralde et al., 1995b). We injected RAE1 into the oocyte
nucleus and quantified the fraction of RAE1 appearing in the cytoplasm at
various time points post-injection by phosphoimager analysis. Figure 6A (lanes
1-6) and B demonstrate that approximately 24% (SD ± 4%, n = 3 independent
experiments) of the RAE1 molecules injected into the nucleus is present in the
cytoplasm within 30 min post-injection and maximal cytoplasmic levels of 31%
(SD ± 4%, n = 3) are achieved within 90 min post-injection. These data suggest
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(a) that an equilibrium between export and import has been established around
90 min post-injection and (b) that the majority of the microinjected RAE1
molecules seems to be export incompetent. In addition, Export of microinjected
RAE1 was completely inhibited at 0oC (Fig. 6C, lanes 3 and 4), indicating that
RAE1 export is temperature dependent and not driven by “simple” diffusion. We
also investigated whether RanGTP mediates nuclear export of RAE1 by
reducing the level of RanGTP via nuclear injection of Rna1p, a normally
cytoplasmic GTPase-activating protein for Ran (Izaurralde et al., 1997b). As
shown in figure 6A (compare lanes 1-6 with 7-12), coinjection of 80 mM Rna1p
(1-10 mM usually induces a significant inhibition in RanGTP-dependent export)
did not significantly inhibit nuclear export of RAE1, while, in accordance with
previous data (Izaurralde et al., 1997b; Richards et al., 1997) nuclear export of
NES-tagged GST substrates was dramatically reduced. As expected from its
nuclear localization, RAE1 protein injected into the oocyte cytoplasm was able to
migrate rapidly into the nucleus (Fig. 6D, lanes 1-6).
Association of RAE1 with the NE requires RNA polymerase II activity
The combination of shuttling and poly(A)+ RNA-binding properties (Kraemer and
Blobel, 1997) led us to hypothesize that RAE1 travels between cellular
compartments as an mRNA export factor. To investigate this possibility we
stopped mRNA synthesis in HtTA cells by adding RNA polymerase II inhibitors
and asked whether the subcellular distribution of RAE1 changed. After 1 h of
treatment with 5 µg/ml AMD, a dose which inhibits both RNA polymerase I and II
activity, the prominent RAE1 staining at the NE normally seen in HtTA cells was
no longer detectable (compare Fig. 7A and C). In contrast, normal levels of
RAE1 at the NE were observed in cells exposed to a dose of AMD that only
inhibited RNA polymerase I activity (0.04 µg/ml AMD; see Fig. 7B). When we
shortened the treatment with 5 µg/ml AMD from 1 h to 15 min, the drop in RAE1
levels at the NE was still detectable, suggesting that the observed effect can be
an immediate early response to RNA polymerase II inhibition. HtTA cells
exposed to 50 µg/ml of the RNA polymerase II inhibitor 5,6-dichloro-b-D-
ribofuranosylbenzimidazole (DRB) showed a RAE1-staining pattern very similar
to that observed in cells exposed to a high dose of AMD (Fig. 7D). The inhibitory
effect of DRB is reversible and we analyzed whether normal RAE1 levels at the
NE would be restored upon reactivation of RNA polymerase II-mediated
transcription. As shown in Figure 7E, a prominent NE staining was observed in
cells cultured for 6 h in the absence of DRB following a 1h exposure to this
component. As expected, the RAE1 levels at the NE were substantially reduced
following a second DRB treatment (Fig. 7F). In both AMD- and DRB-treated
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Figure 7. RAE1’s association with the NE requires RNA polymerase II activity. (A-H) Images of HtTA
cells stained for RAE1 or NUP98 after treatment with RNA polymerase inhibitors. RAE1-stained cells
treated with: (A) 0 µg/ml AMD for 1 h, (B) 0.04 µg/ml AMD for 1 h,  (C) 5.0 µg/ml AMD for 1 h,  (D) 50
µg/ml DRB for 1 h, (E)  50 µg/ml DRB for 1 h and then cultured 6 h in the absence of DRB,  (F)  50
µg/ml DRB for 1 h and then cultured 6 h without DRB and finally treated again with 50 µg/ml DRB for
1 h Images shown are representative for results obtained from three independent experiments. (G
and H) Respectively non-treated and 5.0 µg/ml AMD treated HtTA cells stained with NUP98-specific
antibodies. Note that NUP98 levels at the NE are not dependent on RNA polymerase II activity. (I, J)
Effect of AMD treatment on HtTA cells that moderately express HA1-RAE1.
cells, the decrease for NE-associated RAE1 did not coincide with significant
alterations in the nuclear and cytoplasmic RAE1 levels. Inhibition of RNA
polymerase II activity did not affect NUP98 association with the NE (compare
Fig. 7G and H), demonstrating that the absence of substantial amounts of RAE1
at the NE was not the result of NUP98 relocation. As expected, the nuclear
export receptor hCRM1, which mediates export of certain viral RNAs and U
snRNP, but not cellular mRNA, retained its NE localization in the presence of
AMD (5 µg/ml) or DRB (data not shown). Together, the above experiments
confirm that the NE association of RAE1 is transient rather than stable.
Furthermore, they support the hypothesis that RAE1 associates with the NE as
part of a mRNP complex.
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It has been demonstrated that an AU1-tagged version of human RAE1 localizes
at high levels to the nucleus and at considerably lower levels to the cytoplasm of
HeLa cells (Bharathi et al., 1997). When AU1-RAE1 expressing cells were
treated with RNA polymerase II inhibitors, no major changes in the distribution of
AU1-RAE1 were detected. This result may seem to contradict the data
presented in this report; however, it should be stressed that the effects of RNA
polymerase II activity on AU1-RAE1 levels at the NE could not be evaluated
because the robust nuclear staining masked the NE staining (Bharathi et al.,
1997). To re-evaluate the effect of RNA polymerase II inhibitors on the
distribution of overexpressed RAE1, we transiently expressed HA1-RAE1 in
HtTA cells. Typically, when overexpressed at low to moderate levels, HA1-RAE1
prominently localized to the NE, but significant amounts of RAE1 were also
found in the nucleus and the cytoplasm (see Fig. 7I). More robust
overexpression of HA1-RAE1 resulted mostly in a disproportionate increase of
RAE1 levels in the nucleus, which concealed the NE staining (data not shown).
We determined the effect of RNA polymerase II inhibition on the distribution of
HA1-RAE1 by focussing on cells with a low to moderate level of expression. As
shown in Figure 7J, HA-RAE1 levels at the NE decreased significantly when
cells were treated with 5 µg/ml AMD for 1 h, which is consistent with the results
that we obtained by using non-transfected HtTA cells.
Overexpression of the GLEBS-like motif inhibits nuclear export of poly(A)+
When HtTA cells transiently expressing HA1-NUP98(150-224) or HA1-
NUP98(181-224) were immunostained with 12CA5 and RAE1 antibodies 24-h
post transfection, we noticed a considerable reduction of RAE1 levels at the NE.
As shown in Figure 8A/A’ and B/B’, NE staining of RAE1 is easily detectable in
non-transfected HtTA cells (marked with “nt”) but not in HA1-NUP98(150-224) or
HA1-NUP98(181-224) expressing cells (marked with “t”).  By contrast, NE
staining of RAE1 remained intact when HA1-NUP98(181-224)M (Fig. 8C/C’), a
mutated GLEBS-like motif which does not interact with RAE1 (see also Fig. 1G,
lane 5), or full-length HA1-NUP98 were overexpressed (Fig. 8D/D’). In all cases
NUP98 localization at the pores appeared unchanged (data not shown). The
above results suggest that overexpressed GLEBS-like motif of NUP98 acts as a
dominant negative inhibitor of RAE1-NPC association by titrating RAE1 from the
NPC and/or interfering with RAE1 docking to NUP98 at the NPC.
To assess whether this effect is associated with changes in mRNA export, we
examined the poly(A)+ RNA distribution in HtTA cells expressing the NUP98
GLEBS-like motif by in situ hybridization with an FITC-labeled oligo-(dT) 50 mer
probe (Amberg et al., 1992; van Deursen et al., 1996). With this in situ
hybridization protocol, alterations in nuclear poly(A)+ levels can easily be
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Figure 8. Overexpression of the
GLEBS-like motif of NUP98
results in decreased levels of
RAE1 at the NE. (A/A’-D/D’).
Paired confocal images from
HtTA cells that transiently
express various forms of the
GLEBS-like motif of NUP98.
Cells were double-stained for
HA1-tagged protein using the
12CA5 monoclonal antibody (left
image) and for RAE1 using
affinity-purified RAE1 polyclonal
rabbit antibodies. Cells shown in
the confocal images are
representative for results
obtained in 3 to 4 independent
experiments. High magnification
images are given to illustrate
detai l .  (A/A’  and B/B’)
Overexpression of the GLEBS-
like motif leads to a subtle but
significant decrease in NE
localization of RAE1. Compare
NE staining of cells that do not
overexpress the RAE1-binding
(which are marked with “nt“) and
cells that do (marked by “t”).
(C/C’ and D/D’) Cells expressing
a GLEBS-like motif mutant that
is unable to interact with RAE1
or full-length NUP98 (D/D’),
display an RAE1-distribution
pattern comparable to that of
wildtype HtTA cells.
detected. Hybridized cells were examined by confocal microscopy. As shown in
detail in Figure 9F’, poly(A)+ RNA was detected in both the nucleus and the
cytoplasm of non-transfected HtTA cells. In situ hybridization of transiently
transfected HtTA cells expressing HA1-NUP98(150-224) (Fig. 9B/B’) or
NUP98(181-224) (Fig. 9C/C’) revealed a dramatic increase in nuclear labeling
(for detailed images see Fig. 9G/G’ and H/H’). To confirm that the strong nuclear
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labeling was indeed due to RNA accumulation, HtTA cells expressing HA1-
NUP98(150-224) or HA1-NUP98(181-224) were incubated with RNase for 30
min prior to in situ hybridization. As expected, no labeling was detectable after
such treatment (Fig. 9J/J’). As an additional control that the signal detected in
the nucleus is indeed mRNA, we incubated HA1-NUP98(150-224) expressing
cells for 1 h with DRB prior to in situ hybridization with the oligo-(dT) 50-mer
probe. We quantified the nuclear signal of 20-25 cells by using confocal
microscopy and the software program QUANTIFY. We compared the levels
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Figure 9. Overexpression of the GLEBS-like motif of NUP98 results in accumulation of poly(A)+ RNA
in the nucleus. (A-J) Paired confocal images from HtTA cells that are transiently expressing HA1-
NUP98 mutants. These cells were double-stained for HA1-tagged protein by immunohistochemistry
using the 12CA5 monoclonal antibody (left image) and for poly(A)+ RNA by in situ hybridization using
a FITC-labeled oligo-(dT) 50 mer (right image). The identity of the HA1-tagged NUP98 mutants is
indicated in the left image of each pair. The poly(A)+ RNA accumulation in B’ appears more robust
than that in C’, which represents a photographic rather than a real difference. The arrow in F’ points
to one of the sites of preferred poly(A)+ RNA localization (also reported by Huang and co-workers
1994). (K and L) Shows poly(A)+ distribution in HtTA cells overexpressing mouse RAE1 protein and,
at the same time, HA1-NUP98(150-224) or HA1-NUP98(181-224). Each row of three images shows
the same field of cells stained for either HA1-tagged protein (left), ectopically expressed mouse
RAE1 and native human RAE1 (middle), and poly(A)+ RNA (right). Note that mouse RAE1
overexpression restores proper mRNA export in cells expressing various forms of the GLEBS-like
motif. The combined anti-HA1/poly(A)+ staining procedure does not allow extensive blocking of non-
specific 12CA5 antibody binding. Therefore, non-transfected cells display higher levels of
background staining than those shown in Figure 7.
obtained with those measured in the same amount of non-treated HA1-
NUP98(150-224) positive cells. In three independent experiments, the nuclear
poly(A)+ signal detected in DRB-treated cells was 29, 30, and 36% lower than in
non-treated cells. Thus, a proportion of the nuclear poly(A)+ RNA is either
exported to the cytoplasm or rapidly degraded (or both), suggesting that at least
a proportion of the signal obtained with the oligo-(dT) probe represents nuclear
mRNA and not just stable nuclear poly(A)+ RNA (Huang et al., 1994).
Nuclear accumulation of poly(A)+ RNA induced by HA1-NUP98(150-224) or
NUP98(181-224) expression typically coincided with a decrease in cytoplasmic
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Figure 10. Overexpression of the GLEBS-like motif of NUP98 does not affect nuclear protein import.
(A and B) Representative images of normal and HA1-NUP98(150-224) expressing BHK cells stained
with monoclonal antibody 12CA5 and the FITC-labeled oligo-(dT) 50 mer. Note that HA1-
NUP98(150-224) expressing BHK cells accumulate poly(A)+ RNA in their nuclei. (C and D)
Immunofluorescence detection of the glucocorticoid receptor-b-galactosidase fusion protein in a
representative BHKgrß cell expressing HA1-NUP98(150-224) before and 30 min after the addition of
10 mg/ml dexametasone (DMS).
poly(A)+ RNA levels; however, considerable amounts of polyadenylated RNA
were still found in the cytoplasm (see Fig. 9B/B’, C/C’, G/G’ and H/H’). This was
further corroborated by using an in situ hybridization procedure optimized for
detection of cytoplasmic polyadenylated RNA (for details see materials and
methods), as is illustrated in Figure 9I/I’. No nuclear build-up of poly(A)+ RNA
was found in cells expressing the GLEBS-like motif mutant HA1-NUP98(181-
224)M (Fig. 9D/D’), which confirms that binding of endogenous RAE1 to
overexpressed GLEBS-like motif is essential poly(A)+ RNA accumulation. In
HtTA cells overexpressing mouse RAE1 in addition to HA1-NUP98(150-224), or
HA1-NUP98(181-224) nuclear accumulation of poly(A)+ RNA was either not
seen or hardly detectable (see representative images in Fig. 9K and L). Thus,
proper poly(A)+ RNA export can take place in the presence of transiently
expressed GLEBS-like motif if RAE1 levels are increased above normal. RAE1
overexpression probably restores the cellular pool of “free” RAE1 to a level
required for proper nuclear mRNA export. We verified that overexpression of
HA1-tagged mouse RAE1 (Fig. 9E/E’) or non-tagged RAE1 (not shown) alone
did not induce any measurable alterations in poly(A)+ RNA distribution compared
to non-transfected HtTA cells.
To verify that the poly(A)+ defect was not the result of a nuclear import defect we
used BHKgrß cells. These cells express a glucocoticoid receptor-ß-
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galactosidase fusion protein that is strictly localized to the cytoplasm. When
exposed to dexamethasone, the fusion protein translocates within 30 min to the
nucleus in a quantitative fashion (Bastos et al., 1996). When we transfected
BHKgrß cells with an HA1-NUP98(150-224) construct, they accumulated
poly(A)+ RNA in the nucleus (compare Fig. 10A/A’ and B/B’) with no detectable
effect on the import of the glucocoticoid receptor-b-galactosidase fusion protein
(Fig. 10C/C’ and D/D’). Although only one protein was tested, these results show
that the NLS-mediated nuclear import pathway remained intact, and that the
mRNA export phenotype is not likely to be the result of a general trafficking
defect.
Finally, we wanted to exclude that overexpression of the GLEBS-like motif
induced NPC herniations similar to those seen in yeast nup116- and gle2-
knockouts (Murphy et al., 1996; Wente and Blobel, 1993) and
nup116pD(GLEBS) mutant cells (Bailer et al., 1998). To this end, we purified
transiently transfected HtTA cells expressing both HA1-NUP98(150-224) and
green fluorescent protein (GFP) by FACS sorting and studied their NPC integrity
using an electron microscope. None of the HA1-NUP98(150-224) expressing
cells examined displayed any herniated or clustered NPCs (data not shown).
Thus, the mRNA-export defect is not likely to be secondary to abnormalities in
NPC structure and distribution. Taken together, our results suggest a model in
which a dominant negative GLEBS-like motif directly interferes with export of
poly(A)+ RNA from the nucleus by targeting RAE1 the NUP98-RAE1 interaction,
or both.
Discussion
Details about the mechanism by which mRNA is exported from the nucleus
remain a mystery. Here we identified and characterized an interaction between
human RAE1 and NUP98, and studied its significance in mRNA export. Our
studies support a model in which RAE1 is a shuttling transport factor that
permits efficient export of mRNA through its ability to anchor to a GLEBS-like
NUP98 motif at the NPC. Specifically, we show that: (1) RAE1 binds to the
GLEBS-like motif of NUP98 through multiple domains including the WD
propeller and part of the carboxy-terminal non-WD-repeat extension; (2) the
RAE1-NUP98 interaction is direct and not via another protein or RNA; (3) RAE1
has the ability to shuttle from the nucleus to the cytoplasm and that its
interaction with the NE seems to be transient rather than stable; (4) the GLEBS-
like motif, when overexpressed, binds to RAE1 and inhibits poly(A)+ RNA export
from the nucleus, but not NLS-mediated import and NPC structure or
distribution.
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Shuttling and dynamic properties of RAE1
Analysis of the dynamic properties of RAE1 by microinjection of in vitro-
translated protein into Xenopus laevis oocytes revealed that RAE1 has the
ability to shuttle between the nucleus and the cytoplasm in a rapid manner.
Furthermore, nuclear export of RAE1 appears to be established by a
temperature-sensitive, RanGTP-independent, mechanism. Several studies have
demonstrated that GTP-bound Ran has an essential role in nuclear RNA export.
However, different RNA classes seem to depend differently on RanGTP for their
export from the nucleus. Both U snRNA and tRNA export are highly sensitive
towards RanGTP depletion. On the other hand, some mRNAs, such as H4 and
DHFR mRNA (Izaurralde et al., 1997b), apparently use RanGTP-dependent as
well as RanGTP–independent mechanisms for their nuclear export, whereas
export of adenovirus major late transcripts (Izaurralde et al., 1997b) and heat
shock mRNAs (Saavedra et al., 1997; Stutz et al., 1997) is unaffected by the
absence of nuclear RanGTP. Therefore, the RanGTP-insensitivity of RAE1
export does not argue against the idea that RAE1 may be a shuttling nuclear
export factor for mRNAs. Indeed, no RanGTP-binding exportin has yet been
identified that is directly involved in mRNA export (see also Stutz and Rosbash,
1998), and it remains possible that the effects of RanGTP depletion on mRNA
export are indirect.
Two additional findings reported here support RAE1’s dynamic properties. First,
overexpression of the GLEBS-like motif of NUP98 causes a reduction in the
level of RAE1 associated with the NE. If RAE1 is permanently associated with
NUP98 at the NE, overexpression of the GLEBS-like motif is expected to have
no major effects on RAE1 levels at the NE. On the other hand, if RAE1’s
association with the NE would be transient rather than permanent, RAE1
molecules released from the NE may form a complex with the overexpressed
GLEBS-like motif of NUP98. Once established, such complexes may be
defective in docking to NUP98 at the NE and induce a general decline in RAE1
levels at the NE. The second finding that emphasizes the dynamic properties of
RAE1 is that the level of RAE1 at the NE appears to be dependent on RNA
polymerase II activity. Specifically, we observed that the amount of RAE1 at the
NE dropped considerably if cells were exposed to RNA polymerase II inhibitors.
When RNA polymerase II activity was restored by removal of the inhibitor, RAE1
levels at the NE returned to normal. Thus, RAE1’s translocation from the
nucleus to the NE may be dependent on the availability of gene transcripts
generated by RNA polymerase II. It can be argued that the effect of RNA
polymerase II inhibitors on the NE association of RAE1 is secondary to the
depletion or relocation of one or more other cellular factors of unknown identity.
Although we cannot exclude this possibility, three of our findings argue against
an indirect effect: (1) the RAE1 levels at the NE drop shortly after initiation of
AMD treatment (≤ 15 min); (2) the reversibility of the DRB-induced effect on
RAE1; and (3) the observation that the inhibitors do not alter the distribution of
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the transport factors NUP98 and hCRM1 (Fornerod et al., 1997b). While more
detailed analysis need to be done, the RNA polymerase II inhibition experiments
are consistent with the notion that  RAE1 is a dynamic mRNA export mediator.
On the surface, the observation that the association of RAE1 with the NE
depends on RNA polymerase II activity seems to contradict the data from our in
vitro binding studies, which indicated that mRNA is not a cofactor in the
interaction between RAE1 and the GLEBS-like motif of NUP98. This apparent
paradox can be explained if one assumes that docking of a transport substrate
from the nucleus to the NPC follows a two-step process. In the first step, the
substrate translocates from its site of assembly in the nucleus to the nuclear
periphery. In the second step, the substrate anchors to the NPC. In this light, the
negative effect of RNA polymerase II inhibitors on the association of RAE1 with
the NE may reflect a defect not in the ability to anchor to NUP98 at the nuclear
face of the NPC but rather in RAE1’s translocation of from the nucleus to the
NPC. Guidance of RAE1 to the NPC may be a signal-mediated process relying
on external export signals perhaps provided by proteins within the mRNP
transport substrate. Because so many proteins associated with the mRNA
export substrate, multiple associated proteins may provide independent signals
for export of mRNP.
RAE1 and mRNA export
Our most powerful evidence for a direct role of RAE1 and the RAE1-NUP98
interaction in the mRNA export pathway comes from GLEBS-like motif
overexpression studies. Typically, overexpression of the GLEBS-like motif of
NUP98 resulted in reduced levels of RAE1 at the NE and nuclear accumulation
of poly(A)+ RNA. Presuming that RAE1 is a component of mRNP (Kraemer and
Blobel, 1997) two possibilities could explain these data. It seems fair to argue
that RAE1 associates with mRNP since RAE1 and poly(A)+ RNA can be cross-
linked by UV irradiation in vivo (Kraemer and Blobel, 1997). Thus, at least part of
the cellular RAE1 pool is in close proximity to mRNA, although it remains to be
determined whether RAE1 and mRNA interact directly (RAE1 sequences lack
similarity to any known mRNA-binding motifs), or indirectly via one of the mRNA-
associated proteins. In the first possibility, one might propose that the NUP98
GLEBS-like motif binds to a RAE1 molecule that is in a complex with mRNP.
The presence of the GLEBS-like motif in the resulting complex would then
prevent its anchoring to full-length NUP98 at the NPC. In the second possibility,
one might argue that the GLEBS-like motif associates with “free” RAE1 protein
to affect its binding to mRNP. Lack of RAE1 within the mRNP particle would
then affect its proper anchoring to the NPC.
We found that cells which co-overexpress the GLEBS-like motif together with
full-length RAE1 displayed neither reduced levels of RAE1 at the NE nor
accumulation of poly(A)+ RNA in the nucleus, indicating that the mRNP export
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defect induced by the GLEBS-like motif is not an overexpression artifact but
rather a result of impaired RAE1 function. How could RAE1 overexpression
neutralize the mRNA export defect induced by the GLEBS-like motif? If the
GLEBS-like motif indeed interacts only with RAE1 that is bound to mRNP, as
proposed above in possibility one, then RAE1 overexpression is expected to
have little or no effect on the formation of anchoring-defective complexes.
However, if the GLEBS-like motif only associates with a “free” RAE1 molecule,
as outlined in possibility two, then RAE1 overexpression could simply titrate
GLEBS-like motifs and restore the pool of “free” RAE1 to a level sufficient for
proper mRNP export. Thus, the data from our co-overexpression studies are
apparently more consistent with possibility two than with possibility one.
Additional data presented in this report are consistent with the idea that RAE1
and the RAE1-NUP98 interaction directly serve in the nuclear export pathway for
mRNA. First, NUP98 fragments with point mutations in the GLEBS-like motif that
abolish its association with RAE1 failed to inhibit poly(A)+ RNA export from the
nucleus. Thus, there is a correlation between nuclear accumulation of poly(A)+
RNA and binding of the GLEBS-like motif to RAE1. Second, there is no
evidence to suggest that the observed poly(A)+ RNA accumulation phenotype
results from impaired NLS-mediated protein import, loss, clustering or herniation
of nuclear pores, or release of NUP98 from the NE. In particular the absence of
any gross defects in NPC structure and distribution is of importance with respect
to earlier work in the yeast system. In gle2 mutant yeast, as well as those with
gle2 or nup116 null alleles (Murphy et al., 1996; Wente and Blobel, 1993), a
block in poly(A)+ RNA export is always accompanied by severe clustering and
herniation of the nuclear pores. Because of these NPCs perturbations, it has
been difficult to ascertain whether Gle2p and Nup116p are mediators of RNA
transport. Nup116(∆GLEBS) mutants (Bailer et al., 1998), which are defective in
the docking of Gle2p to Nup116p at the NPC, display very similar spatio-
structural NPC defects as gle2 or nup116p mutants. Because of these defects, it
is difficult to study the export function of the Gle2p-Nup116p interaction in the
nup116(∆GLEBS) mutants. An interesting difference between S. cerevisiae
Gle2p and S. pombe Rae1p is that a lack of Rae1p function results in poly(A)+
RNA accumulation in the absence of any detectable NPC defects (Brown et al.,
1995; Whalen et al., 1997). It is conceivable that Gle2p and Rae1p functions
have diverged, and that Gle2p may perform separate functions in both mRNA
transport and NPC structure. Insight in how Gle2p and Rae1p function in the
pathway for nuclear export of mRNA is required in order to address such issues.
In S . cerevisiae, it will be important to establish whether the Nup116p-Gle2p
interaction at the NPC serves directly in the RNA export pathway. Perhaps
GLEBS-overexpression studies similar to those presented in this paper can yield
such information. To gain insight in how Rae1p functions in fission yeast, a
crucial step will be to identify whether S. pombe contains an S. cerevisiae
Nup116p homologue that has a GLEBS-like binding site, and if so, whether this
site directly functions in mRNA export.
105
Could RAE1 serve as the exportin for mRNA or as a factor that provides the
NES signal to mRNA (Ohno et al., 1998; Ullman et al., 1997)? Unlike Rae1p in
S. pombe (Brown et al., 1995), Gle2p in S. cerevisae (Murphy et al., 1996) is not
a strictly essential protein indicating that mRNA export is impaired rather than
completely blocked in the absence of functional Gle2p. Thus, Gle2p does not
seem to operate as the sole exportin or NES-containing factor for mRNA export.
Instead, Gle2p and its homologues in fission yeast (Rae1p) and mammals
(RAE1) more likely participate in mRNA export as mRNP-interacting proteins
necessary for efficient anchoring of the transport complex to the NPC.
Evidence for specialization of WD-repeats in RAE1
RAE1 is a member of superfamily of WD-repeat proteins. Given the high
conservation the WD repeats, it is likely that they all fold into a propeller
structure (Garcia-Higuera et al., 1996a). Members of this family do not have an
immediately obvious common function. Rather, the common thread between
WD repeat proteins seems to be that they make up part of large macromolecule
assemblies. The capacity to assemble multiple proteins may be an essential part
of their function, including that of RAE1 (Neer et al., 1994a). The signal-
transducing WD-repeat protein Gß binds to Gγ to form a heterodimer that in turn
interacts with Gα or a variety of different effector proteins (Clapham and Neer,
1997). The various interactions with Gß are established through unique as well
as overlapping contact sites involving specific blades of the Gß propeller (Li et
al., 1998). Similarly, the blades of the RAE1 propeller might serve as contact
sites for multiple distinct RAE1 partners. This idea has some support from the
observation that the interaction of RAE1 and the GLEBS-like motif of NUP98 is
highly sensitive to a point mutation in blade 4, but not those in blades 2 and 3.
Additionally, studies in S. pombe have demonstrated that a conserved 10-
residue basic motif at the carboxy-terminus of Rae1p is necessary for Rae1p
function. Here we found that this motif is not essential for the RAE1-NUP98
interaction, which is in keeping with the idea that RAE1 may be involved in an
additional protein-protein interaction. A future goal to provide further insight into
the complex mechanism of mRNA export from the nucleus now is to determine
whether RAE1 preferentially interacts with specific kinds of mRNA molecules
and to define how RAE1 interacts with mRNP particles. Preliminary in vivo
cross-linking studies suggest that RAE1 indeed interacts with at least one other
protein besides NUP98.
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The coactivators CBP (Cre-element binding protein (CREB)-
binding protein) and its paralogue p300 are thought to supply
adaptor molecule and protein acetyltransferase functions to
many transcription factors that regulate gene expression1. Nor-
mal development requires CBP and p300, and mutations in these
genes are found in haematopoietic and epithelial tumours2–6. It is
unclear, however, which functions of CBP and p300 are essential
in vivo. Here we show that the protein-binding KIX domains of
CBP and p300 have nonredundant functions in mice. In mice
homozygous for point mutations in the KIX domain of p300
designed to disrupt the binding surface for the transcription
factors c-Myb and CREB7–9, multilineage defects occur in hae-
matopoiesis, including anaemia, B-cell deﬁciency, thymic hypo-
plasia, megakaryocytosis and thrombocytosis. By contrast,
age-matched mice homozygous for identical mutations in the
KIX domain of CBP are essentially normal. There is a synergistic
genetic interaction between mutations in c-Myb and mutations
in the KIX domain of p300, which suggests that the binding
of c-Myb to this domain of p300 is crucial for the development
and function of megakaryocytes. Thus, conserved domains in
two highly related coactivators have contrasting roles in
haematopoiesis.
The KIX domain is one of several domains in CBP (also known as
Crebbp) and p300 that bind transcriptional regulators (Fig. 1a); it is
highly conserved in evolution, with 90% identity in human CBP
and p300 (Fig. 1b). The three-dimensional structure of the CBPKIX
domain in a complex containing a portion of the CREB activation
domain has been determined (ref. 9 and Fig. 1c). Speciﬁc hydro-
phobic residues on the surface of the KIX domain are important for
binding the a-helical activation domains of CREB and c-Myb7,8.
We tested the role of the KIX domain transcription factor-
binding surface in vivo by mutating three highly conserved residues
that lie on one face of the a3 helix in the KIX domain of CBP (Fig.
1b, c): Tyr 650 forms part of the hydrophobic surface that makes
crucial contacts with CREB; the small side chain of Ala 654 allows
the close packing of CREB; and Tyr 658 forms hydrophobic
interactions with CREB and forms hydrogen bonds with phos-
phorylated Ser 133 of CREB9. Thus, we thought that replacing Tyr
650 and Tyr 658 with alanines should disrupt bonding with CREB,
and replacing the Ala 654 methyl group with a bulkier glutamine
side chain should sterically hinder CREB binding. Accordingly, the
individual mutations of Tyr650Ala, Ala654Gln, and Tyr658Ala each
diminish CREB and c-Myb binding to KIX (refs 7, 8, and data not
shown). Structure prediction analyses using AGADIR and PSIPRED
predicted that KIX secondary structure would not be affected by a
Tyr650Ala, Ala654Gln, Tyr658Ala triple mutation (refs 10, 11, and
data not shown).
We introduced this triple mutation into the CBP and p300 loci of
embryonic stem (ES) cells by homologous recombination (Fig.
1d, e). For p300, the corresponding residues, Tyr 630, Ala 634 and
Tyr 638, were mutated. Correctly targeted ES cells were used to
produce mice carrying mutant alleles of the KIX domain of CBP
(designated CBPKIX) or p300 (designated p300KIX; Fig. 1d, e).
CBPKIX/KIX and p300KIX/KIX homozygous mice were viable,
although some died of unknown causes before they were 3 weeks
old (mostly p300KIX/KIX mice; see Supplementary Information).
Surviving 4-week-old p300KIX/KIX mice averaged about 50–70% of
the size of wild-type or heterozygous littermates, and CBPKIX/KIX
mice also tended to be smaller than their littermate controls.
Analysis of the surviving CBPKIX/KIX age-matched mice was unre-
vealing apart from a slight reduction in thymocyte numbers
(Supplementary Information). By contrast, p300KIX/KIX mice had
a marked reduction in thymocyte numbers (,5% of wild type) and
severe anaemia (haematocrit 20.2 ^ 5.3 versus 42.3 ^ 1.4% for
wild type) and thrombocytosis ((5.0 ^ 1.1) £ 109 versus (1.2 ^
0.2) £ 109 platelets per ml for wild type). Numbers of neutrophils
were generally in the normal range (data not shown). The blood
from p300KIX/KIX mice showed increased variation in erythro-
cyte size (compare Fig. 2b with Fig. 2a, c) and the presence of
megathrombocytes (Fig. 2b, broken arrow). CBPþ/KIX and
p300þ/KIX mice were essentially normal (except for a small
increase in platelets in p300þ/KIX mice), which showed that the
mutations were not overtly dominant (Supplementary Information).
The bone marrow of p300KIX/KIX mice showed megakaryocytic
hyperplasia with a corresponding decrease in other bone marrow
elements (compare Fig. 2d with Fig. 2e). Megakaryocytosis was
evident in the spleens of these mice (compare Fig. 2g with Fig. 2f, h)
and was indicated further by widespread staining for acetylcholin-
esterase enzyme (compare Fig. 2j with Fig. 2i) and factor VIII
(data not shown). Megakaryocytosis in p300KIX/KIX mice was also
indicated by ﬂow cytometric analysis of bone marrow and spleen
cells, which contained an overabundance of CD41-positive cells as
compared with CBPKIX/KIX and wild-type mice (Fig. 2k). Serum
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concentrations of thrombopoietin (Tpo), which stimulates mega-
karyocytopoiesis, were reduced about ﬁvefold in p300KIX/KIX mice
(probably owing to Tpo internalization and degradation by excess
platelets), which indicated that overproduction of Tpo was not
the cause of the megakaryocytosis (Supplementary Information).
We assessed the development of p300KIX/KIX megakaryocytes
by quantifying the DNA content in CD42d-positive bone marrow
cells (Fig. 2l). p300KIX/KIX mice had more immature megakaryo-
cytes with a modal ploidy of 8n, as compared with 16n in control
mice.
Thymuses from p300KIX/KIX mice had an apparently normal
distribution of single- and double-positive CD4 andCD8 thymocytes
(Fig. 2n). Despite the decreased absolute number of p300KIX/KIX
thymocytes, peripheral single-positive CD4 and CD8 T-cell popu-
lations seemed to be in the normal range (data not shown). By
contrast, there was a deﬁcit of B220-positive, immunoglobulin-m
(IgM)-positive, immunoglobulin-d (IgD)-positive mature B cells in
p300KIX/KIX mice (Fig. 2m).
To determine whether the p300KIX/KIX phenotype was intrinsic to
the bone marrow, we transplanted p300KIX/KIX bone marrow cells
into wild-type mice that had been lethally irradiated. Mice that
received p300KIX/KIX bone marrow cells developed a phenotype
comparable to that of p300KIX/KIX mice, with severe anaemia,
thrombocytosis and B-cell deﬁciency, indicating that p300KIX/KIX
bonemarrow cells were sufﬁcient to confer the disease (Supplemen-
tary Information, and data not shown). A mix of p300KIX/KIX
bone marrow cells with equal numbers of wild-type cells conferred
a milder anaemia with thrombocytosis (Supplementary Infor-
mation).
The stability and expression of CBP and p300 proteins were
unaffected by mutations in the KIX domain, as judged by western
blot analysis of nuclear extracts from the brains of CBPKIX/KIX and
p300KIX/KIX mice (Fig. 3a). Histone acetyltransferase (HAT) activi-
ties of immunoprecipitated mutant CBP and p300 were also
indistinguishable from those of wild-type mice (Fig. 3b). By con-
trast, several independently derived CBPKIX/KIX and p300KIX/KIX
primary mouse embryonic ﬁbroblast (MEF) lines were compro-
mised in their ability to support CREB and c-Myb activity in
transient transfection assays by about two- to fourfold as compared
with wild-typeMEFs. This was true for both endogenous CREB and
ectopically expressed c-Myb and the Gal4 DNA-binding-domain
fused to CREB or c-Myb (Fig. 3c–e). Notably, Gal4 fusions of
activators that depend on other domains of CBP and p300 or other
coactivators (Ets-1 and VP16) were unaffected in p300KIX/KIXMEFs
(refs 12–14 and Fig. 3d, e). Expression of wild-type CBPor p300, but
not mutant CBP, could restore Gal4–CREB activity in CBPKIX/KIX
MEFs (Fig. 3f, g). Cyclic-AMP-dependent induction of the
endogenous CREB target genes encoding c-Fos, JunB and the
ICER form of CREM were not measurably different in mutant
and wild-type MEFs, which suggests that the KIX domain is not
limiting for these genes in MEFs (data not shown). Together, these
data indicate that a 50% reduction in the expression of wild-type
KIX domains results in the speciﬁc attenuation of CREB and c-Myb
activities in certain promoter contexts.
We compared CBP and p300 proteins in MEFs, megakaryocytes,
thymus and relatively unaffected tissues from wild-type mice.
Western blot analysis of nuclear extracts made from highly enriched
megakaryocytes showed increased concentrations of p300 relative
to CBP when compared with brain, heart and MEFs (Fig. 4a). The
thymus also had a higher p300/CBP protein ratio (data not shown).
We veriﬁed the increased ratio of p300 to CBP inmegakaryocytes by
analysing mRNA levels in megakaryocyte and brain by quantitative
polymerase chain reaction with reverse transcription (RT–PCR).
p300mRNAwas about six timesmore abundant thanCBPmRNA in
Figure 1 Mouse KIX domain mutations. a, Domains in CBP and p300: nuclear receptor
interaction domain (RID), cysteine/histidine-rich domains (CH1, CH2, CH3), KIX
bromodomain (Br), IRF3-binding domain (IBiD) and HAT. b, KIX domains from mouse,
human, Drosophila melanogaster and Caenorhabditis elegans. Conserved residues are
indicated. Produced with Boxshade. c, Structure of the KIX domain from CBP (green) and
the KID domain9 from CREB (magenta) with the side chains of Tyr 650, Ala 654, Tyr 658
and the phosphoserine 133 (P-Ser133) of CREB highlighted. Produced using Protein
Explorer and data from the Protein Data Bank. d, e, Targeting strategies for CBP (d) and
p300 (e), and Southern blots of mouse tail DNA. Star indicates a mutated exon, ﬁlled
boxes indicate probes and exons and arrowhead indicates loxP site. X, XbaI; H, HindIII; B,
BamHI; N, NheI; S, SpeI.
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megakaryocytes (t-test, P , 0.01; Fig. 4b). Protein binding assays
using glutathione S-transferase (GST)–Myb and GST–CREB did
not identify tissue-speciﬁc differences in the binding of CBP and
p300 from nuclear extracts, which suggests that the KIX domains of
CBP and p300 are functionally equivalent when isolated from
different sources (data not shown). Thus, cells with an increased
p300/CBP ratio conceivably might be more susceptible to
mutations in the KIX domain of p300.
Because c-Myb homozygous null mice have a deﬁciency in
haematopoiesis15,16, we investigated whether defects in the
p300KIX/KIX mice were caused by an attenuation of c-Myb activity.
We examined mice with a single c-Myb null allele, either alone or in
combination with a single p300KIX gene. For c-Mybþ/2 mice we
reasoned that if mutations in KIX lead to a reduction in c-Myb
function, then decreased concentrations of c-Myb might result in a
p300KIX/KIX-like phenotype. Similarly, mice heterozygous for
Figure 2 Haematopoietic defects in p300 KIX/KIX mice. a–j, Blood (a–c), bone marrow
(d, e), spleen (f–j) from wild-type (a, f, i), p300 KIX/KIX (b, d, g, j) and CBP KIX/KIX (c, e, h)
mice; examples are shown of giant (broken arrow) and normal (small arrow) platelets and
megakaryocytes (large arrows). Acetylcholinesterase-positive megakaryocytes in spleen
are shown at low magniﬁcation (i, j). k, CD41-positive megakaryocytes in p300 KIX/KIX
bone marrow and spleen. l, p300 KIX/KIX megakaryocytes have low modal ploidy (8n). The
peaks in the histogram (top) correspond to 2n to 32n cells (left to right). m, B-cell
deﬁciency in p300 KIX/KIX mice. n, Normal population distribution of double-positive CD4
CD8 thymocytes in p300 KIX/KIX mice.
116
mutations in both c-Myb and the KIX domain of p300might show a
synergistic phenotype if the interaction between c-Myb and the KIX
domain of p300 is limiting for c-Myb-dependent transcription and
haematopoietic development17,18.
Two- to three-week-old c-Mybþ/2p300þ/KIX double heterozy-
gous mice had a large increase in platelets ((3.05 ^ 0.47) £ 109
versus (1.22 ^ 0.22) £ 109 platelets per ml for wild type; t-test,
P , 0.01) that was more than additive relative to single hetero-
zygotes and approached concentrations seen in p300KIX/KIX mice
(Fig. 4c). Notably, platelet counts in c-Mybþ/2p300þ/KIXmice aged
5–6 weeks were similar to those in the single heterozygotes,
suggesting that the interaction between c-Myb and the KIX domain
of p300 is less crucial in adult thrombopoiesis (data not shown).
Thymocyte numbers were not vastly different between wild type
and single heterozygotes, but were reduced by about 40% in
c-Mybþ/2p300þ/KIX mice as compared with wild type, suggesting
that there is an interaction between c-Myb and the p300 KIX
domain in these cells (analysis of variance, P , 0.01, n ¼ 13–21
per strain; data not shown). Other aspects of c-Mybþ/2, p300þ/KIX
and c-Mybþ/2p300þ/KIX mice appeared normal (data not shown),
except that the single heterozygotes had slightly more platelets than
did their wild-type littermates ((1.52 ^ 0.29) £ 109 for c-Mybþ/2,
and (1.55 ^ 0.27) £ 109 platelets per ml for p300þ/KIX, t-test,
P , 0.01; Fig. 4c).
When we examined megakaryocyte ploidy in mice aged 5–6
weeks, c-Mybþ/2p300þ/KIX cells showed a synergistic reduction in
DNA content as compared with the single heterozygotes, with
ﬁvefold more cells with 8n, similar numbers of cells with 16n, and
12-fold fewer cells with 32n relative to wild type (Fig. 4d, g).
c-Mybþ/2 megakaryocytes had a noticeable but less marked ‘left
shift’ (that is, about twofold more 8n and twofold less 32n cells),
whereas p300þ/KIXmegakaryocytes seemed to have an intermediate
phenotype (Fig. 4d–f). This left shift towards a modal ploidy of 8n,
which is reminiscent of p300KIX/KIX megakaryocytes (Fig. 4h), is
abnormal19,20. There was also a signiﬁcant increase in the percentage
ofmegakaryocytes (CD42dhi cells) in the bonemarrowof c-Mybþ/2
and c-Mybþ/2p300þ/KIX mice as compared with wild-type mice
(t-test, P , 0.01; Fig. 4i), which is consistent with a trend towards
megakaryocytosis. Together, these ﬁndings suggest that decreased
c-Myb-dependent transcription, either by reduction of c-Myb
protein (c-Mybþ/2) or by a transactivation function (p300KIX/KIX),
results in abnormal megakaryocytopoiesis and predisposes mice to
develop thrombocytosis.
Although the p300KIX/KIX phenotype does not simply recapitulate
the phenotypes of knockout mouse models of CREB, c-Myb or
other known KIX-binding proteins, connections between p300 KIX
and c-Myb were identiﬁed nonetheless. c-Myb2/2 mice die in
embryogenesis owing to a multilineage failure of haematopoiesis,
but megakaryocytes are still present, which suggests that any loss of
c-Myb function preferentially favours megakaryocytes over other
haematopoietic lineages15,21. Whether binding of the p300 KIX
domain to c-Myb or CREB is necessary for the development of
other haematopoietic lineages affected by mutations in c-Myb
(erythroid, myeloid and B cells) or CREB (thymocytes) remains
to be tested15,16,22. Notably, the haematopoietic phenotype is speciﬁc
for p300KIX/KIX mice even though previous work has shown that
Figure 3Mutant CBP and p300 affect CREB and c-Myb. a, CBP and p300 western blots.
b, HAT activity in immunoprecipitated CBP and p300 (n ¼ 2). c, Activity of c-Myb and
CREB in CBP KIX/KIX and p300 KIX/KIX MEFs (n ¼ 2–4). CD13–Luc is a c-Myb responsive
reporter; CMV is the empty vector. FI, forskolin plus isobutylmethylxanthine; RLU, relative
light units. d, Activity of Gal–CREB, but not Gal–Ets-1, is attenuated in CBP KIX/KIX MEFs
(n ¼ 2–5). Gal–DBD, Gal4 DNA-binding domain. e, Activity of Gal–Myb and Gal–CREB,
but not Gal–Ets-1 and Gal–VP16, is affected in p300 KIX/KIX MEFs (n ¼ 3). f, g, Activity of
Gal–CREB is rescued in FI-treated CBP KIX/KIX MEFs (n ¼ 6, f; n ¼ 4, g). RSV–CBP, CBP;
CMV–p300, p300; RSV–CBP mut, KIX-mutant CBP. Means ^ s.d. are shown in c–g. WT
1–6, p300 KIX/KIX 1–3 and CBP KIX/KIX 1–4 indicate independent MEF lines.
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CBPþ/2, but not p300þ/2, mice tend to develop multilineage
defects in haematopoietic differentiation4. Taking into account
our ﬁndings that p300 may be relatively more abundant in an
affected lineage, a comparison of the CBPþ/2 and CBPKIX/KIX
phenotypes implies that other domains besides KIX (or other KIX
residues) are limiting for haematopoiesis. Finally, our ﬁndings imply
that mutations in the KIX domain of p300 and in c-Myb may
contribute to human haematopoietic diseases, particularly those
with abnormal megakaryocytopoiesis and thrombopoiesis. A
Methods
Mice
Targeting vectors for CBP and p300 (Fig. 1d, e) were made from DNA that was isogenic
with the E14 ES cells used in this study. We generated point mutations in the KIX exons
using PCR with the following primers: CBP, 5
0
-CATTTACTGCAGGAGAAAATCGCT
AAAATACAAAAAGAACTAGAA-3
0
and 5
0
-GATTTTCTCCTGCAGTAAATGAGCGTA
TTCATCCTAAAAAGAAAT-3 0 ; p300, 5 0 -CACCTCCTGCAGGAGAAGATCGCTAAGAT
CCAGAAGGAACTAGAA-3
0
and 5
0
-GATCTTCTCCTGCAGGAGGTGAGCGTATT
CCGCCTTGAAGAAATT-3
0
. The Hartwell Center at St Jude supplied oligonucleotides
and DNA sequencing. Mutations in the KIX exon were conﬁrmed by PCR. Correctly
targeted ES cells were conﬁrmed by Southern blot. Transiently expressed Cre recombinase
was used to excise neomycin r and the thymidine kinase gene ﬂanked by loxP sites (NeoTK)
in correctly targeted ES cells; 2 0 -ﬂuoro-2 0 -deoxy-5-iodouracil-b-D-arabinofuranoside
(FIAU) negative selection was used to enrich for clones that lost NeoTK. We generated
chimaeric mice from ES cells by standard methods. KIX mutant mice for initial
phenotypic analyses were on a 129Ola/C57BL/6 mixed genetic background; these were
comparable to F1 hybrid KIX mutant mice derived from mating C57BL/6 and 129Ola
backcrossed mice. For the c-Mybþ/2 p300þ/KIX experiments, c-Mybþ/2 and p300þ/KIX
parents were maintained on a C57BL/6 background. In bone marrow transplant
experiments, 106 or 2 £ 106 bone marrow cells (varied by experiment) were injected into
the tail veins of lethally irradiated (1,100 rad) C57BL/6 mice. We determined Tpo
concentrations with an enzyme-linked immunabsorbent kit (R&D Systems).
Flow cytometry
Cells were stained with antibodies to CD41, CD45R (B220), CD4, CD8 (Pharmingen),
IgM and IgD (Southern Biotechnologies) conjugated to ﬂuorescein isothiocyanate (CD41,
IgD), phycoerythrin (CD8, IgM), allophycocyanin (B220) or biotin (CD4). Biotinylated
antibody was used with a streptavidin–RED613 conjugate (Invitrogen). We carried out
megakaryocyte ploidy analysis as described23.
Plasmids and antibodies
The reporter and expression plasmids have been described8,13,24–26. Gal–Myb contained
residues 186–325 of c-Myb, Gal–Ets-1 contained residues 2–210 of Ets-1, and Gal–CREB
contained residues 1–283 of CREB. We generated RSV–CBPmut by introducing the
Tyr650Ala, Ala654Gln, Tyr658Ala triple mutation into CBP expression plasmid pRC/
RSV–mCBP–HA–RK (a gift from R. Goodman) by site-directed mutagenesis. The SV40–
Renilla reporter plasmid pRL–SV40 was from Promega. Antibodies were from Santa Cruz
(CBP, A22; p300, N15; p300, C20; GST, Z5).
Cell culture and transient assays
We obtained megakaryocytes from the fetal livers of C57BL/6 £ 129Ola F1 hybrid wild-
type mice (E13.5)27. After 5 d of culture, highly enriched primary megakaryocytes were
isolated using a bovine serum albumin step gradient (R. Shivdasani, personal
communication). We isolated MEFs from E12.5–E14.5 embryos; growth rates were
comparable between wild-type and mutant cells. For transient transfection assays,
3 £ 104 cells per well were cultured overnight in 24-well plates. Cells were washed with 1ml
of DMEM medium without fetal bovine serum (FBS) or antibiotics. We added 0.25ml of
DMEM containing 2.5ml of 2mgml21 Lipofectamine Reagent (Gibco-BRL) and plasmid
DNA (0.25mg of reporter, 0.25mg of expression plasmid, 5 ng of pRL-SV40, 1mg of RSV–
CBP, 0.25mg of CMV–p300) according to the protocols of Gibco-BRL. After 2 h, the DNA/
Lipofectamine was removed and 1ml of DMEM plus 10% FBS without antibiotics was
added. We incubated the cells overnight and treated them optionally the next morning with
10mM forskolin plus 100mM isobutyl-methylxanthine (IBMX) for 6–8h.
Cell extracts were prepared by washing the cells with PBS followed by in situ lysis with
50ml of passive lysis buffer (Promega). Dual luciferase assays were carried out according to
the manufacturer’s protocols (Promega), but with 50% of the recommended volumes. We
normalized luciferase activity to Renilla luciferase derived from the cotransfected SV40–
Renilla internal control reporter for all experiments. Most data are reported in relative
light units relative to the activity of CREB in one line of wild-type MEFs without CBP or
p300 overexpression (arbitrarily set to 100). For CBP and p300 rescue experiments, MEFs
were maintained on a 3T9 protocol (cells were plated every 3 d to the equivalent of
9 £ 105 cells per 6-cm dish), and the empty vector control had equal moles of RSVor CMV
expression plasmid, mass balanced with Bluescript SKII DNA (Stratagene).
Nuclear extracts, western blots and HAT assays
Nuclear extracts were prepared by standard methods using buffer A (10mM HEPES, pH
7.9, 1.5mMMgCl2, 10mM KCl and 1mM EDTA) and buffer C (20mM HEPES, pH 7.9,
Figure 4 c-Myb and p300 KIX functionally interact to regulate megakaryocytopoiesis. a,
Western blot of CBP and p300 using wild-type nuclear extracts. Meg, megakaryocyte.
Results are normalized to CBP. b, Quantitative real-time RT–PCR analysis of CBP and
p300 mRNA in wild-type tissues. Shown are the means ^ s.d. relative to CBP mRNA in
brain (set to 1) after normalization to GAPDH mRNA (n ¼ 12 or 18). c, Platelet counts of
littermates aged 2–3 weeks (n ¼ 9–15). Double het indicates p300 þ/KIXc-Myb þ/2
mice. d–h, Ploidy analysis of megakaryocytes from littermates aged 5–6 weeks (the
p300 KIX/KIX mice in h were not littermates). Shown are the means ^ s.d. percentages of
megakaryocytes (n ¼ 2–3). i, Percentage of CD42dhi cells (megakaryocytes) in bone
marrow (n ¼ 4–5).
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1.5mM MgCl2, 420mM KCl, 25% glycerol and 0.2mM EDTA) Both buffers contained
1mM dithiothreitol, 1mM phenylmethylsulphonyl ﬂuoride, 0.5 mgml21 leupeptin and
1 mM pepstatin. Each brain was homogenised in 5ml of buffer A; nuclear proteins were
eluted in 1ml of buffer C. Extracts were not dialyzed.We carried out western blot transfers
of CBPand p300 in cold transfer buffer containing 0.1% SDS for 2 h at 400mA.HATassays
were done as described, with the nonspeciﬁc control antibody GST Z-5 (ref. 13). Western
blot analysis of immunoprecipitates following the HAT assays showed that equivalent
amounts of CBP or p300 precipitated from mutant and wild-type extracts (data not
shown).We used equal amounts of wild-type andmutant total nuclear protein for western
blot analysis and HAT assays.
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Supplementary Information
Table 1
Features of CBPKIX and p300KIX mutant mice and bone marrow transplant recipients
CBP+/+ CBP+/KIX CBPKIX/KIX p300+/+ p300+/KIX p300KIX/KIX
Number  68 143 41 131 262 22
at weaning
Expected 1 2 1 1 2 1
ratio
Observed 1 2.1 0.60 1 2 0.17
Ratio
BodyWeight 13.5 ± 3.8 14.8 ± 3.6 9.2 ± 1.6 15.6 ± 3.3 15.2 ± 3.3 7.6 ± 2.8
males (grams)  (n=9) (n=7) (n=5) (n=7) (n=19) (n=6)
Hematocrit 41.9 ± 2.4 43.0 ± 1.3 42.4 ± 3.4 42.3 ± 1.4 44.1 ± 2.0 20.2 ± 5.3
(%) (n=10) (n=13) (n=10) (n=14) (n=24) (n=9)
Platelet count 1.3 + 0.4 1.3 + 0.3 1.6 ± 0.3 1.2 + 0.2 1.5 ± 0.3 5.0 ± 1.1
(x109/ml) (n=5) (n=5) (n=3) (n=9) (n=9) (n=5)
Serum Tpo level ND ND 3017 ± 506 3910 ±  962 ND 506 ± 123
(pg/ml) (n=3) (n=5) (n=5)
Thymus/Body  ND ND 3 ± 0 4 ± 1 ND 2 ± 1
Weight (mg/g) (n=3) (n=6) (n=6)
Thymocyte count ND ND 73 ± 30 145 ± 21 ND 8 ± 9
(x106) (n=3) (n=4) (n=4)
Bone Marrow Transplanted p300+/+ p300+/+plus p300KIX/KIX p300KIX/KIX
Hematocrit of  BL6 recipient mice 44.9 ± 1.6 34.7 ± 2.7 8.6 ± 1.6
40 days post transplant (%) (n=8) (n=9) (n=8)
Platelet Count of BL6 recipient mice 1.1 ± 0.2 5.2 ± 2.8 2.3 ± 0.5
40 days post transplant (x109/ml) (n=8) (n=9) (n=8)
ND = not done, Tpo = thrombopoietin;  BL6 = C57BL/6 wild type mice.
Mice were produced by breeding heterozygous animals and genotyped at weaning. Weights and
hematocrits are shown for 4-week
old  mice. Data shown as mean + SD
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Summary
NUP98 is an FG repeat-containing nucleoporin that has been found to be
involved in multiple leukemia-associated chromosomal translocations, of which
the most common is the t(7;11)(p15;p15) rearrangement, which links NUP98 to
the class I homeotic transcription factor HOXA9.  In our initial studies we sought
to answer two main questions: First, what is the contribution of NUP98 to the
oncogenic potential of the NUP98-HOXA9 fusion protein?  Second, what is the
normal role of NUP98 in the cell?  In the process of investigating these first two
questions, our findings led us to pose two more questions: What are the normal
functions of the NUP98-interacting protein Rae1?  What are the roles in
hematopoiesis for the transcriptional coactivators, CBP and p300, which
physically and functionally interact with NUP98-HOXA9?
Our first approach was to test the various domains of NUP98-HOXA9 for cellular
transformation and transactivation function using transfection assays and DNA
constructs of NUP98-HOXA9 bearing specific deletions and mutations (Chapter
3).  We found that the FG repeats contributed by NUP98 were required for in
vitro cellular transformation and gene transcription transactivation potential.  We
also showed that this transformation and transactivation potential correlates with
the ability to interact with CBP and p300.  These results suggested that the
oncogenicity of the NUP98-HOXA9 fusion protein results from its aberrant
transcriptional properties.
To clarify the means by which NUP98 might contribute to the oncogenic
potential of the NUP98-HOXA9 fusion, we examined the normal functions of
NUP98 via a mouse knockout approach (Chapter 4).  NUP98-deficient mice
could not be generated indicating that NUP98 is required for normal
development.  Studies of cells derived from NUP98 knockout embryos revealed
that loss of NUP98 did not affect the number of nuclear pore complexes (NPC)
per cell, but that the architecture and transport ability of the NPCs was altered.
In the absence of NUP98, NUP358, NUP214, NUP88 and p62 were
underrepresented in the nuclear pores of mutant cells compared to wild type.  In
addition, mutant cells showed an increase in annulate lamellae in the cytoplasm
and NUP358, NUP214, NUP88 and p62 were shown to be associated with
these structures.  Some, but not all protein import pathways are disrupted in the
NUP98 null cells indicating that specific nucleoporins have roles in specific
nuclear import and export pathways.
We also looked for proteins that interact with the N-terminal portion of NUP98,
which is found in leukemia-associated fusion proteins, and showed that Rae1
interacts with NUP98 via its GLEBS-like motif (Chapter 5).  Further analysis of
Rae1 demonstrated that it acts as an mRNA export factor.  Our studies showed
that the localization of Rae1 to the nuclear envelope is dependent on ongoing
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synthesis of mRNA, and overexpression of the GLEBS-like motif, which acts as
a competitor for binding of Rae1 to NUP98, causes accumulation of poly(A)+
RNA in the nucleus and loss of Rae1 localization to the nuclear envelope.
These results support the importance of the Rae1-NUP98 interaction in mRNA
nuclear export.
Given the important role that CBP and p300 appear to play in the oncogenicity
of the NUP98-HOXA9 fusion protein, we wanted to elucidate the role of p300
and CBP in normal hematopoiesis. To this end, we made targeted mutations in
the KIX domain of these proteins, which were designed to interrupt the
interaction of p300 or CBP with CREB and c-Myb, both transcription factors with
known roles in hematopoiesis (Chapter 6).  These studies revealed that while
mice bearing homozygous mutations in the KIX domain of CBP were relatively
normal, p300KIX/KIX mice had defects in multiple hematopoietic lineages including
reduced numbers of erythrocytes and B-lymphocytes, small thymuses, and
increased numbers of megakaryocytes and platelets.  In addition, mice
heterozygous for both the p300 KIX mutation and a knockout allele of c-Myb,
displayed a more than additive increase in platelets and decreased
megakaryocyte ploidy compared to the single heterozygotes.  The phenotype of
the compound heterozygotes was similar to, but less dramatic than that seen in
p300KIX/KIX mice.  These results suggest that the interaction between c-Myb and
the KIX domain of p300 is important for certain aspects of megakaryocyte
development and function.
125
Discussion
The results of our research bring to mind several interesting questions that
future studies may address.  First, do proteins that interact with the NUP98-
HOXA9 fusion protein contribute to its oncogenicity?  In the case of CBP and
p300 our data present a clear argument for the importance of this interaction in
the leukemogenic potential of the fusion protein, but the question remains open
for other interacting proteins.  A recent paper by Babu et al. shows that Rae1
functions as a mitotic checkpoint regulator and is important for maintaining
correct chromosome segregation (Babu et al., 2003).  These findings suggest
that chromosomal instability that could potentiate oncogenesis may be altered
by the interaction of Rae1 and the NUP98-HOXA9 fusion protein.  In our studies,
NUP98-HOXA9 constructs lacking the GLEBS-like motif (necessary for binding
Rae1) still had transforming and transactivating potential in NIH-3T3 cells;
however, the interaction of Rae1 with the NUP98-HOXA9 fusion protein may
contribute to oncogenesis at the level of the organism.
Another interesting question is whether other leukemic fusion proteins involving
NUP98 (and perhaps the FG repeat-containing nucleoporin, NUP214) also
interact with p300 and CBP, and whether this interaction contributes to their
leukemogenesis.  The presence of the FG repeat-containing region in all the
leukemia-associated fusion proteins involving NUP98 (and NUP214) that have
been found to date, argue for the importance of this domain and provide the
possibility of interaction with CBP and p300.  Whether the FG repeats of
NUP214 can also interact with CBP and p300 has not been shown; however,
our data indicate that these repeats conferred similar transforming and
transactivating potential.  The fact that of the fourteen known chromosomal
translocations involving NUP98, eight also involve a homeobox protein that
contributes its DNA binding domain to the fusion is strong evidence that aberrant
transcriptional activity is critical to the oncogenic potential of these fusion
proteins.  In addition, five of the six (the sixth was not tested) remaining fusion
partners of NUP98, as well as both fusion partners of NUP214, contribute
domains that are predicted to form coiled-coil structures that could allow
oligomerization with transcription factors or cofactors (Hussey and Dobrovic,
2002).  This evidence of a transcriptional basis for the leukemogenic properties
of these fusion proteins fits well with a possible interaction with p300 and CBP.
It has not been determined whether NUP98 might interact with p300 and CBP in
the context of a normal cell. Recent studies linking NUP98 to the transcriptional
process raise the possibility that NUP98 and p300/CBP could interact during
normal transcription.  If this is so, then the FG repeat region of NUP98 might
form the basis of that interaction.  NUP98 has been shown to localize within the
nucleus in a transcription and FG motif-dependent manner; however, NUP98
does not seem to colocalize with the active form of RNA Polymerase II (Griffis et
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al., 2002).  It is possible that NUP98 may have a role in the movement of RNA to
the NPC for transport out of the nucleus in addition to its role at the NPC.  Our
studies showing the interaction of NUP98 and Rae1 support a role in RNA
transport, and the studies reported in Griffis et al. indicate that blocking RNA
synthesis causes NUP98 to lose its normal mobility within the nucleus.  It seems
likely that NUP98 may accompany the RNA from the nuclear interior to the NPC
and it is conceivable that NUP98 and CBP/p300 may interact via the FG repeats
at some point during this process, although it is not immediately clear what the
significance of this interaction might be.
Since p300 and CBP act as coactivators for such a wide range of transcription
factors, the loss or disruption of p300 or CBP can be expected to have
widespread implications for transcription.  We sought to dissect out the effect of
the interaction of CBP and p300 with specific transcription factors by making a
targeted mutation in the KIX domain that was predicted to inhibit binding to
CREB and c-Myb without affecting the overall structure of p300 or CBP;
however, the effect of our mutation on other transcription factors that bind the
KIX domain was not known.  Recent studies have made it clear that not all
transcription factors that bind to the KIX domain bind to the same surface.  MLL
has been shown not only to bind to a different portion of KIX than that bound by
CREB and c-Myb, but the binding of MLL to KIX has been shown to increase the
affinity of CREB and c-Myb for the KIX domain (Goto et al., 2002).  Similarly, the
immediate early transcription factor, c-Jun, can bind to KIX simultaneously with
CREB, by using a distinct surface (Campbell and Lumb, 2002).  These studies
are important to our results in several regards.  First, they indicate that the
mutations we made in the KIX domains of p300 and CBP most likely disrupt the
interaction of p300 and CBP with only a subset of the transcription factors
known to bind to the KIX domain.  Second, the studies by Goto et al. bring up an
important point with regard to domain-targeted mutations as they showed that
MLL and c-Myb bind to distinct areas of the KIX domain in a cooperative
manner.  This reminds us that a mutation that interrupts binding of p300 or CBP
to a single transcription factor could have a wider impact by disrupting
cooperative interactions between transcription factors that are mediated by p300
and CBP acting as scaffolds.
A question that has yet to be answered definitively is to what degree do p300
and CBP function redundantly?  Our results, which present such different
phenotypes for identical mutations in p300 and CBP, can be interpreted in at
least two ways.  One interpretation is that the strikingly different phenotypes of
p300KIX/KIX and CBPKIX/KIX mice represent separate and distinct functions of p300
and CBP.  This view would seem to be supported by the results of studies on
mice heterozygous for either p300 or CBP, which indicate that loss of a single
allele of p300 results in different hematologic defects and oncogenic potential
than loss of a single CBP allele (Kung et al., 2000; Rebel et al., 2002).  A
multitude of other experiments; however, have indicated redundant roles for
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p300 and CBP, including those that showed that a compound heterozygous
knockout mutation in both p300 and CBP results in an embryonic lethal
phenotype (Yao et al., 1998).  Thus, a second possible interpretation of our
results is that p300 and CBP are highly redundant and that the relative
abundance of p300 and CBP in specific tissues can result in different
phenotypes.  Our data suggest that the ratio of p300 to CBP protein levels
varies in tissues, with p300 appearing to be relatively more abundant compared
to CBP in tissues that are affected in p300KIX/KIX mice.  It is likely that reality lies
somewhere between these two interpretations and that p300 and CBP possess
both specific and redundant functions.
There is evidence that p300 and CBP may function as both tumor suppressors
and oncoproteins.  The loss of a single allele of CBP has been shown to lead to
a greater than normal incidence of oncogenesis in both mice and humans, and
transplant studies indicate that loss of a p300 allele can also lead to an increase
in hematologic neoplasms (Kung et al., 2000; Miller and Rubinstein, 1995; Rebel
et al., 2002). The means by which p300 and CBP function as tumor suppressors
is not clear, but our research indicates that at least some aspects of this function
could be narrowed down to the KIX domain.  While the phenotype of the
p300KIX/KIX mice does not include oncogenesis, the extreme overproduction of
megakaryocytes and the relative immaturity of these cells are clearly abnormal,
and such dysplasias could lead to cancer.
In addition to evidence of roles as tumor suppressors, the involvement of p300
and CBP in multiple leukemia-associated fusion proteins indicates that they may
also function as oncogenes.  It seems likely that dysregulation of their normal
functions as adaptor molecules and acetyltransferases could account, at least in
part, for the oncogenic potential of these fusion proteins.  In the case of the MLL
fusions, the coupling of MLL’s transcriptional activity to p300 or CBP’s ability to
interact with the basal transcription machinery and acetylate chromatin to make
genes accessible for transcription can be envisioned to lead to dysregulated
transcription.  When CBP or p300 is fused to MOZ or MORF, the additional
acetyltransferase activity could cause increased gene activation when a
transcription factor recruits CBP or p300 in the context of the fusion, which again
could lead to dysregulated gene expression that results in leukemia.  The
implications of this dual role for p300 and CBP as both tumor suppressors and
oncoproteins are only beginning to be understood.
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In addition to the involvement of the NUP98-HOXA9 chromosomal translocation
in a subset of acute myeloid leukemia (AML), HOXA9 itself has been found to be
deregulated in most AML cases. (Golub et al., 1999) The correlation of  HOXA9
overexpression with poor prognosis makes it attractive as a target of therapeutic
drugs for the treatment of AML.  Since the NUP98-HOXA9 fusion protein utilizes
the DNA binding domain of HOXA9 in its aberrant transcriptional capabilities, it
is likely that the normal targets of HOXA9 are the same genes subject to
misregulation by the fusion protein.  Both of these findings point to the
importance of identifying HOXA9 target genes.
Although accounting for a small subset of leukemias, NUP98, as of this writing,
is a partner in at least fifteen leukemia-associated chromosomal translocations.
Interestingly, recent studies show that aberrant expression of NUP98 and RAE1
causes mitotic checkpoint failure and chromosomal instability.  It will be
interesting to explore further whether mitotic checkpoint deregulation is a shared
pathogenic effect of NUP98-containing fusion proteins.
I believe that further mouse models mutating other protein binding domains of
p300 and CBP or even bearing different mutations in the KIX domain will be of
great value in allowing the study of specific interactions involving these rather
promiscuous coactivators.  This type of approach, particularly when combined
with genetic crosses involving predicted binding partners to look for synthetic
phenotypes should prove helpful in answering mechanistic questions that are
often not easily addressed in vivo.
To address in greater detail biochemical and transcriptional questions regarding
the effects of these mutations, it will be necessary to reduce the effect of
remaining wild type alleles of p300 or CBP.  One possibility is the generation of
mouse embryonic fibroblasts (MEFs) with three or four KIX domain mutations in
p300 and CBP.  Alternatively, a “knock-down” approach using RNA interference
technology could be used in MEFs bearing a homozygous mutation in the KIX
domains of p300 to reduce the effect of the unmutated CBP domains or vice
versa.  These cells would be very valuable in assessing the specific interactions
of transcription factors with p300 and CBP.
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Abbreviations used in this thesis
AML acute myeloid leukemia
C carboxy
CBP CREB-binding protein
CLP common lymphoid precursor
CML chronic myeloid leukemia
CMP common myeloid precursor
CRE cyclic AMP response element
CREB CRE-binding protein
EPO erythropoietin
ES embryonic stem
FG phenylalanine-glycine
FXFG phenylalanine -any amino acid- phenylalanine-glycine
GLEBS Gle2p-binding sequence
GLFG glycine-leucine-phenylalanine-glycine
HAT histone acetyltransferase
HOX homeobox
HSC hematopoietic stem cell
MDS myelodysplastic syndrome
MHC major histocompatibility complex
N amino
NES nuclear export signal
NK natural killer
NLS nuclear localization signal
NPC nuclear pore complex
NUP nucleoporin
Ph Philadelphia
RT-PCR reverse transcription polymerase chain reaction
RTS Rubinstein-Taybi Syndrome
T-ALL T-cell acute lymphoid leukemia
t-AML therapy-related acute myeloid leukemia
t-CML therapy-related chronic myeloid leukemia
TCR T-cell receptor
t-MDS therapy-related myelodysplastic syndrome
TPO thrombopoietin
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